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Importance of dimerization in aggregation and neurotoxicity of Prion and «- 
Synuclein in prion and Parkinson's diseases
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Les maladies neuroddgdneratives sont associyes a la perte progressive des 
propridtes structurales ou fonctionnelles des neurones, ce qui engendre la mort des 
cellules. De R en tes ytudes indiquent que tous les dysordres neuroddgdndratifs, 
sporadiques ou transmissibles, peuvent avoir un mecanisme pathologique commun au 
niveau moleculaire. Ce dispositif commun se compose de l'agregation de proteines, de 
la propagation des agregats, et de l'accumulation d’agrdgats toxiques dans les cellules 
neuronales, menant k l'apoptose et k la neurotoxicite cellulaire. Les maladies
XI
neurodegeneratives peuvent affecter la pensee abstraite, les mouvements habiles, les 
sentiments emotifs, la connaissance, la memoire et d'autres capacites cognitives. Ce 
groupe divers de maladies inclut la maladie d'Alzheimer (AD), de Parkinson (PD), de 
Huntington (HD), les maladies k prions ou encephalopathies spongiformes 
transmissibles (TSEs) et la sclerose laterale amyotrophique (ALS).
Dans mon projet j'ai travaille sur le mecanisme moldculaire de l'agregation, de 
la propagation et de la neurotoxicite d'agregats protdiques dans la maladie de Parkinson 
et les maladies k prions. Ces deux maladies sont associees a un mauvais repliement et a 
l'agregation de 1’ a-Synuclein (a-Syn) et de PrPc, respectivement. En depit de 
l’importance de ces deux desordres neurodegeneratifs, les mecanismes moleculaires 
d'agregation et d’amyloidogendse de PrPc ou de l’a-Syn sont encore peu clairs dans les 
maladies a prions et la maladie de Parkinson. En outre, les especes protdiques toxiques 
dans la PD n'ont pas encore dtd caracterisdes. Dans cette etude nous caractdrisons le 
mecanisme de mauvais repliement d'a-Syn et de PrP° en conditions physiologiques in 
vitro en absence d'agregats d’a-Syn, de l’isoforme agregee de PrPc (PrPRes), de 
denaturants ou encore d'environnement acide.
Plusieurs etudes indiquent que la dimerisation de PrPc ou de a-Syn peut etre 
une etape principale dans le processus d'agregation. Pour evaluer cette hypothese nous 
avons verifie si la dimerisation imposee de PrPc ou de a-Syn peut induire un 
changement conformationnel similaire k celui observe lors de la conversion de PrPc ou 
de l’a-Syn en agregats de PrPRes ou de a-Syn, respectivement. Nous avons employe une 
strategic bien connue de dimerisation inductible dans laquelle un domaine de 
dimerisation appeie 'FK506-binding protein' (Fv) a ete fusionne dans la sequence de
Prpc ou a-Syn afin de produire les proteines chimdriques Fv-PrP et a-SynFv. Un ligand 
divalent AP20187 a dtd utilise pour induire la dimerisation des proteines. L'addition 
d'AP20187 k Fv-PrP recombinant en condition physiologique a induit un changement 
conformationnel rapide caractdrisd par une augmentation de la structure de feuillet-P (|3- 
Sheet) et l'agrdgation simultande des proteines. Cependant, Fv-PrP non-dimdrisd a aussi
XII
adopte une conformation en feuillet-(3, mais avec une vitesse reduite. En presence 
d'AP20187, nous rapportons egalement un changement conformationnel rapide de 
'random coil' en feuillet-P de l’a-SynFv en moins de 24 h, tandis que le type sauvage de 
l’a-Syn a montre 24 h de retard pour atteindre la structure de feuillet-P apres 48 h. Des 
experiences de microscopie electronique ont demontre que la dimerisation a induit la 
formation de fibres amyloi'des apres 48 h pour Fv-PrP et a-SynFv, tandis qu'en l'absence 
du ligand dimerisant AP20187, Fv-PrP ou a-Syn ont pris 3 jours ou plus pour former 
des fibres amyloi'des. Les agregats de Fv-PrP induits par la dimerisation etaient 
partiellement resistants a la digestion par la proteinase K, qui est une des 
caracteristiques naturelles de PrP*65. Les taux d'amyloi'dogen&se en condition de 
dimerisation ont ete egalement caracterises par 1’utilisation de la sonde fluorescente 
Thioflavin T (ThT). Bien que la structure stable de Fv-PrP n'a montre aucun liaison k 
ThT pendent plus de 60 h d'incubation k 37°C, l'addition d’AP20187 a Fv-PrP a eu 
comme consequence une augmentation dependante du temps de la liaison de ThT. Dans 
le cas de a-SynFv, la dimerisation a acceldre le taux de formation de fibres amyloi'des 
ainsi que la liaison de ThT en comparaison au taux plus lent d'amyloidogenese de a-Syn 
de type sauvage. L'impact de la dimerisation sur l'agregation de l’a-Syn a ete encore 
davantage dtudie grace la fluorescence de la sonde ANS, indiquant une affinite plus 
elevee entre les agrdgats dimeris^s de a-SynFv et l'ANS comparee aux agregats d’a-Syn 
de type sauvage. Ces resultats indiquent que la dimerisation augmente la vitesse du 
processus d'agregation et d'amyloidogenesis pour Fv-PrP et a-SynFv. De plus, des fibres 
amyloi'des de a-SynFv et Fv-PrP ont ete propagees avec succes in vitro par le cycle de 
'protein misfolding cyclic amplification' (PMCA). Ces resultats sont en accord avec la 
theorie que toute les proteines agregeant dans les maladies neurodegeneratives se 
propagent avec le meme mecanisme moleculaire que celui ayant lieu dans les maladies 
k prions.
La neurotoxicite des agregats recombinants de Fv-PrP et de a-SynFv a ete 
determines dans des cellules en culture et in vivo, respectivement. Les agregats de Fv- 
PrP dtaient toxiques pour les cellules cultivees tandis que Fv-PrP soluble et les fibres 
amyloi'des ne 1’etaient pas. Par ailleurs, une fois injecte dans le cerveau des souris, les
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agregats pre-fibrillaires de a-SynFv et de a-Syn ont ete internalises par les cellules et ont 
induit de la neurotoxicite dans l'hippocampe des souris. Ces agregats recombinants 
toxiques ont ete convertis en fibres amyloi'des non-toxiques qui ont ete amplifiees avec 
succes par la methode de PMCA, foumissant la premiere evidence pour la propagation 
in vitro des agregats synthetiques de l’a-Syn.
Ces resultats suggerent un role important pour la dimerisation des proteines 
dans l’agregation et l’amyloidogendse, et done dans la pathologie de la maladie de 
Parkinson et des maladies a prions. Les similitudes entre l’agregation, l’amyloidogenese 
et la toxicite de PrPc et de l’a-Syn foumissent de nouvelles preuves de l’existence d’un 
mecanisme ’prion-like’ dans toutes les maladies neurodegendratives lides a l ’agrdgation 
proteique.
Mots-cles (7): PrPc, cellular prion protein; PrPRes, protease-resistant prion protein; a- 
Syn, a-Synuclein; Fv, FK506 binding domain; PD, Parkinson’s disease; PMCA, Protein 
Misfolding Cyclic Amplification
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SUMMARY
Neurodegenerative diseases are associated with progressive loss of structure or 
function of neurons which results in cell death. Recent evidence indicate that all 
neurodegenerative disorders, sporadic or transmissible, may have a common 
pathological mechanism at the molecular level. This common feature consists of protein 
aggregation and accumulation of harmful aggregates in neuronal cells resulting in 
cellular apoptosis and neurotoxicity. Neurodegenerative diseases can affect abstract 
thinking, skilled movements, emotional feelings, cognition, memory and other abilities. 
This diverse group of diseases includes Alzheimer’s disease (AD), Parkinson’s disease 
(PD), Huntington’s disease (HD), prion diseases or transmissible spongiform 
encephalopathies (TSEs) and amyotrophic lateral sclerosis.
In my project I worked on the molecular mechanism of protein aggregation, 
propagation and neurotoxicity in Parkinson's disease and prion disease. Prion disease 
and PD are associated with misfolding and aggregation of PrPc and a-Synuclein (a- 
Syn), respectively. Despite being two important neurodegenerative disorders, molecular 
mechanisms of a-Syn or PrPc aggregation and amyloidogenesis are still unclear in PD 
and prion disease. Furthermore, the toxic protein species in PD have not been 
characterized yet. In this study we characterize the mechanism of a-Syn and PrP 
misfolding in a physiological-like cell free condition in the absence of a-Syn 
aggregates, PrP° ggregated isoform (PrP*6*), denaturants or acidic environment.
A number of studies indicate that dimerization of PrPc or a-Syn may be a key 
step in the aggregation process. To test this hypothesis we verified if enforced 
dimerization of PrP0 or a-Syn may induce a conformational change reminiscent of the 
conversion of PrP0 or a-Syn to PrF*** or a-Syn aggregates, respectively. We used a 
well-described inducible dimerization strategy where a dimerizing domain called 
FK506-binding protein (Fv) was fused to PrPc or a-Syn in order to produce chimeric 
proteins Fv-PrP and a-SynFv. A divalent ligand AP20187 was used to induce protein 
dimerization. Addition of AP20187 to recombinant Fv-PrP in physiological-like 
conditions resulted in a rapid conformational change characterized by an increase in
XV
beta-sheet (p-Sheet) structure and simultaneous aggregation of the proteins. However, 
non-dimerized PrP formed p-Sheet conformation in very slower rates. In the presence of 
AP20187, we also report a rapid random coil into P-sheet conformational
Pvtransformation of a-Syn within 24 h, whereas wild type a-Syn showed 24 h delay to 
achieve P-sheet structure after 48 h. Electron microscopy experiments demonstrated that 
dimerization induced amyloid fibril formation after 48 h for both Fv-PrP and a-SynFv, 
whereas in the absence of dimerizing ligand AP20187, PrP or a-Syn converted into 
amyloid fibrils after 3 days or even later. Dimerization-induced Fv-PrP aggregates were 
partially resistant to PK digestion which is a characteristics of the naturally occurring 
PrpRcs j j ie rates o£ amyloidogenesis in the presence of dimerization was also 
characterized by Thioflavin T (ThT) fluorescence probing. Whereas the stable structure 
of Fv-PrP showed no ThT binding for over 60 h of incubation at 37°C, the addition of 
AP20187 to Fv-PrP resulted in a time-dependent increase in ThT binding. As for a- 
SynFv, dimerization accelerated the rate of ThT binding and amyloid formation 
comparing to the slower amyloidogenesis rate of wild type a-Syn in the absence of 
dimerizer AP20187. The impact of dimerization on a-Syn aggregation was further 
determined by Fluorescence ANS probing, indicating a higher affinity of dimerization- 
induced a-SynFv aggregates for binding to ANS comparing to wild type a-Syn 
aggregates. These results indicate that dimerization increases the aggregation and 
amyloidogenesis processes for Fv-PrP and a-SynFv. Both Fv-PrP and a-SynFv amyloids 
were successfully propagated in vitro by protein misfolding amplification (PMCA) 
cycle. These results ar in agreement with the theory that all protein aggregates in 
neurodegenerative diseases propagate with the same molecular mechanism.
Neurotoxicity of recombinant Fv-PrP and a-SynFv aggregates was determined in 
cellulo and in vivo, respectively. Aggregates of Fv-PrP were toxic to cultured cells 
whilst soluble Fv-PrP and amyloid fibres were harmless to the cells. When injected to 
the mice brain, both a-SynFv and a-Syn pre-fibrillar aggregates internalized cells and 
induced neurotoxicity in the hippocampus of wild-type mice. These recombinant toxic 
aggregates further converted into non-toxic amyloids which were successfully amplified 
by PMCA method, providing the first evidence for the in vitro propagation of synthetic 
a-Syn aggregates.
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These results suggest an important role for protein dimerization in aggregation 
and amyloidogenesis, and therefore, in the pathology of PD and prion disease. The 
similarities between aggregation, amyloidogenesis and toxicity of PrPc and a-Syn 
provide further evidence on the existance of a prion-like mechanism in all 
neurodegenerative disorders.
Key words (7): PrPc, cellular prion protein; PrP*65, protease-resistant prion protein; a- 
Syn, a-Synuclein; Fv, FK506 binding domain; PD, Parkinson’s disease; PMCA, Protein 
Misfolding Cyclic Amplification
1INTRODUCTION
1. Protein Conformational Disorders
Protein misfolding has been proposed to be the central aspect of over 40 
diverse diseases which are now classified as proteinopathies or protein conformational 
disorders (PCDs) (O n fe l t  et al., 2004, R a e b e r  et a l, 1992) (C a r r e l l  &  L o m a s , 
1997, H e t z  &  So t o , 2003, So t o , 2001). PCDs include transmissible spongiform 
encephalopathies (TSEs), Alzheimer disease, diabetes type 2 and amyotrophic lateral 
sclerosis, Huntington disease, serpin-deficiency disorders, Parkinson disease or PD, 
amyloid polyneuropathy, haemodialysis-related amyloidosis and several others (SOTO, 
2003). The basic characteristics of all PCDs is misfolding and progressive 
polymerization of otherwise soluble proteins into aggregates and amyloid fibrils and 
accumulation of these aggregated species is a diagnostic feature of PCDs. Deposition of 
these protein aggregates which could be cytoplasmic, nuclear or extracellular (ROSS &  
POIRIER, 2005) can cause cell damage and eventually progressive tissue injury may 
destroy organs and lead to death. One of the important risk factors for PCDs is aging. 
This is because senescent cells have less ability to degrade or remove abnormal proteins 
due to lack of an efficient cellular proteostatic control machinery (CRUNKHORN, 2012). 
One of the important categories of human PCDs are neurodegenerative disorders that 
have received a lot of attention in recent years.
2. Neurodegenerative Diseases
Neurodegenerative diseases (Table 1) are associated with progressive loss of 
structure or function of neurons which results in cell death. Recent evidence indicate 
that all neurodegenerative disorders, sporadic or transmissible, may have a common 
pathological mechanism at the molecular level. This common feature consists of protein 
aggregation and accumulation of harmful aggregates in neuronal cells (Figure 1) 
resulting in cellular apoptosis and neurotoxicity (K a r pin a r  et al., 2009, SANDBERG et 
al., 2011). Neurodegenerative diseases can affect abstract thinking, skilled movements,
2emotional feelings, cognition, memory and other abilities (M a rtin , 1999). This diverse 
group of diseases (Table 1) includes Alzheimer’s disease, Parkinson’s disease, 
Huntington’s disease and related polyglutamine disorders including several forms of 
spinocerebellar ataxia or SCA, TSEs, which include several human and animal diseases, 
and amyotrophic lateral sclerosis (S o t o , 2003). A list of some neurodegenerative 
disorders and implicated proteins in each disease is provided in Table 1.
Disease Clinical
features
Affected brain 
regions
Protein
involved
Alzheimer’s Progressive Hyppocampus, Amyloid-p
dementia cerebral cortex andtau
Parkinson’s Movement Substantia a-
disorder nigra,
hypothalamus
Synuclein
Huntington’s Dementia, 
motor and 
psychiatric 
problems
Striatum, 
cerebral cortex
Huntingtin
Amyotrophic Movement Motor cortex, Superoxide
lateral sclerosis disorder brain stem desmutase
Transmissible Dementia, Disease- Prion
spongiform ataxia, dependent protein
encephalopathies psychiatric
problems,
insomnia
various
regions
Table 1. List of important neurodegenerative disorders and the proteins involved 
in these diseases.
3Neurodegenerative disorders have three causes: first, alterations in the coding sequence 
or in the gene of disease-related proteins resulting in protein overexpression in the 
nervous system or improper folding of proteins after translation (H e l l e r , 2010), 
second, environmental factors such as exposure to toxins can induce cellular stress and 
consequent protein aggregation (T y e d m e r s  et al., 2010) and third, aging is one of the 
factors that can be involved in protein aggregation (D ellin &  COHEN, 2011).
Protein aggregation and pathology are associated in all neurodegenerative 
disorders. In fact, protein aggregation and formation of amyloid inclusions are 
pathological features of neurodegenerative diseases (Figure 1). Neurodegeneration 
results from the formation of oligomeric toxic species formed during protein 
conformational transformation and amyloidogenesis process. Amyloids are insoluble 
fibrous protein aggregates with cross-P structures. Soluble proteins usually transform 
into unstable pre-fibrillar aggregate intermediates which are believed to be neurotoxic. 
These unstable intermediate aggregated species eventually transform into amyloid 
fibrils.
Progression of pathology which occurs during propagation of aggregates and 
amyloid fibrils in the nervous system is another important feature of neurodegenerative 
diseases. Many researchers believe that propagation of protein aggregates in the nervous 
system in all neurodegenerative diseases are similar to prion disease. Recently, 
pathological mechanism of a-Synuclein (a-Syn) aggregation and propagation was 
proposed to be a prion-like mechanism (ANGOT et al., 2010). In this study, we focus on 
the molecular mechanism of protein aggregation and propagation in prion and 
parkinson's diseases.
3. Prion disease
Prion diseases are fatal neurodegenerative disorders of humans and animals 
with no effective therapy available. They are rare neurodegenerative disorders affecting 
~1 person per million world-wide per annum. Despite their rarity, remarkable attention 
has been recently focused on these diseases. This is because of both their unique
4biology and the epidemic importance of a newly recognized bovine prion disease, 
bovine spongiform encephalopathy or 'mad cow disease', that could pose a threat to 
public health through dietary exposure to prion infected meat (COLLINGE, 1997). 
Differing from other neurodegenerative diseases and amyloidoses such as Alzheimer’s 
disease and Parkinson’s disease, prion diseases have a unique feature in that they are 
transmissible among humans and across species.
Alzheimer's plaques Parkinson's Lewy Prion amyloid p laques
Huntington's Amyotrophic lateral
intracellular inclusions sclerosis aggregates
Figure 1. Protein misfolding and accumulation of aggregates and amyloid fibrils in 
brain tissue in the indicated neurodegenerative disorders.
Extracellular amyloid plaques (white arrows) and intracytoplasmic neurofibrillary tangles 
(yellow arrows) are the pathological signature of Alzheimer’s disease. Intracytoplasmic 
aggregates (white arrows) are found in the neurons of people affected by Parkinson’s 
disease and amyotrophic lateral sclerosis. Intranuclear inclusions of huntingtin (white 
arrows) are observed in Huntington’s disease patients and extracellular prion amyloid 
plaques (white arrows) that are located in different brain regions are present in some cases 
of prion diseases. Adapted from Sotto (SOTO, 2003).
5Due to infectious and fatal features, prion diseases have strongly influenced 
medical, agricultural, economic and even political concerns in Europe and even North 
America. Prion diseases include Kuru, Creutzfeldt-Jakob disease (CJD), Fatal Familial 
insomnia (FFI) and Gerstmann-Straussler-Scheinker Syndrome in humans; Chronic 
Wasting Disease (CWD) in deer and elk, scrapie in sheep, and BSE in cows 
(CHAKRABORTY et a l, 2005). Human prion diseases are classified into three groups as 
infectious/iatrogenic, familial/genetic and sporadic and diseases of all three groups can 
be transmitted to primates (B r o w n  et al., 1994).
3.1. Kuru and iatrogenic CJD
The infectious or transmitted group of prion diseases consists of kuru, 
iatrogenic Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD). The identification 
of ritual cannibalism as the mechanism of disease transmission first occurred in 
highlands of Papua New Guinea. Since 1957, 2700  cases of kuru have been recorded 
within the people of kuru region (G a jd u se k  &  Z ig a s , 1957, W il l , 2003). CJD is a 
general term used for human prion diseases. vCJD typically affects younger people less 
than 30 years of age and is associated with eating meat from cows infected with bovine 
spongiform encephalopathy. Transmission of CJD from case to case has occurred by a 
number of routes involving accidental inoculation with human prions, infectious agent 
composed of misfolded PrP protein, as a result of medical procedures. Such iatrogenic 
routes include the use of inadequately sterilised neurosurgical instruments, dura mater 
and comeal grafting, and use of human cadaveric pituitary derived growth hormone or 
gonadotrophin (COLLINGE, 1997).
3.2. Familial/genetic
All inherited cases of prion disease are caused by a range of mutations within 
the open reading frame of the prion protein gene (PRNP) which is responsible for 
expression of PrPc protein. These mutations lead to structural transformation of PrPc 
into PrP80 which is the pathogenic aggregated isoform of PrPc. Some mutations involve
6expansion of the octapeptide repeat region at the N-terminal of PrP. Other mutations 
that have been identified as a cause of inherited prion disease occur at positions 102, 
117 & 198, 178, 200, 210 & 232 (genetic CJD) (G a jd u se k , 1994) and 178 that causes 
fatal familial insomnia (M e d o r i et al., 1992). Genetic prion diseases account for 
approximately 15% of all cases of human prion diseases in humans.
3.3. Sporadic
The sporadic form of the disease, also known as sporadic Creutzfeldt-Jakob 
disease (CJD), or classical CJD, accounts for approximately 85% of all recognised 
human prion diseases. Sporadic prion diseases are not caused by infection and there is 
no association with a mutant PrP allele (Well, 1993). The exact reason for development 
of sporadic CJD in humans is still unknown.
4. CELLULAR PRION PROTEIN (PrPc)
The normal cellular form of PrP which is named PrPc is a membrane 
glycoprotein expressed mainly in cells of the central nervous system but it is also found 
in the tonsils, lymphoid system, blood, peripheral nerves, muscles, spleen, Peyer’s 
patches and appendix (A g u z z i &  H e ik e n w a l d e r , 2006). The nascent PrPc protein is 
expressed as a 254 amino acid protein and multiple transcriptional start sites has been 
identified 140-160 basepairs upstream of the ATG start codon. There are no differences 
in PRNP mRNA expression levels between infected and uninfected brains, or during 
infection. PrP° has an amino-terminal signal peptide and a hydrophobic carboxy- 
terminal domain for membrane attachment via a glycosylphosphatidylinositol (GPI) 
anchor (Figure. 2A). After translocation of PrPc to the endoplasmic reticulum, an NH2- 
terminal signalling peptide including 22 amino acids is cleaved and peptide 231-254 is 
replaced by the GPI anchor by which PrP attaches to the outer-membrane of cell. The 
mature human prion protein has 209 amino acids and depending upon the extent of 
glycosylation molecular mass of PrP varies from 33 to 35 kD (R ie sn er , 2003). (L y s e k
7et al., 2005). PrPc usually binds to membranes by its C-terminal GPI-anchor (S t a h l  et 
al., 1987), and is mostly present in sphingolipid and cholesterol-rich membrane 
microdomains known as detergent-resistant membranes, or lipid rafts (B a r o n  &  
C a u g h e y , 2003).
4.1 PrPc Structure
Three dimensional structure of PrPc has been resolved by solution NMR 
spectroscopy (Z a h n  et a l, 2000). PrPc is composed of two main domains, namely, an 
unstructured N-terminal domain (NH2-PrPc) and a structured globular C-terminal 
domain (Figure 2B). The flexible NH2-PrPC domain (amino acids 23-125) may be 
divided into four different consecutive domains, a first charge cluster or CC1, four 
tandem copies of the octapeptide repeat (OR) with the sequence of PHGGGWGQ , a 
second charge cluster or CC2, and a hydrophobic domain termed HD. The repeated 
amino acids are between residues 51 to 91. These are flanked by one nonrepeat 
(residues 92 to 98; GGGTHNQ) region that could also bind copper (L e l iv e l d  et al., 
2006). The highly conservation of NH2-PrPc domain segments between different 
species is remarkable and would propose functional importance for this PrPc domain 
(B e l a n d  & Roucou, 2011).
The C-terminal domain of PrPc (amino acids 126-231) is entirely structured 
with a globular conformation. The structure composed of three a-helices encompassing 
amino acids 144-154, 175-193 and 200-219. There is a short anti-parallel p-sheet 
comprising the residues 128-131 and 161-164. Within the globular domain, three 
polypeptide segments show increased disordered structure such as a loop of residues 
167-171, the residues 187-194 at the end of helix 2, and the residues 219-228 in the C- 
terminal part of helix 3 (Figure 2B). PrP protein contains a single disulfide bond 
linking Cys residues at positions 179 and 214 within helix 2 and helix 3, respectively. 
Spectroscopic findings showing that PrPc has a secondary structure which contains 
approximately 43% a-helix and is almost devoid of p-sheet conformations (P a n  et al.,
81993). There is no report on the effect of glycosylation on the secondary structure of
C ' pPrP . One possible factor that may bring about some conformational changes of PrP is 
its binding to the membrane lipids (R ie s n e r , 2003).
4.2. Biological function and PrPc interactome
Although the exact biological function of PrPc is still a matter of debate, some 
researchers have tried to find functional links through characterization of the proteins or 
ligands that interact with PrPc. Identification of prion interactome is also important as it 
may show functional differences for PrPc before and after its conversion into an 
infectious agent during prion disease pathology. The octapeptide repeats in the N- 
terminal portion of the protein are Cu2+ binding sites. The NH2 terminal of PrPc has 
been proposed to bind to Cu2+ (Figure 2A) and the copper-PrPc interaction has been 
linked to cellular resistance to oxidative stress (B r o w n  et a l, 2001, St o c k e l  et a l, 
1998). However, the exact biological activity of prion protein is still under debate. 
Concentrations of Cu2+ similar to that in the extracellular spaces of the brain induce a 
rapid internalization of PrPc in neuronal cells (L e e  et a l, 2001, PAULY &  HARRIS, 
1998). The transmembrane LRP1 (LDL receptor-related protein 1) is required for Cu2+- 
mediated endocytosis of PrP , and deletion of the N-terminal octapeptide repeats or an 
insertional point mutation within the repeats results in abolition of this endocytosis 
(Ta y l o r  & H o o p e r , 2007).
Recombinant bovine PrP interacts with the catalytic a/a’ subunits of casein 
kinase 2 (CK2), (M eg g io  et al., 2000). This association stimulates the 
phosphotransferase activity of CK2 and counteracts the inhibitory activity of the CK2a 
subunit. Since CK2 is one of the most pleiotropic protein kinases and is known to 
interact with many proteins involved in different cell functions, particularly in signal 
transduction and gene expression pathways, PrP0 may have the potential to modulate
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Figure 2. PrP0 structure
(A) Schematic representation of PrPc primary structure. Yellow, octapeptide region; 
Red, signal peptide; Orange, C-Terminal fragment which is cleaved and replaced by a 
GPI anchor; SS, disulfide bridge between amino acids 179 and 214. (B) Tertiary 
structure of PrPc (Zahn  et al., 2000).
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numerous cellular activities. Recombinant human PrP has been also used as probe in Far 
Western Blotting to screen for specific ligands in brain extracts from mice and nuclear 
ribonucleoprotein A2/B1 (hnRNP A2/B1)., (S t r o m  et al., 2006). This finding provides 
evidence that PrPc could be involved in nucleic acid metabolism.
PrPc also binds to different neuronal cell adhesion molecules (D u r a n d  et al.) 
that are involved in cell signalling processes. It is known that PrP interacts with and 
sequesters NCAM into lipid rafts, thereby activating the Fyn kinase to induce NCAM- 
dependent neuritogenesis (S a n t u c c io n e  et a l, 2005). This interaction can regulate the 
activity of Fyn kinase which in turn induces intracellular signalling cascades and 
triggers downstream protein-protein interactions.
4.3. PrPSc
PrPSc is a pathogenic abnormal isoform of PrP0 resulting from post- 
translational modifications of PrP° (B o r c h e l t  et al., 1990). According to the "protein- 
only" hypothesis, the infectious agent of all TSEs consists principally, if not entirely, of 
PrPSc. Despite having identical primary structures with identical amino acid sequences, 
PrPc and PrP80 have different secondary and tertiary structures as well as different 
biochemical and biophysical properties. PrPc is mainly a helical protein whereas PrP80 
undergoes conformational transition to give a protein rich in p-Sheet content. After PrPc 
to PrPSc conversion, PrP80 leaves cell membrane and internalize cells by adsorbing into 
endosomal vesicles and accumulate in the lysosomes which contain proteolytic 
enzymes that degrade unwanted entities such as proteins and other cellular components 
(A r n o l d  et al., 1995). Replication and accumulation of PrP8c in the lysosomal 
components can physically damage lysosomes and breakes their integrity which results 
in the mutiple damages into cell by releasing lysosomal degrading enzymes and PrP80 
into cells. This process which can co-occur in many nerve cells can progressively 
destroy brain tissue, giving it an spongiform appearance that characterizes prion 
diseases (Figure 3). Typical neuropathological changes (Figure 3) for prion diseases
11
include vacuolation  o f  the neuropil in  th e  g ray  m atter, synaptic  a lte ra tio n s , p ro m in en t 
neuronal loss, exuberan t reactive astrog liosis and  cereb ral accum ulation  o f  p rio n  p ro te in  
aggregates (B u d k a , 2003).
PrPc is soluble in non ionic detergents whereas PrP50 is insoluble in most 
detergents. PrPc is protease-sensitive and therefore, it is sometimes called PrP5*11 but the 
pathological isoform PrP80 is partially protease-resistant for which it is also called 
PrPRes (Figure 4A). PrP80 resistance to Proteinase K digestion has been a diagnostic tool 
to detect scrapie isoform of PrPc. After digestion with PK, PrPc is completely digested, 
whereas, PrP80 is partially digested and usually a fragment with molecular mass of 27- 
30 kD remains resistance to PK digestion (Figure 4A).
4.3.1. PrPc —► PrPSc Conversion
A high resolution structure of PrP8c is essential to understand the mechanism 
of PrPc —* PrP80 conversion at the molecular level. However, NMR or crystal structure 
has not yet been obtained for PrP80 due to its highly insoluble aggregated structure and 
impure or low yields of scrapie purifications from infected brains. The only well 
defined mechanistic issue is that interaction of PrP8c with soluble PrP° is essential for 
the conversion and replication of PrP80 in brain tissue (P r u sin er  et al., 1990). 
Mutations in the PRNP gene in the inherited prion diseases can lead to expression of 
PrPc proteins with susceptibility to convert into PrP80. Also, PrPc can be spontaneously 
converted into PrP80 in an sporadic manner and this happens in more than 85% of CJD 
and some cases of GSS (P r u sin e r , 1998). PrP retrogradely transported out of the 
endoplasmic reticulum produce both amorphous aggregates and a PrPSc-like 
conformation in the cytosol (M a  &  L in d q u is t , 2002). It has been proposed that the 
efficiency with which PrP° converts to an insoluble, PrPSc-like form depends upon the 
degree of mistargeting of PrPc and cellular retrograde transport of PrP80 that can further 
induce more accumulation of PrP80 in cells. For sporadic diseases this may happen 
through spontaneous misfolding events, that may be increased through fluctuations in 
the glycosylation and oxidative potential of the cell.
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PrP^ Synaptic and Spongiform Brain Neuronal
Deposition dendritic lost degeneration inflammation death
Prion
infected
Control
Figure 3. Multiple neurodegenerative pathways are implicated in TSEs.
PrPSc deposition determined after immunohistochemical staining with anti-PrP 
antibodies (black arrowheads). Dendrites are labeled by Golgi-silver staining to 
illustrate the substantial decrease on dendrites and synaptic connections in prion- 
infected animals. Spongiform degeneration is characterized by hematoxylin and eosin 
staining. Astrogliosis (brain inflammation) is detected by immunohistochemical staining 
of reactive astrocytes. Apoptosis was detected by staining with caspase-3 antibody (red 
indicated by white arrowheads) and DAPI staining of nucleus. Adapted from Soto et al. 
(2011).
111 1 1■■■
13
For inherited diseases PRNP mutations may increase the likelihood of the 
initial misfolding and PrP80 formation processes that can also initiate the quality control 
retrograde transport mechanism involved in cellular accumulation of misfolded PrP80 
(Ma & L in d q u is t , 1999). Another cellular mechanism that may be involved in PrP80 
formation/accumulation is proteosomal degradation system. When proteasome activity 
is blocked, PrP accumulates in the cytosol (M a  & L in d q u is t , 2001). In the events that 
population of PrP molecules delivered to the cytosol exceeds its quality-control 
capacity, some PrP might convert to a PrPSc-like insoluble and partially PK-resistant 
form (M a  &  L in d q u is t , 2002). It is also known that under conditions of proteosome 
inhibition, cytoplasmic forms of PrP aggregates are associated with neurotoxicity such 
as aggresomes (Kr ist ia n se n  et al., 2005). However, cytoplasmic PrP aggregates are 
different from PrP80 since they are not infectious.
4.3.2. Mechanisms of prion conversion
The first hypothesis about how prions replicate in a protein-only manner is the 
'heterodimer model' (Figure 5A). According to this model the PrP8c is propagated due 
to its ability to form dimers with PrPc so that PrP8c serves as a template in converting 
PrPc to a diseased form during the dimerization process. The heterodimer model 
proposes that PrP80 can exist in monomeric forms. Spontaneous transition PrPc —► PrP80 
is unlikely due to a high energy barrier. As a result of PrP0—► PrP8c conversion, 
homodimers PrP8c/PrP8c are formed, which may upon infection of an appropriate host 
cell, the incoming PrP8*1 starts a catalytic cascade using PrP° or a partially unfolded 
intermediate arising from stochastic fluctuations in PrP° conformations as a substrate, 
converting it by a conformational change into a new p-sheet-rich protein. The newly 
formed PrP80 will in turn convert new PrPc molecules into pathogenic conformations 
(Figure 5A). According to the heterodimer model, initial physical interaction of PrP0 
with PrP80 is essential for PrPc —► PrP80 conversion (P r u s in e r , 1991). Formation of an 
aggregated form of the protein is not obligatory for prion conversion and is considered 
as a secondary process, not associated with initial conformational rearrangement of
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Figure 4. Comparison of PrP0 and PrP8^  structures
(A) Primary structure of PrP° before and after post translational modifications and 
comparison of protease sensitivity between PrP and PrP80. (B) Three-dimensional 
models of PrPc (right) and PrP80 (left) structures (H u a n g  et al., 1995).
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prion. Aggregates of PrPSc account for further propagation across the cells of nervous 
tissue.
A modified version of heterodimer model which counts for spontaneous 
conversion of PrPc —> PrPSc is called 'template assisted model (C o h e n  &  P r u s in e r , 
1998). This model (Figure 5B) postulates that there is a substantial energy barrier 
between PrP80 and PrPc and the high barrier prevents formation of PrP80 under normal 
steady conditions. However, the process of conversion can be facilitated by exogenous 
administration of PrP80 or involvement of other cellular factors such as chaperones. 
According to this model PrP° exists in equilibrium with a transient conformational 
intermediate (named PrP*), which, after interaction with a cellular chaperone (protein 
X), is able to heterodimerize with PrP80. Spontaneously, this heterodimer is converted 
into a PrP80 homodimer, consisting of the old and newly formed PrP80 molecules (S o t o  
&  S a b o r io , 2001).
The third model for prion conversion is 'nucleation-polymerization' model 
(B r o w n  et al., 1991, H a r pe r  &  L a n s b u r y , 1997). In this model the conformational 
change of PrPc into PrPSc is thermodynamically controlled: PrPc and PrP80 coexist in a 
thermodynamic equilibrium and the conversion is a reversible process based on an 
equilibrium that strongly stabilizes the native conformation of PrPc (Figure 5C). 
Converted PrP80 is stabilized only when it interacts with a fibril-like seed or aggregate 
of PrP80. This is because PrP80 monomer is unstable and becomes stable upon 
aggregation with other PrP80 molecules. PrP8° aggregates promote the conversion of 
PrPc by binding to the monomeric PrP80 and displacing the equilibrium toward 
formation of the pathological conformer. In this model the infectious agent is a 
multimeric, highly ordered aggregate of PrP80 and the rate-limiting step is the formation 
of a nucleus that acts as a seed for further stabilization of PrP80. Once a seed is present, 
further monomer addition is accelerated (So t o  &  S a b o r io , 2001) (Figure 5C).
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Figure 5. Prion conversion models.
(A,B) Homodimer formation and template-directed assistance models postulate an 
interaction between exogenously introduced disease-associated prion protein (PrPSc) and 
endogenous cellular prion protein (PrPc), which is induced to transform itself into more 
PrP50. A high-energy barrier might prevent the spontaneous conversion of PrPc to PrP50. 
However, the presence of protein X can facilitate the conversion. (C) The ‘seeding’ or 
nucleation-polymerization model proposes that PrPc and PrPSc are in a reversible 
thermodynamic equilibrium. So, only if several monomeric PrPSc molecules are 
mounted in a highly ordered seed can more monomeric PrP50 be recruited and 
eventually aggregate to form amyloids (A g u z z i &  S ig u r d so n , 2004, S o t o , 2004).
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4.3.3. Ultrastructure of PrP^
Secondary structure studies by fourier transform infrared (FTIR) spectroscopy 
have shown that PrP50 has around 43% P-Sheet and 34% a-helix comparing to PrPc 
which displays an entirely helical structure with 43% a-helix and less that 3% P-Sheet 
component (Pa n  et a l, 1993). Based on an approach that combines computational 
techniques with experimental data, a three dimensional model of a biologically 
important fragment of PrPSc (residues 108-218) has been also proposed (Figure 4B), 
(H u a n g  et al., 1995). Recent studies demonstrated that there is a complete a-helix —* P 
Sheet conformational transformation during PrP to PrP conversion and PrPSc is 
exclusively composed of P-Sheet structure (Sm ir n o v a s  et al., 2011). After prion 
conversion, PrP50 accumulates in cells in different forms such as aggregates and 
amyloid fibrils (Figure 6A). One of the main challenges in understanding the molecular 
mechanism of prion disease is to find effective biophysical approaches to characterize a 
high-resolution structures of noncrystalline fibrillar structure of PrPSc. Studies on highly 
purified preparations of PrP80 from infected brains have characterized amyloid-like 
structures formed from prion aggregation during disease (M e r z  et al., 1981, P r u s in e r  
et a l, 1983). Visualization of the protein core of wild-type prion fibrils can be obscured 
by heavy glycosylation and GPI anchors. Therefore, a research group recently purified 
unglycosilated and anchorless PrP50 amyloids from the brain of transgenic mice 
expressing such prions (S im  &  C a u g h e y , 2009). These fibrils are composed of 
protofilaments 3.0-3.5 nm in width as measured by negative-stain transmission electron 
microscopy (Figure 6A).
The protofilament widths and twist periodicities can vary significantly with 
scrapie strain, indicating strain-dependent fibril ultrastructures. This expands the list of 
strain-dependent features of PrP80, which includes secondary structures, proteolytic 
sensitivities, glycoform patterns, stabilities, and conformational templating activities 
(Ca u g h e y  et a l, 2009).
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Recently, infectious PrP80 preparations were structurally characterized by 
electron crystallography and two-dimensional crystals that appeared along with fibrils 
were analysed (WiLLE et al., 2002) (Figure 6B). This study demonstrated a hexagonal 
lattice of prion amyloids (Figure 6B). Image processing and electron crystallography of 
these structures revealed that they were likely composed of PrP trimers and on the basis 
of molecular modeling and mutational analyses, a P-helix model was proposed 
(G o v a er t s  et al., 2004) (Figure 6 C,D). In this model, a flexibly disordered domain 
and helix 1 of PrPc are coiled into a P-helix, which then aligns with the p-helices of two 
other PrP80 monomers to form a trimer. N-linked glycans are displayed on the outside of 
the trimer (C a u g h e y  et al., 2009). To initiate a fibril, two trimers could assemble by 
hydrogen bonds linking the top of one a-helix and the bottom of the next layer of PrP 
27-30 (Figure. 6E). As shown, the C-terminal a-helices can easily stack in a fashion 
that allows the sugar moieties to point away from the trimer. The result of this head-to- 
tail arrangement is an oriented fibril (Figure. 6F). In general, amyloids are introduced as 
protein aggregates with a P-sheet secondary structure and cross-P X-ray diffraction 
pattern that can be easily stained with Congo red and Thioflavin S and T.
Apart from amyloid fibrils, other structures of PrPSc have been also observed in 
prion infected brain tissues. PrPSc of scrapie-effected sheep is associated with 
endosomes, lysosomes, plasma membranes of neurons and glia. Electron and light 
microscopy experiments demonstrate that these ultra-structures of PrPSc, which are 
associated with cell membranes and abnormal coated pits and vesicles, may have 
diffuse granular or punctate patterns (Je ffr e y  et al., 2009). It is believed that GPI 
anchor can play an important role in morphology of PrP510 plaques as well as in the 
cellular localization of aggregated prion. In fact, amyloid fibrils are predominantly 
diagnosed in pathology of human diseases such as kuru and GSS. For example 
Mutations in human PrP leading to C-terminally truncated polypeptides lacking the GPI 
signal sequence, which cause the inherited prion disorder GSS disease, are known to 
result in the production of secreted, highly amyloidogenic forms of PrP (G h e t t i et al.,
2003). In animals, when transgenic mice expressing anchorless (GPO PrPc are infected 
with prion scrapie, PrP80 accumulates almost exclusively in prominent extracellular
Figure 6. Ultrastructures and models of PrP"* fibrils
A) Negative-stained transmission electron micrographs of proteinase K-treated wild- 
type or GPI-anchorless PrP1** amyloid fibrils. (B) Electron micrographs and 
crystallographically refined images of hexagonal two-dimensional (2D) crystals and of 
proteinase K-treated PrP"*. (C) Model of PrPSc. (D) (i-helical model of PrP50 trimeric 
structures. (E) Two discs of PrP 27-30 can assemble through polar backbone 
interactions between the lower P-helical rung of the top disk and the upper rung of the 
bottom disk. This assembly provides enough room for the a-helices to stack and the N- 
linked sugars to extend away from the center of the structure. (F) A model for the PrP 
27-30 is constructed by assembling five trimeric discs. Figures are adapted from 
Caughey et al., and Govaerts et al.,(C a u g h e y  et al., 2009, G ova erts  et al., 2004).
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am yloid  p laques tha t assem ble  around  b ra in  vessels (CAUGHEY et al., 2009 , CHESEBRO 
et a l, 2005).
Studies have reported that the pathogenic protein aggregates are the non- 
fibrillar oligomeric species of distinct morphology (protofibrils) preceding mature 
fibrils in the aggregation pathway. The earliest protofibrils typically appear as globular 
assemblies 2.5-5 .0  nm in diameter spontaneously organizing into chains and variously 
sized rings comprising small doughnuts with a central pore, further organising into 
ribbons, protofilaments and mature fibrils (HOSHI et al., 2 003 , Relini et al., 2004).
4.3.4. In vivo and in vitro propagation of PrP80
One of the important aspects of prion disease is the transmissibility of 
infectious prions within cells of brain tissue and across the different species. In fact, 
transmission of pathology throughout the central nervous system (CNS) is associated 
with propagation of PrPSc aggregates and amyloid fibrils in brain tissue. Therefore, 
characterization of PrP80 propagation through the nervous system is essential to 
understand the mechanism of prion pathology. It is also important to describe peripheral 
routes of PrPSc transmission before reaching the CNS.
4.3.4.I. Prion replication in peripheral organs
In acquired prion disease, neuroinvasion usually starts by ingestion of the 
PrpSc passage 0f prion through the protective intestinal epithelium cells occurs 
through an as yet unknown mechanism. It is proposed that PrP80 is first taken up by the 
migratory dendritic cells, the cells that directly interact with antigens within the 
intestinal organ. In the next step, PrP80 is phagocytosed by cells containing antigens 
such as macrophages and dendritic cells. PrP80 may be obsorbed by macrophages or 
dendritic cells. Whereas macrophages can degrade and remove PrP80 (M a b b o t t  &  
M a c P h e r s o n , 2006), dendritic cells can transport PrP80 to follicular dendritic cells
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(FDCs) which reside in the primary B-cell follicles and germinal centres of lymphoid 
tissue. One theory proposes that PrPSc is delivered by dendritic cells into B-cell follicles, 
where FDCs can internalize PrP50 (MABBOTT &  MACPHERSON, 2006). PrPc expression 
is essential for sustaining TSE infectious and therefore, FDCs which express high levels 
of PrPc (Br o w n  et al., 1999) are good sites of prion replication and accumulation. 
Prions replicate in lymphoid organs during the early stages of infection (H il l  et al., 
1997) and at least one PrP-positive (PrP+) tissue is needed before reaching the CNS. 
After incubation in lymphoid tissue such as spleen, prions spread to CNS via the enteric 
nervous system (Figure 7).
4.3.4.2. PrPSc transmission within neuronal cells
In order for PrPSc to promote pathology throughout the brain tissue, four basic 
requirement must be met. First, the prion aggregates must polymerize and amplify 
themselves by recruiting and converting soluble PrPc, as discussed above, and then 
fragment to generate additional conversion sites to amplify aggregation/polymerization. 
Second, expression of native soluble PrPc molecules by infected cells is essential to 
provide enough substrate for prion conversion process. In the absence of PrPc, PrP80 
cannot be generated and PrP-null mice do not propagate infectivity or develop 
pathology on infection with scrapie (B u e l e r  et a l,  1993, Sa iler  et al., 1994). Third, 
the prions must be released from cells. Fourth, aggregates must be able to bind and enter 
recipient cells.
4.3.4.3. Prion uptake and release by cells
Recent studies on neuronal cell lines have demonstrated that cells can 
internalize PrP80 aggregates into vesicles positive for markers of late endosomes and/or 
lysosomes but not synaptic, early endocytic, or raft-derived vesicles (M a g a l h a e s  et al., 
2005). Control experiments demonstrated that in these cell lines receptor- and lipid raft- 
mediated endocytotic pathways were operative, but the lack of co-localization of early
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endosomes and lipid raft markers with PrP50 suggested that these pathways might not be 
responsible for most exogenous PrP50 internalization. Therefore, it was proposed that
CNS
Injested
prion
Blood streal 
P lasm inogen?
PrPVPrP
Lymphotoxin B
S
GULT
Blood stream  
Plasminogen?
M
Spleen and  
o th e r  
lymphoid 
organs
PrP+
SNS
N eurons
Payer's patches
Spinal cord
Figure 7. PrP^ transmission from peripheral organs to CNS
After absorption through the intestinal epithelium, prions reach the peyer’s patches, via 
blood constituents (Plasminogen that bind to PrP80). Follicular dendritic cells (FDCs) 
are infected in the patches and in other lymphoid organs, including the spleen. In the 
lymphoid tissues, early accumulation of PrPSc occurs within the germinal centers of B 
cell follicles on FDCs. Prions can also reach the spleen by a B-cell independent route 
involving complement factors. Other factor that is required for spreading infection to 
the CNS is lymphotoxin (stimulus for FDCs). Adapted from (PANDEYA et al., 2010).
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exogenous PrP80 could be possibly taken up by a relatively nonselective process such as 
macropinocytosis or absorptive pinocytosis. Macropinocytosis occurs in many cell 
types and results in the delivery of internalized substances to acidic late endosomal or 
lysosomal organelle (M a g a lh a e s  et al., 2005).
In neuroblastoma cells, PrPc is known to reside in the Golgi apparatus, on the 
plasma membrane, and in early and recycling endosomes (Bo r c h e l t  et al., 1990, 
P r a d o  et al., 2004). In scrapie-infected cells, PrPc is converted to PrPSc after transport 
to the cell surface but before degradation in lysosomes (C a u g h ey  &  R a y m o n d , 1991). 
Therefore, interaction between PrP° and exogenous PrPSc for conversion should happen 
on the cell membrane or along an endocytic pathway to lysosomes. However, more 
experimental evidence is needed to characterize the exact site(s) of prion conversion 
after PrP80 infection of cells (Go o l d  et al., 2011).
Cells can release aggregates either by a vesicle-mediated exocytic process or 
by lysosomal exocytosis (Ja isw a l  et al., 2007, V o g ia t z i et al., 2008). In certain cell 
types, endosomal multivesicular bodies may fuse with the cell surface in an exocytic 
manner. During this process, the small 50-90-nm-diameter vesicles contained in their 
lumen which are called exosomes are released into the extracellular environment 
(Fe v r ie r  et al., 2005). Recent findings have implied an unexpected role for exosomes 
and their mode of membrane exchange in the transmission of PrPSc (F e v r ie r  et al., 
2004). It has been proposed that multivesicular bodies (MVBs) which fuse to pre­
existing lysosomes to degrade their contents (F u t t e r  et al., 1996, Luzio et al., 2001), 
may internalize and transfer PrP80 to the cell membrane. MVBs containing PrP80 are 
then fused with the cell membrane and PrP80 is released from cells in vesicular 
exosomes. Exosomes are also a way for transporting proteins, lipids or pathogenic 
agents between cells (F ev r ie r  &  R a p o s o , 2004, P o r n il l o s  et al., 2002). Therefore, 
PrP8e-containing exosomes may fuse to the membrane of adjacent cells, thereby starting 
a new endosomal pathway in the newly PrP8c-infected cell (Figure 8A).
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Tunneling nanotubes (TNTs) are a newly described cell-cell communication 
system allowing the transfer of molecular signals between cells, such as calcium fluxes 
(O n f e l t  et al., 2005), membrane components (O n f e l t  et a l, 2004), organelles such as 
mitochondria and even pathogens such as viruses and bacteria (Ko y a n a g i et al., 2005, 
O n fe l t  et al., 2006, S o w in sk i et al., 2008). Recently, it has been described that prions 
can be transferred from cell to cell through TNTs (G o u s s e t  et a l, 2009) (Figure 8B). 
This finding proposed a possible mechanism by which PrP50 could travel, following 
ingestion, from the gut to the central nervous system where it causes disease. In 
addition, it has been shown that PrPc induces TNT formation, probably through a 
receptor independent mechanism. The effect of PrPc on TNT formation can explain why 
PrPc overexpressing mice show a reduced incubation time after oral infection with 
prions as compared to wild type mice (P r u s in e r , 1998). Part of this early onset in the 
disease can be attributed to an increase in substrate reservoir available for PrPc to PrP80 
conversion process in those mice, even if the amount of PrP80 aggregates in the brain 
cannot be directly correlated to the disease state. Another possibility would be that a 
facilitated formation of TNTs in those transgenic mice could induce a more rapid 
transfer of prions to the CNS, and an increased spreading within the brain itself, thus 
explaining the early onset of disease.
Regardless of the pathway mechanism underlying PrPSc transfer across the 
neuronal cells, the interaction of PrP80 with PrPc must occur to promote PrP8c 
conversion and propagation. Many research groups have focused their studies on the 
characterization of the molecular mechanism of prion conversion/propagation as this is 
fundamental for understanding the process of PrP80 propagations over cells and tissues 
of the CNS. Recent studies have developed in vitro conversion assays for a detailed 
characterization of prion conversion/amplification. Therefore, in the next section, in 
vitro methods for PrP80 generation and amplification will be described.
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Figure 8. Intercellular transmission of PrP^
(A) Schematic representation of exosome release from scrapie-infected cells and 
exosome targeting to recipient cells. PrP80 (red) transits through endocytic 
compartments of an infected cell (gray) and exits cell through exosomes. The secreted 
exosomes fuse with membrane (1) of noninfected cells (yellow) and induce conversion 
of PrPc at the plasma membrane. Internalized PrP80 (2) goes to endosomes (3) and is 
routed to MVBs (4,5). Alternatively, PrP8c-exosomes internalize by the non-infected 
cells (1', 2') before being transferred to endosomes (3'). The newly endocetosed 
exosomes then fuse with the MVB membrane (4'). In this process, PrP80 is incorporated 
into the limiting membrane (5'), allowing conversion of PrPc in he endocytic pathway.
(B) PrP80 (green) can transfer within cells through tunneling nonotubes. Adapted from 
Fevrier et al., (F ev r ie r  et al., 2005).
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4.3.5. In vitro conversion/propagation of prions
Several biochemical in vitro conversion assays have been developed to study 
the requirements for the conformational conversion of PrP0 into PrP^. The task of 
recreating prions in a test tube is immensely challenging, but benefits from research in 
this area include better understanding the mechanisms of prion diseases and providing 
insight into physiological conditions affecting disease events. The first experiments of 
mimicking prion conversion via an in vitro assay was done in 1992 (R a e b e r  et al., 
1992). Attempts were made to convert chimeric mouse/hamster PrPc expressed in N2a 
cells or metabolically labeled PrPc of neuroblastoma cells infected with PrPSc (ScN2a 
cells) in the presence of either exogenous or endogenous PrP80 by incubating overnight. 
Although these experiments failed to efficiently convert PrPc to a protease-resistant 
PrPSc form, new methods and ideas were provided which founded the development of 
subsequent in votro assays which could efficiently convert and propagate prions in a 
cell free conversion systems.
4.3.5.I. Cell-free conversion assay
The first successful cell-free conversion assay for prions was established in 
1994 (K o c isk o  etal., 1994). The cell free conversion assay was composed of 
GdnHCl-treated PrPSc purified from prion-infected brains and radio-labeled PrPc from 
mouse fibroblast cells to measure the conversion of PrPc to PrPSc. The stoichiometry of 
the assay was established so that PrPSc needed to be in excess of PrPc, (i.e., 50 times 
more PrP50 than PrP0) in order for a minimal amount of conversion to occur; 
approximately 10-20%, as measured by autoradiography (R you &  M a y s , 2008). In 
1999, Saborio et al.(Sa b o r io  et al., 1999) attempted to establish a cell-free conversion 
assay using purified substrate (i.e., purified PrPc and PrP8*), but were unsuccessful to 
reproduce PrP811. Conversion was only possible when cell components were not purified 
and remained in a cell lysate form. This represented an improvement for in vitro cell- 
free conversion assays since PrP80 was required in only 10 times excess of PrPc
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(S a b o r io  et al., 1999).This finding underscored the necessity of unidentified factors 
required for the conversion process.
Another in vitro assay was established in 2005 and termed assay of ACC or 
‘autocatalytic conversion’ (B a s k a k o v  &  B o c h a r o v a , 2005). ACC uniquely involves 
the re-folding of denatured recombinant PrP (rPrP) in the absence of PrP50 (B a s k a k o v ,
2004). Urea or GdnHCl are used to denature rPrP, while continuous shaking induced the 
folding of the 6-oligomers into amyloid fibrils (B a s k a k o v  et al., 2002, B a s k a k o v , 
2004, B o c h a r o v a  et al., 2005). The formation of amyloid fibrils can be monitored by 
fluorometry and the conversion rate depends on a number of parameters (i.e., pH, 
concentrations of urea). The advantages of this assay include, the presence of a disulfide 
bond in rPrP, which closely resembles the native state of prions, along with the 
complete elimination of both the cellular substrate (PrPc) and infectious seed (PrPSc), 
making it a good system to study the aspects of spontaneous disease.
These in vitro systems are currently not fully trusted as they require PrPSc in 
excess of PrPc (cell-free conversion, cell lysate conversion assay) which is 
contradictory to the mechanism of prion pathology. More importantly, none of these 
tools have been shown to conclusively amplify the infectious form of the prion protein.
4.3.S.2. Protein Misfolding Cyclic Amplification (PMCA
The PMCA assay has emerged as a novel technology that uses PrP80 as a 
template for propagating the misfolding of native PrPc from brain homogenates using a 
series of incubation and sonication or agitating cycles (A t a r a sh i et al., 2008, C a s t il l a  
et al., 2005, C a still a  et al., 2005, So t o , 2002).The first essential requirement of 
PMCA is a source of native soluble PrPc to be used as the substrate to proceed the 
conversion reaction. The PrP source is typically crude brain homogenates. Difficulty in 
obtaining consistent and reproducible amplification in some prion disease models has 
been overcome with the use of transgenic mice as a source of PrPc. The second 
requirement for PMCA is a ‘seed’ or ‘PrP^ infectious unit’ to trigger the misfolding
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chain reaction. The PrPSc template is usually homogenate from infected brain of the 
same species (i.e., use of hamster brains as a PrP source for amplification of hamster 
263K scrapie) or infected tissues, fluids or environmental samples containing infectious 
prion particles. Third, PrPc and PrPSc must be incubated in a stable condition at 37 °C 
(Lu c a sse n  et al., 2003). Finally, an important element in PMCA assay is sonication or 
agitating samples. The purpose of sonication/agitation is to disrupt aggregates of PrP8® 
after being formed during incubation. Bursts of sonication or agitation stress break up 
aggregates or PrP80 seeds to provide additional ‘seeds’ or conversion sites that are able 
to recruit and convert more molecules of PrPc into PrP80. The PMCA assay also 
requires a minimum infectious unit that amplifies PrPSc without a reduction in 
infectivity, and for which the size of PrP80 aggregates that are generated correlate with 
animal infectivity (B ie sc h k e  et al., 2004, P ie n in g  et al., 2005, W e b e r  et al., 2006).
Briefly, PMCA assay composed of a mixture of prion-infected brain 
homogenate is diluted in a >1000 fold excess of normal, uninfected brain homogenate 
following by lh incubation at 37 °C to allow the amplification of PrPSc (Figure 9). 
According to the original protocol, at the end of incubation time samples undergo 
consecutive sonication pulses. Incubation facilitates conversion and aggregation of PrP 
isoforms, while sonication multiplies the number of small aggregates available to induce 
PrPSc conversion (R y o u  &  M a y s , 2008). After sonication, aliquots from newly formed 
PrPSc samples are taken and diluted (1/1000 in brain homogenates containing excess 
amounts of soluble PrPc and the same incubation/sonication period is repeated. It is 
important to state that in the subsequent PMCA cycles the quantity of initially added 
PrP80 from infected brain used in the first cycle becomes negligible due to successive 
1/1000 dilutions. Therefore, PMCA assay is able to induce de novo generation of 
infectious PrP80 aggregates (Figure 9).
4.3.S.3. PMCA as a tool for PrP80 diagnosis
To date, PMCA has been known as the only in vitro assay capable of efficient 
conversion of cellular prion to infectious PrP80 in limiting quantities. PMCA can be also
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used for diagnostic purposes. The PMCA method has been used to successfully detect 
prions in the buffy coat layer of blood collected directly from the heart of a scrapie- 
infected hamster at an advanced stage of disease (C a s t il l a  et al., 2005). The most 
significant advantage of the PMCA assay over other assays, is its level of sensitivity, 
being able to amplify -26 molecules of protein monomers (i.e., 1 x 10'12 dilution) of 
scrapie hamster brain to detectable levels by western blot after 7 rounds of PMCA (S a a  
et al., 2006). Moreover, it is the only in vitro assay that has been confirmed to generate 
infectious prion units.
4.3.5.4. PMCA under non-denaturing conditions
One of the critics of PMCA protocol was the use of denaturing conditions such 
as sonication or involvement of anionic detergents such as sodium dodecyl sulfate 
(SDS). These conditions may potentially denature cellular protein factors and alter the 
normal biochemical processes involved in the prion conversion pathway (L u c a s s e n  et 
al., 2003, R y o u  &  M a y s , 2008). In 2004 Supattapone et a l, (Su p a t t a p o n e , 2004), 
attempted to set up a PMCA assay under non denaturing conditions. In this assay the 
sonication step had been replaced by agitating the samples. The assay was performed 
using a dilution factor of 1:50 of 10% infected brain homogenate into ormal brain 
homogenate. The conversion reaction was allowed to proceed by incubating samples for 
48 h in the shaking condition at 37 °C. Incubation time and temperature play essential 
roles in this assay. For example, conversion reactions incubated at 16 h produced 6-fold 
increase of PrP*** production compared to the initial PrPSc seed, whereas, in 48 h 
conversion reactions about 10-fold increase was observed in PrP116* levels compared to 
the initial PrP80 seed concentration used in the assay. As for the temperature, more de 
novo PrP1*68 was generetated in the assays done at 37 °C comparing to those assays that 
were done at 25 °C and 4 1.Although this assay conserved all the biological properties 
on prion conversion reaction, the rate of prion amplification is very low comparing to 
the conventional PMCA Therefore the usefulness of PMCA under non-denaturing 
conditions has been restricted to the identification of cellular co-factors involved in the
PrpSc conversion.
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Figure 9. PMCA assay
Conversion/elongation phase: PrP80 is incubated with higher quantities of PrPc to allow 
prion conversion at 37 “C. Fractionation phase: at the end of incubation time, newly 
polymerized PrP50 samples are subjected to sonication or agitation. This will help to 
break elongated aggregates into smaller sizes to provide new conversion sites or 'seeds'. 
Newly generated aggregates are then used to start another conversion/elongation cycle 
in the presence of soluble PrPc proteins.
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4.3.5.5. Recombinant PMCA (rPMCA) assay
The PMCA was recently modified by Caughey and colleagues so that 
bacterially expressed recombinant PrP was used as soluble monomeric substrate to 
amplify PrP1*65 and the method was named rPrP-PMCA or simply rPMCA (A t a r a s h i et 
a l, 2007). Due to its high sensitivity resulting from precise quantification of soluble 
rPrP substrate, rPMCA can be used for both PrP1*65 amplification and diagnostic 
purposes. rPMCA allows amplification of PrP1*6* from either crude infected brain 
homogenate or purified PrP80 from infected brains. One advantage of this method is that 
the amplified PrP1*6* is distinguishable from the other species of rPrP1*6* formed 
spontaneousely by rPrP self-aggregation due to the molecular size differences. (R y o u  &  
M a y s , 2008). The rPMCA assay was successfully applied to detect PrPSc in cerebral 
spinal fluid (CSF) of animals at the terminal stage of disease but the increase of PrPSc 
was not quantified for the experiment. A more advanced rPMCA method termed 
‘quaking-induced conversion’ or ‘QUIC’ method, replaces the sonication steps of 
rPMCA with automated tube shaking to achieve similar, yet more reproducible levels of 
conversion than rPMCA (A t a r a sh i et al., 2008). The QUIC PMCA has been applied to 
sheep brain derived PrP80, and was able to distinguish between infected and uninfected 
sheep via amplification and detection of PrP8c in CSF in less than 24 hours.
These modifications to conventional PMCA use a more reliable and available 
PrP substrate, report greater simplicity and ease of duplication, however, rPrPRes 
generated from rPrP-PMCA or QUIC have never been tested in vivo for the infectivity 
(R y o u  &  M a y s , 2008).
4.4. Possible cellular factors involved in prion conversion
Some researchers have proposed the presence of co-factors in conformational 
conversion of PrP. In gonadotropin-releasing hormone (GnRH) neuronal cells (GT1 
cells) infected with Chandler scrapie strain, the laminin receptor or its precursor are
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crucial co-factors for PrPSc formation. Although it is unclear how glycosaminoglycans 
(GAGs) contribute to PrPSc biogenesis, cell surface GAGs might bind to both PrPc and 
PrPSc to generate PrPc to PrPSc conversion ( K r a m m e r  et al., 2009, L e e  et al., 2007).
Another evidence on the involvement of co-factors in the conversion process 
emerged from PMCA studies in which purified hamster PrPc is converted when added 
brain homogenate to the sample but not converted when mixed with highly purified PrPSc 
( A b i d  et al., 2010, S A B O R I O  et al., 1999). These results suggest that unknown factors in 
brain homogenate are essential for prion replication. Also there is evidence for involvement 
of nucleic acids such as RNA in prion replication ( D e l e a u l t  et al., 2003, D e l e a u l t  et al.,
2010). Supattapone’s group has shown that natural or synthetic RNA can act as conversion 
factors and catalyze prion replication in hamsters but not in mice and the negative charge of 
RNA is responsible for the interaction with PrP ( D e l e a u l t  et al., 2005). In addition, 
synthetic anionic phospholipids are required for PrP80 replication ( W A N G  et al., 2010) and 
higher infectivity was reported with lipid membrane-associated PrPSc ( B a r o n  et al., 2006). 
However, treatments that eliminate nucleic acids, lipids, or proteins do not prevent prion 
replication in vitro. Indeed, the addition of various classes of molecules (synthetic nucleic 
acids, heparin, albumin or fatty acids) produces a small but detectable effect on enhancing 
prion replication in vitro, suggesting that various different compounds might act as a 
conversion factor in vitro, that elimination of only some of them does not prevent prion 
replication ( A b i d  et al., 2010, S o t o ,  2011)
PrP0 is a protein expressed in neurons and various other cell types and diverse 
activities and ligands have been described for PrP0 ( C a u g h e y  &  B a r o n ,  2006, M a r t i n s  et 
al., 2002, R O U C O U  &  L e B l a n c ,  2005, W a t t  &  H o o p e r ,  2003). These ligand may also act 
as cofactors in prion replication process. At least five different scenarios can be proposed 
for the involvement of cellular co-factors in prion propagation, (i) The co-factor might 
integrate into the infectious agent, alter PrP80 folding, and provide biological information to 
the infectivity process, perhaps by determining strain characteristics, (ii) The co-factor 
might act as an essential catalyst for prion replication, perhaps by interacting with PrPc, 
altering its folding, and permitting its interaction with PrP80. (iii) Through binding and
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i n t e g r a t i o n  i n t o  t h e  P r P 80 p o l y m e r ,  t h e  c o - f a c t o r  m i g h t  h e l p  t o  s t a b i l i z e  t h e  c o n f o r m a t i o n  o f  
P r P 5 0 .  ( i v )  T h e  c o - f a c t o r  m i g h t  p a r t i c i p a t e  i n  t h e  k e y  p r o c e s s  o f  f r a g m e n t i n g  P r P 50 p o l y m e r s  
t o  p r o d u c e  s m a l l e r  s t r u c t u r e s ,  a n d  m u l t i p l y i n g  t h e  n u m b e r  o f  s e e d s  t o  a l l o w  t h e  c o n t i n u a t i o n  
o f  p r i o n  r e p l i c a t i o n ,  ( v )  T h e  c o - f a c t o r  m i g h t  b i n d  t o  P r P 8 0 ,  t h u s  i n c r e a s i n g  i t s  b i o l o g i c a l  
s t a b i l i t y ,  r e d u c i n g  i t s  c l e a r a n c e  in vivo, a n d  i n c r e a s i n g  i t s  c h a n c e s  t o  r e a c h  t a r g e t  o r g a n s .  I t  
i s  i m p o r t a n t  t o  h i g h l i g h t  t h a t  t h e s e  p o s s i b i l i t i e s  a r e  n o t  m u t u a l l y  e x c l u s i v e ,  a n d  i n d e e d ,  i t  i s  
l i k e l y  t h a t  a  c o - f a c t o r  c o u l d  b e  i n v o l v e d  i n  s e v e r a l  o f  t h e s e  p r o c e s s e s  s i m u l t a n e o u s l y  ( S O T O ,  
2011).
4.5. PrP80 interactome
A major issue in the TSE field is the identification of proteins associated with 
PrP80. Such information would likely illuminate many aspects related to the 
transmission, pathogenesis and diagnosis of these disorders. Moreover, the differences 
between PrPC and PrPSc interactome may give new insights into the biology of prion 
conversion and pathological mechanism of prion disease. In a preliminary study 
recently published, proteins from a highly purified fraction containing ovine PrP80 were 
separated by 2-DE, in-gel digested, and analyzed by LC-MS/MS ( P e t r a k i s  et al., 
2009). Twelve proteins were identified, including various types of collagen, 
components of the desmosome (desmoglein 1, plakoglobin), ubiquitin, versican 3, 
ferritin, the alpha subunit of calcium/calmodulin-dependent protein kinase 2, and PrP. 
The presence of ferritin is particularly interesting since previous studies have 
demonstrated that PrP80 and ferritin can form detergent insoluble complexes and that 
the brain iron homeostasis is abnormal in TSEs ( M i s h r a  et al., 2004, S i n g h  et al., 
2009). Comparing to the PrPc interactome, these results clearly demonstrate that PrPc 
change its biological functions after being converted to PrP80.
4.6. Role of dimerization in prion aggregation/propagation
Protein dimerization has a fundamental role in aggregation of a variety of 
proteins associated neurodegenerative diseases or even other PMDs. Serpinopathies are 
associated with polymerization and aggregation of serpin protein which causes a
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progressive loss of cellular function that results in diseases as diverse as cirrhosis and 
emphysema. Studies have shown that serpin dimers stabilize formation of (1-Sheet 
structures in serpin polymers (Y a m a s a k i et al., 2008). Another example is the 
formation of soluble Ap oligomers extracted from Alzheimer's disease brains which 
potently impair synapse structure and function and that dimers are the smallest 
synaptotoxic species (Sh a n k a r  et al., 2008).
As discussed in above sections and according to the studies on transgenic mice 
(Pr u sin er  et a l, 1990), formation of dimers through assembly of a transient complex of 
PrPc/PrPSc occurs during the conversion process. This means that PrPc tends to make 
heterodimers with PrPSc, and possibly, homodimers with another PrPc molecule which 
theoretically has the identical amino acid sequence as PrP8*1. Based on these possibilities 
Warwicker et al. proposed a model for prion homodimer/heterodimer formation 
(W a r w ic k e r , 1997, W a r w ic k e r , 2000). According to this model, amino acids 122 to 
228 of PrPc constitute a nonpolar segment (Figure 10A) which can form dimer about a 
vertical axis, across P-hairpin faces (Figure 10B). Addition of dimers through hairpin 
stacking would extend a PrP oligomer perpendicular to the view of Figure 10B and 
would require (from simple packing considerations) a large-scale rearrangement of the 
a-helical domain. The dimer-dimer interactions may potentially force the unfolding of 
a-helical domain that is also influenced by mutation, membrane proximity and pH. This 
model favours dimer (over monomer) addition to a PrPSc seed, since a dimer is proposed 
to stabilise the P-haiipin core (W a r w ic k e r , 2000).
Although recombinant PrPc exists in a monomeric form, experiments on brain 
tissue have confirmed the presence of a monomer-dimer equilibrium of PrP of bovine 
brain (M e y e r  et al., 2000). One reason that dimerization is not observed in the 
recombinant PrPc purifications may be the use of denaturants during the purification 
process which can destruct protein dimers. Another possibility would be the presence of 
glycosylation in native brain expressed PrPc that may induce structural alterations that 
favor PrP0 dimer formation.
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In crystallographic studies, human PrP has a domain-swapped dimer structure 
with two polypeptide chains related by crystallographic two-fold symmetry (Figure 
IOC) and the disulfide bonds are rearranged and occupy an intermolecular position 
( K n a u s  et a l, 2001).
Dimers of PrPc have been also observed in the uninfected hamster and mouse 
brains ( B e n d h e i m  &  B o l t o n ,  1986) as well as in murine neuroblastoma cells 
expressing hamster PrP0 ( P r i o l a  et a l, 1995). Prion dimers have been also identified in 
the infected hamster brains after gentle dissaggregation or after large scale purification 
of prion from infected brains ( S k l a v i a d i s  et al., 1989, T u r k  et al, 1988).
4.6.1. Prion dimerization is associated with disulfide bridge rearrangement
The formation of a domain-swapped dimer in the crystal structure is associated 
with some conformational transition of PrPc including the rearrangement of disulfide 
bonds. First, monomers should have their intramolecular disulfide bonds reduced and 
the two helices 3 must be kept out and far from the dimer interface core to swap and 
pack against the other half of the dimer (Figure 10C), and second, two disulfide bridges 
rearrange and form within proteins ( K n a u s  et a l, 2001). The addition of reducing 
agents such as dithiothreitol and denaturants causes PrP monomers, which normally 
contain an intramolecular disulfide bond, to dissociate from infectious PrPSc aggregates 
( H e r r m a n n  &  C a u g h e y ,  1998, T u r k  et al., 1988). This suggests that disulfide bridge 
arrangement is important during prion dimer formation. Thiol-disulfide exchange is the 
principal reaction by which disulfide bonds are formed and rearranged in a protein. The 
rearrangement of disulfide bonds within a protein generally occurs via intra-protein 
thiol-disulfide exchange reactions; a thiolate group of a cysteine residue attacks one of 
the protein's own disulfide bonds. Disulfide reshuffling is generally much faster than 
oxidation/reduction reactions, which change the number of disulfide bonds within a 
protein ( W E D E M E Y E R  et al., 2002). Oxidative folding studies have shown that 
denaturation can initiate disulfide reshuffling within a protein with free thiol groups by
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Figure 10. Models for prion dimerization
(A) Secondary structure model of PrP: 125-228 (yellow). Purple marks regions 128-131, 
133-134, and 159-164 that exhibit conserved main-chain hydrogen-bonding outside of 
a-helices. (B) A dimer of prion composed of non-polar segments. Two monomers form 
a dimer about a vertical axis, across {3-hairpin faces. Each hairpin connects to a helical 
segment that binds into the groove of the opposing monomer ( W a r w i c k e r ,  2000). (C) 
Stereo view ribbon diagram of the human prion protein dimer crystal structure ( K n a u s  
et al., 2001). Backbone C„ traces (106-117 and 134-141) and full backbone (118-133) 
are shown with putative hydrogen-bonding ( W a r w i c k e r ,  2000).
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eliminating the tertiary structure protecting its disulfide bonds from intramolecular 
thiol/disulfide exchange reactions ( N a r a y a n  et al., 2000, W e l k e r  et al., 2001). This 
may explain why PrP80 formation is favored in acidic conditions such as pH 6.0 and 
lower pH ( B o r c h e l t  et al., 1992, M a i t i  &  S u r e w i c z ,  2001, T a r a b o u l o s  et al., 
1992). The human PrP dimer has its disulfides rearranged into intermolecular bonds 
(Hosszu et al., 1999), which shows that disulfide reshuffling may be involved in 
dimerization/ polymerization leading to PrPSc formation. Reduction of the single 
disulfide bridge in the prion protein with millimolar concentrations of dithiothreitol 
results in transformation of the a-helix-rich to the (3-sheet-rich conformation, with 
concomitant decrease in solubility. In more physiologically relevant conditions, the use 
of thioredoxin/thioredoxin reductase coupled with NADPH efficiently reduces 
recombinant Syrian hamster (29-231) prion protein and the reduced protein immediately 
becomes insoluble and precipitates ( R e q u e n a  &  L e v i n e ,  2001). These disulfide 
rearrangements can induce structural transitions between soluble PrPc and aggregated 
PrPSc-like structures ( M e h l h o r n  et al., 1996). Based on these results a model was 
proposed to describe the role of disulfide rearrangement and dimerization in PrP80 
replication ( T o m p a  et al., 2002) (Figure 11). According to this model, interaction 
between PrP50 and PrPc can destabilize the tertiary structure of PrPc and induce 
flactuations in the arrangment of intramolecular disulfide bond. Then the terminal 
thiolate group of a PrP80 polymer attacks the intramolecular disulfide bond of a PrP° 
monomer to form an intermolecular disulfide bond, thus lengthening the PrP8c polymer 
while maintaining a terminal thiolate group ( W e l k e r  et al., 2001).
4.7. Mechanism of neurodegeneration
The mechanism of prion neurotoxicity which brings about neurodegeneration 
has been a focus of intensive research in recent years. Two important questions to be 
answered concern the nature of prion oligomers involved in neurotoxicity and the 
mechanism of neurodegeneration. There is growing evidence that intermediary 
oligomeric structures of prion instead of PrP80 are toxic species involved in prion 
disease pathology ( C o l u n g e  et al., 1995, L a s m e z a s  et al., 1997, T e l l i n g  et al., 1996).
PrP** PrP^PrP*
kd
Figure 11. Prion dimerization and disulfide rearrangement are involved in PrP^ 
replication
Interaction of PrP80 dimer with a soluble PrPc dimer can destabilize the tertiary 
structure of soluble PrPc dimer. This results in a rearrangement of intramolecular PrPc 
disulfide bridge and formation of intermolecular disulfide bonds. The global tertiary
p  o
structural changes and disulfide rearrangement induce PrP to adopt a more stable PrP 
structure. Adapted from ( T o m p a  et a l,  2002).
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T h e  n e u r o t o x i c i t y  o f  g r a n u l a r  o l i g o m e r i c  s t r u c t u r e s  o f  p r i o n  h a s  b e e n  d e m o n s t r a t e d  in 
vitro a n d  in vivo ( S a n g h e r a  et al., 2008, S l M O N E A U  et al., 2007). H o w e v e r ,  t h e  
m e c h a n i s m  o f  n e u r o d e g e n e r a t i o n  h a d  n o t  b e e n  c h a r a c t e r i z e d  u n t i l  r e c e n t l y .
Emerging evidence suggest an uncoupling of infectivity and toxicity in prion 
disease. According to this theory, during prion infection and propagation, PrPSc interacts 
with PrPc and catalyzes the formation of neurotoxic species from PrPc ( S a n d b e r g  et 
al., 2011). The accumulation of prion aggregates is associated with phosphorylation of 
the a-subunit of eukaryotic translation initiation factor eBF2, resulting in increased 
phosphorylated eEF2a (eIF2a-P) and the increased protein unfolding response 
( M O R E N O  et al., 2012). The elevation of eEF2a-P results in translational repression of 
protein synthesis. Consequently, there is a decline in synaptic function in the absence of 
important synaptic proteins which cause neurodegeneration.
4.8. Prion-like disorders
One important characteristics of prion disease is that the infectious agent PrPSc 
has the ability to promote its self replication/propagation by recruiting PrPc monomers 
and convert them into the aggregated infectious conformations. Prion-like propagation 
of protein misfolding and accumulation of misfolded proteins as P-Sheet aggregates 
have been implicated in Alzheimer’s, Parkinson’s and Huntington’s diseases, 
amyotrophic lateral sclerosis and the tauopathies. For example, mechanism of tau 
aggregation and propagation in models of Alzheimer's disease is reminiscent of PrPSc 
propagation in prion disease. Injection of brain extract of the mice expressing disease- 
causing mutant of tau (P301S) into the brain of transgenic wild-type tau-expressing 
animals induces assembly of wild-type human tau into filaments and spreading of 
pathology from the site of injection to neighboring brain regions ( C L A V A G U E R A  et al., 
2009). Recently, it was demonstrated that tau fibrils internalize cells in an endocytic 
pathway and seed the aggregation of cell expressed soluble tau proteins (Guo & LEE,
2011). These results confirm that propagation of pathology in Alzheimer's disease is 
similar to a prion-like mechanism.
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Protein misfolding and aggregation into cross-P-conformation amyloid 
structures has been also implicated in pathology of the Parkinson's disease. Recent 
findings have confirmed that aggregation and propagation of a-Syn protein in PD is 
similar to a prion-like mechanism (Li et a l, 2008). In the next sections the mechanism 
of a-Syn aggregation and propagation will be discussed.
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5. PARKINSON’S DISEASE
The synucleinopathies are a distinct group of neurodegenerative disorders 
characterized by neuronal loss and by the presence of intracellular inclusions of 
aggregates composed largely of fibrillar a-Syn protein. This group of neurodegenerative 
disorders includes Parkinson’s disease, dementia with Lewy bodies, Lewy body variant 
of Alzheimer’s disease, multiple system atrophy and neurodegeneration with brain iron 
accumulation type 1 ( A r a w a k a  et a l, 1998, B a b a  et al., 1998, S p i l l a n t i n i  et al., 
1997, S p i l l a n t i n i  et al., 1998, W a k a b a y a s h i  et al., 1998).
Parkinson's disease, originally described by James Parkinson in 1817, is the 
second most common late-onset neurodegenerative disorder after Alzheimer’s disease. 
PD is a slowly progressive condition. It may take 20 years to develop and it is 
characterized by various symptoms, which can be divided into motor symptoms and 
non-motor symptoms. Patients suffering from PD live through several disease stages. 
PD pathology usually starts with symptoms which are non-motor and include subtle 
cognitive deficits ( K o r c z y n  &  G u r e v i c h ,  2010). The cognitive deficits which appear 
in the early stages of PD include deficit in behavioral regulation in sorting or planning 
tasks, defective use of memory stores, and impaired manipulation of internal 
representation of visuospatial stimuli ( D u b o i s  &  P i l l o n ,  1997, P o e w e ,  2008). Motor 
symptoms normally appear at the end of first stage. These motor-symptoms include 
bradykinesia, cogwheel rigidity, postural instability, and rest tremor ( E r i k s e n  et al., 
2005, I s a a c s o n  &  H a u s e r ,  2009, K o r c z y n  &  G u r e v i c h ,  2010). In the late stages of the 
PD, patients may experience depression, apathy and psychosis, and finally dementia 
with is characterized by the presence of Lewy bodies in the affected regions of the brain 
( K o r c z y n  &  G u r e v i c h ,  2010). The appearance of psychosis, dementia and related 
behavioral changes puts serious risks on the life quility of patients with PD ( G o e t z  et 
a l, 1998, T r u o n g  et al., 2008).
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Figure 12. Schematic representation of the location of the substantia nigra in the 
human brain. A decrease of dopaminergic neurons in, among others, the substantia 
nigra has been demonstrated in PD patients. Adapted from A.D.A.M. Inc. National 
Institutes of Health (http://www.nlm.nih.gov/medlineplus/ency/imagepages/19515.htm).
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5.1. Pathophysiological hallmarks of PD
PD is associated with a progressive degeneration of dopaminergic neurons in 
the substantia nigra pars compacta (Figure 12) and various other regions of basal 
ganglia, brainstem, autonomic nervous system and cerebral cortex. The loss of 
dopaminergic neurons results in dopamine deficiency in the striatum. This results in the 
characteristic PD symptoms, including tremor, rigidity, bradykinesia and postural 
disturbances ( B e y e r  et al., 2009, D e k k e r  et al., 2003, S i m u n o v i c  et al., 2009). 
Besides loss of dopaminergic neurons, also proteasomal dysfunction in the substantia 
nigra has been identified in PD patients ( C h e s s e l e t ,  2003).The ubiquitin-proteasome 
system and autophagy-lysosome system are major intracellular cell-systems for 
elimination of abnormal proteins. Alterations in the functioning of these systems seem 
to be important in the development of PD ( B e y e r  et al., 2009).
5.2. Lewy bodies (LBs)
Fritz Heinrich Lewy (1885-1950) discovered what was later named “Lewy 
bodies” during his research on parkinsonism in 1912. The designation LB was 
suggested by Tretiakoff in his thesis in 1919. In 1923 Lewy published his monograph 
concerning 43 patients with parkinsonism of which 21 were demented ( A l a f u z o f f  et 
al., 2009, R o d r i g u e s  e  S i l v a  et a l, 2010).
Another important neurodegenerative disorder related to LB formation and 
pathology is Dementia with Lewy Bodies initially discovered by Okazaki who studied 
two clinical cases which suffered from dementia. Okazaki showed a rapid progression 
of clinical symptoms in DLBs including dementia, disorientation, hallucinations with 
profound motor symptoms. The presence of cortical LBs, which had a similar 
morphology as LBs in PD, were then characterized in the autopsy samples obtained 
from DLB affected brains ( O k a z a k i  et al., 1961).
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LBs are characteristic hallmark of PD which are present in damaged 
dopaminergic neurons in affected brain regions (Figure 13). Structurally, LBs are 
intraneuronal fibrous inclusions that predominantly consist of a-Syn and ubiquitin 
proteins ( B e y e r  et a l, 2009, T s u b o i  et al., 2007). There are two types of LBs: classic 
brainstem LBs, and cortical LBs. Classic brainstem LBs (Figure 13A and B) are large 
spherical eosinophilic structures, located in dopaminergic neurons of the substantia
Figure 13. Classic brainstem LBs and cortical LBs in different brain regions
A and B. Neuron in the substantia nigra (indicated by the arrows) with multiple classic 
LBs. H&E staining and anti a-Syn immunostaining, respectively. C and D. Cortical LBs 
in the cingulated cortex (indicated by the arrows). Adapted from ( K o v a r i  et a l, 2009).
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nigra and locus coeruleus ( K o v a r i  et al., 2009, M a r i e s  et al., 2003, O b e s o  et al.,
2010).Classic brainstem LBs are enclosed by a characteristic clear ring ( M c K e i t h  et al., 
1996). Cortical LBs (Figure 13C and D) are present in small neurons in the limbic and 
neocortal areas of the brain. Their size is smaller compared to classic LBs ( K o v a r i  et 
al., 2009).
The appearance of LBs during PD pathogenesis is not limited to only one brain 
region and studies have reported progressive formation of LBs in different brain regions 
as the disease advances. Braak and colleagues performed anatomical neuropathological 
studies in order to characterize the cerebral progression of a-Syn-positive LBs and 
neurites as the disease process continued and they established an association between 
LB pathology and clinical symptoms ( B r a a k  et al., 2002, B r a a k  et al., 2003, B r a a k  
et al., 2004). According to these studies, progression of LB pathology in brain was 
devided into six stages. In stage 1, the first Lewy pathology appears in dorsal motor 
nucleus of the vagal nerve and the olfactory bulb. In this step, the pathology is 
manifested as lesions in the dorsal IX/X motor nucleus and/or intermediate reticular 
zone. In stage 2, LB pathology spreads within the medulla oblongata and pontine 
tegmentum and lesions are observed in caudal raphe nuclei, gigantocellular reticular 
nucleus, and coeruleus-subcoeruleus complex. In stage 3, pathology progresses to the 
midbrain and basal forebrain with subsequent spread into the substantia nigra pars 
compacta and midbrain lesions are particularely observed in pars compacta of the 
substantial nigra. In stage 4, LB pathology progrecess to basal prosencephalon and 
mesocortex and lesions extend to prosencephalic region and cortical areas includind 
temporal mesocortex and allocortex. The first symptoms of PD may appear at this stage. 
In stages 5 and 6 , pathology spreads through neocortex and lesions are detected in first 
and high order sensory association areas of the neocortex and premotor areas, 
occasionally mild changes in primary sensory areas and the primary motor field. At 
stages 5 and 6 , the cognitive dysfunctions and severe motor symptoms are diagnosable 
( B r a a k  et al., 2003, D u d a  et al., 2000, H a w k e s  et a l, 2010).
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The pathology of LBs is associated by deterioration of the affected brain areas 
( B e y e r  et al., 2009, F u x e  et a l, 2007). Among several proteins in LBs, a-Syn, 
ubiquitin, phosphorylated neurofilaments, parkin, components of the ubiquitin- 
proteasome system and molecular chaperons have been identified ( B e y e r  et al., 2009, 
C h e s s e l e t ,  2003, O b e s o  et al., 2010, Z h u  et al., 2006). Generally, the a-Syn protein 
have been characterized as the main component of LBs.
5.3. The Synuclein family
The synucleins are a family of small proteins (~14k Da) that are expressed at 
high levels in the brain. In humans there are three members of this family: a-, 0- and y- 
synuclein, that are products of three genes located on chromosomes 4 ( S h i b a s a k i  et al., 
1995), 5 ( S p i l l a n t i n i  et al., 1995) and 10 ( L a v e d a n  et al., 1998), respectively. Both a- 
and P-synucleins are abundant in the central nervous system where they are 
concentrated in the presynaptic nerve terminals ( J a k e s  et al., 1994), whereas y- 
synuclein (y-Syn)comes from is expressed mainly in the peripheral nervous system and 
seems to be present throughout nerve cells ( A k o p i a n  &  W o o d ,  1995, C l a y t o n  &  
G e o r g e ,  1999).
The name “synuclein” comes from discovery of a protein isolated from the 
electric organ of the Pacific electric ray (Torpedo califomica) which is usually localized 
in both nuclear envelope and the presynaptic nerve terminals ( M a r o t e a u x  et al., 
1988). The synuclein family proteins were identified independently. P-Synuclein (p- 
Syn) was first referred as phosphoneuroprotein 14 ( T o b e  et al., 1992), whereas a-Syn 
was first known as non-amyloid-P component precursor protein (NACP) because of 
apparent localization of an internal fragment (Figure 15), the non-amyloid-P component 
(NAC), in some amyloid plaques of patients with Alzheimer’s disease ( U e d a  et al., 
1993). However, it has not been determined conclusively whether NAC is a component 
of amyloid plaques ( B a y e r  et al., 1999). Both proteins NACP and phosphoneuroprotein 
14 were found to be similar to synuclein from Torpedo califomica and consequently
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a-syn MPVDPDNEAYEMPSEEGYQDYEPEA 140
p-syn PLMEPEGESYEDPPQEEYQEYEPEA 134
y-syn GEASKEKEEVAEEAQSGGD  127
Figure 14. Sequence comparison of human a-, P- and y-Syn
The protein sequences can be divided in three regions: (1) the amino terminal region 
(blue residues); the hydrophobic central region (green residues); (3) the carboxy 
terminal region (red residues). The black amino acids in (3- and y-Syn sequences are the 
residues non-identical to the a-Syn sequence. The residues in boxes indicate six repeats 
of the hexameric KTKEGV motif. The three sites of early-onset PD-linked mutations 
(positions 30,46 and 53) are shown by arrows in the a-Syn sequence.
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identified and named as persyn ( B u c h m a n  et al., 1998). Sequence analysis (Figure 14) 
revealed the existence of three Synuclein proteins which were named a-, 0- and y-Syn, 
respectively ( J a k e s  et al., 1994). a- and P-synucleins have conserved carboxy termini 
(YQ[D/E]YEPEA) and three identically placed tyrosin residues, whereas, y-Syn has a 
shorter caboxy terminal domain and lacks Tyr residues. a-Syn (140 residues) shows 
more homology with P-Syn (134 residues) than with y-Syn (127 residues). However the 
principle distinguishing feature between a- and P-Syn is the absence of 11 residues 
within the NAC domain in P-Syn ( C l a y t o n  &  G e o r g e ,  1998). Of the three synucleins, 
only a-Syn has been found in the Lewy body aggregate inclusions and is thought to play 
a role in the pathogenic process of synucleinopathies and PD ( S p i l l a n t i n i  et al., 1997, 
S p i l l a n t i n i  et al., 1998). In vitro studies have shown that a-Syn is more fibrillogenic 
than P- and y-Syn and can not seed the aggregation of its homologs ( B i e r e  et al., 2000). 
Moreover, a- and P-Syn interact with each other and P-Syn inhibits a-Syn aggregation 
(Li et al., 2002, P a r k  &  L a n s b u r y ,  2003). Also, it has been shown that in transgenic 
mice expressing both a- and P-proteins, the PD-phenotypes are more pronounced 
( H a s h i m o t o  et al., 2001).
5.4. Biological function of a-Syn
a-Syn is a 140-amino acid, intrinsically disordered protein (Figure 15) mainly 
expressed in the CNS with its primary localization in presynaptic nerve terminals 
( J a k e s  et al., 1994). The SNCA gene is mainly expressed in brain areas including the 
thalamus, the substantia nigra, the caudate nucleus and the amygdala.a-Syn is 
predominantly found in neuronal cells present in the brain and the central nervous 
system (CNS) ( M a r t i n  et al., 2004). a-Syn is expressed by neuronal cells and is 
located in presynaptic nerve terminals ( M a r t i n  et al., 2004, M c F a r l a n d  et al., 2008). 
However, it can also be found in blood platelets, haematopoietic cells, neuromuscular 
connections and cardiac tissue ( M a r t i n  et al., 2004).
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The exact physiological role of a-Syn is unclear although some reports suggest 
that it is involved in neurotransmitter regulation ( S p i l l a n t i n i  et a l,  1997). Several 
studies indicate that this protein might have a role in synaptic development, function 
and plasticity ( C a b i n  et al., 2002, C l a y t o n  &  G e o r g e ,  1998, M u r p h y  et al., 2000). 
Also, a-Syn can bind to lipid membranes suggesting that it might be a lipid-binding 
protein ( D a v i d s o n  et al., 1998, Jo et al., 2000, M c L e a n  et al., 2000, P e r r i n  et al., 
2000). In addition to binding to lipids, a-Syn can interact with other proteins such as 
synphilin ( K a w a m a t a  et al., 2001), ( P a y t o n  et al., 2001), tau ( J e n s e n  et al., 1999) 
and 14-3-3 proteins, a family of chaperons with which a-Syn has homology 
( O s t r e r o v a  et al., 1999), suggesting that it could have a chaperone activity. Mice that 
lack a-Syn have been found to show an increased release of striatal dopamine, 
suggesting that the protein could act as a negative regulator of dopamine 
neurotransmission ( A u l u c k  etal., 2010).
a-Syn is highly expressed during neuronal development ( R a j a g o p a l a n  &  
A n d e r s e n ,  2001) and is likely to be involved in neuronal differentiation ( M a r t i n  et 
al., 2004). Furthermore, there seems to be a role for a-Syn in the aetiology of several 
human neurodegenerative disorders, including PD, dementia with Lewy bodies, 
multiple system atrophy (MSA) and amyotrophic lateral sclerosis ( M a r t i n  et al., 2004, 
R a j a g o p a l a n  &  A n d e r s e n ,  2001).
5.5. a*Syn structure
In aqueous solution, monomeric a-Syn is highly flexible and belongs to the 
class of intrinsically disordered proteins, with transient long-range interactions 
stabilizing a closed conformation ( B e r t o n c i n i  et al., 2005, D e d m o n  et al., 2005). The 
nature of disordered structure of a-Syn is believed to be due to the very high net 
negative charge at neutral pH and the low intrinsic hydrophobicity of the molecule.
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Structurally, a-Syn is made up of three domains (Figure 15): first, the 
amphipathic N-terminal region (1-60 residues), this domain is responsible for binding 
with lipid and a-helical forming structures ( V a m v a c a  et al., 2009). It inhibits the 
formation of p-sheet structure ( K e s s l e r  et al., 2003). The N-terminal region is 
composed almost entirely of six variants of a degenerate 1 1 -amino acid consensus motif 
with slight variations of the sequence KTKEGV (Figure 14). The 11-mer repeats 
comprise an apolipoprotein-like-A2 helix, which mediates binding to phospholipid 
vesicles. These 11-mer repeats are highly conserved among the a-, P-and y-Syn (Figure 
14). Second, the Hydrophobic central core (61-95 residues)(Figure 15), also called non­
amyloid component (NAC region) which is responsible for the formation of P-Sheet 
structures and also for protein aggregation. The NAC region of a-Syn contains two of 
the 11-mer repeats (Figure 14). This region has a crucial role in amyloidogenesis and 
thus, a-Syn lacking the NAC region doesn’t form amyloid fibrils ( S h u l t s ,  2006). 
Third, the C-terminal region composed of amino acids 95-140 (Figure 15). This portion 
is rich in proline and acidic amino acids. It is negatively charged and hence in the 
normal conditions does not bind to the membrane. However, in the presence of calcium 
the C-terminal binds to the lipid membrane and once C-terminal binds to the lipid 
membrane a-Syn forms P-Sheet structures (TA M a m i z u - K a t o  et al., 2006). This a-Syn 
region undergoes several post-translational modifications ( G o e d e r t ,  2001).
5.6. a-Syn aggregation
a-Syn has little or no detectable secondary structure in its native form in 
solution and therefore, it is referred to as natively unstructured ( B e r n a d o  et a i, 2005, 
C o o k s o n ,  2005, U l m e r  et al., 2005). a-Syn with its natively unfolded structure and 
hydrophobic NAC region has a high propensity to misfold into the conformations that 
have a higher tendency to aggregate. The process of misfolding and aggregation is 
induced in PD and other synucleinopathies either by the missense mutations in the 
SNCA gene or by sporadic factors ( L a n s b u r y  &  L a s h u e l ,  2006, M o o r e  et al., 2005).
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Figure 15. a-Syn structure
(A) Nuclear magnetic resonance (NMR) prediction of human a-Syn structure. The 
amino-terminal of the protein is highly conserved, includes a number of imperfect 
repeats (KTKEGV) and is associated with lipid binding (1-60). Also located in the N- 
terminal region are the mutations linked to either early-onset PD (A30P, A53T) or DLB 
(E46K). The middle part consists of hydrophobic residues and is also known as the 
NAC region (61-95), which is believed to facilitate a-Syn aggregation and 0-sheet 
formation. The carboxy-terminal region includes a high proportion of acidic residues 
and is characterized by a random coil structure (96-140). Adapted from (Ulm er et al., 
2005). (B) Schematic representation of a-Syn regions.
52
Generally, the genetic perturbations in a-Syn gene or familial forms of PD have early- 
onset and greater severity than the sporadic cases and they are also associated with a 
greater amount of protein aggregates ( H a r d y  &  S e l k o e ,  2002).
Increase in the a-Syn expression levels in the CNS is one of the factors 
involved in a-Syn misfolding and aggregation. For example, duplications or 
triplications in SNCA gene cause earlier onset and increased severity of symptoms of 
PD in a dose-dependent manner ( I b a n e z  et al., 2009, I k e u c h i  et al., 2008, Ross et al., 
2008), and mutations in a-Syn’s promoter region are a risk factor for the idiopathic PD. 
Point mutations in the SNCA gene as shown in Figure 15 (A53T, A30P, E46K) increase 
the propensity of a-Syn protein to aggregate in vitro ( C o n w a y  et al., 1998, 
F r e d e n b u r g  et al., 2007, N a r h i  et al., 1999), and impair the proteasome system in 
vivo ( T a n a k a  etal., 2001).
The aggregation of recombinant wild type (WT) a-Syn and its two pathogenic 
mutants (A53T,A30P) has been studied in vitro. All three proteins along with carboxy- 
terminal truncated forms assemble into filaments with similar characteristics 
(morphology, dimension, and staining properties) to those extracted from disease- 
affected brain ( C o n w a y  et al., 1998, C o n w a y  et al., 2000, C r o w t h e r  et al., 1998, E l -  
A g n a f  et al., 1998, N a r h i  et al., 1999).
Electron paramagnetic resonance and protease digestion studies suggest that 
the central region of a-Syn (-70 amino acids), packed in a highly ordered parallel 
fashion, constitutes the core unit of the filaments, whereas the N-terminal is structurally 
more heterogeneous. The C-terminal region (residues 103-140) remains unstructured 
probably due to the electrostatic repulsion within this region (Figure 15) ( D e r -  
S a r k i s s i a n  et al., 2003, M i a k e  et al., 2002). Although the acidic C-terminal is not 
incorporated in the aggregated core, it modulates the aggregation process. It has been 
shown that the C-terminal truncated fragments aggregate faster than full-length a-Syn 
( C r o w t h e r  et al., 1998, H o y e r  et al., 2004, M u r r a y  et al., 2003, S e r p e l l  et al., 
2000).
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The a-Syn aggregation displays the characteristics of a nucleation- 
polymerization mechanism with a long lag phase (several weeks) in the absence of 
external factors (stirring, agitation, low pH, high temperature) followed by a rapid 
growth phase and a steady state. The fibrillization follows first-order kinetics with 
respect to a-Syn concentration and the critical concentration has been determined to be 
28 pM when the protein was incubated at 371 ,  pH 7.5 and continuous shaking ( N a r h i  
et al., 1999, W o o d  et al., 1999). Consistent with this mechanism, addition of preformed 
wild type and Ala53Thr fibrils to a fresh solution containing wild type soluble a-Syn 
(homologous and heterologous seeding) resulted in a significant reduction of the lag 
phase (Figure 16) ( C o n w a y  et al., 2000, W o o d  et al., 1999). The lag time and the 
growth phase also depend on the identity of the a-Syn mutant ( C o n w a y  et al., 1998, Li 
et al., 2001, N a r h i  et al., 1999) and the incubation conditions (low pH, high 
temperature) ( H a s h i m o t o  e ta l,  1998, Li etal., 2001).
5.6.1. Toxicity of a-Syn aggregates
Apart from fibrillar and amyloid inclusions with antiparallel P-sheet structure 
( C o n w a y  et al., 2000, N a r h i  et al., 1999), other aggregated species such as nonfibrillar 
a-Syn aggregates (termed also as nonfibrillar oligomers or protofibrils) with distinct 
morphologies such as spheres, chain of spheres, rings (circularized chains), have been 
also reported ( D i n g  et al., 2002, L a s h u e l  et al., 2002). These pre-fibrillar aggregates 
are formed during a-Syn amyloidogenesis process (Figure 17). The exact link between 
a-Syn inclusions and cytotoxicity, leading to disease onset and progression, is unclear 
but accumulating evidence suggests nonfibrillar dimers and oligomers of a-Syn, 
intermediates for the formation of fibrillar inclusions and Lewy, play an important role 
in neurodegeneration ( L a n s b u r y  &  B r i c e ,  2002, O u t e i r o  et al., 2007). Several 
experimental studies support the hypothesis that the pathogenic species are the 
oligomers rather than fibrils: (1) mice overexpressing a-Syn develop PD-phenotypes
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Figure 16. a-Syn amyloidogenesis is accelerated in the presence of aggregate seeds
Amyloid formation process by soluble recombinant a-Syn is usually long and may take 
up to one month in the stationary conditions. This process include three phases: (1) lag 
phase; (2) linear growth of amyloids and (3) steady state. However, in the presence of 
aggregated seeds (for example seeds obtained from aggregation of WT or mutant form 
of a-Syn Ala53Thr) amyloid formation is accelerated. In these conditions, the slower 
lag phase is eliminated and amyloidogenesis occurs in a fast linear manner.
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without developing fibrillar inclusions ( M a s l i a h  et al., 2000, v a n  d e r  P u t t e n  et al., 
2000); A30P mutant forms oligomers faster than wild type, whereas A30P fibrillization 
is relatively slow ( C o n w a y  et al., 2000); (3) membrane permeabilization by a-Syn 
oligomers could be a mechanism of neurotoxicity in PD ( D i n g  et al., 2002, L a s h u e l  et 
al., 2002, V o l l e s  et al., 2001). In addition, expression of a-Syn soluble oligomers with 
reduced fibrillization propensity induced neurotoxicity in worms, flies and mammalian 
neurons ( K a r p i n a r  et al., 2009).
These important evidences have turned attentions towards understanding the 
biological aspects of a-Syn neurotoxic oligomerization and also formation of other toxic 
aggregates involved in neurodegenerative disorders. Many efforts have been gone into 
understanding the molecular mechanism involved in the formation of a-Syn neurotoxic 
oligomers but there is no evidence to characterize the mechanism of a-Syn oligomer 
formation at the molecular level. Also, formation of amyloid fibrils from these pre- 
fibrillar oligomers is another important mechanistic issue which should be 
characterized.
Soluble pre-fibrillar oligomers of misfolded proteins can diffuse and interfere with 
many neuronal functions. They can affect synaptic physiology, structure and function, 
thereby changing the overall plasticity and integrity of individual neurons and neuronal 
networks. Studies done on the soluble A0-42 oligomers formed by the Amyloid-0 (A0) 
and polyglutamine-rich Huntingtin oligomers have demonstrated that oligomerization of 
misfolded protein can initiate a cascade of events that finally result in dementia and 
cognitive dysfunction ( H a a s s  &  S e l k o e ,  2007). In vivo pathogenicity of the soluble 
pre-fibrillar oligomers of a-Syn was recently tested in an animal model ( W i n n e r  et al.,
2011). a-Syn mutants that promote oligomer or fibril formation were designed and 
expressed in rat brain using a rat lentivirus system to investigate loss of dopaminergic 
neurons in the substantia nigra. The most severe dopaminergic loss in the substantia 
nigra was observed in animals with the a-Syn variants that form oligomers (i.e., E57K 
and E35K), whereas the a-Syn variants that form fibrils very quickly were less toxic.
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Figure 17. Model of a-Syn aggregation based on different species observed by 
AFM during the time-course of protein fibrillization
The aggregation process occurs via a multi-step transition involving the intermediacy of 
oligomeric species. The mechanism by which these intermediates may cause neuronal 
death is not clear. Adapted from ( G o l d b e r g  &  L a n s b u r y ,  2000).
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5.6.2. Propagation of a-Syn aggregates
Several studies have highlighted similarities between neuropathology of prion 
disease and PD ( A n g o t  et al., 2010). The notion of a-Syn propagation recently gained 
much attention after two studies showed host to graft propagation of a-Syn in a long 
term transplanted Parkinson’s patients ( K o r d o w e r  et a l,  2008, K o r d o w e r  et al., 
2008, Li et a l, 2008). Transplantation with fetal dopaminergic neurons were started two 
decades ago to restore dopaminergic transmission in Parkinson’s patients. Histological 
studies in post-mortem brain revealed LB pathology in some transplants ( K o r d o w e r  et 
al., 2008, K o r d o w e r  et a l, 2008, Li et a l,  2008). Therefore, it is possible that the a- 
Syn aggregation and deposition observed in transplanted dopaminergic neurons is 
initiated by misfolded a-Syn in the host, which has transmitted into grafted cells.
Transmission of a-Syn aggregates within host cells and grafted tissue requires 
several .mechanisms to facilitate a-Syn release and uptake by cells (Figure 18). It is 
known that a-Syn is secreted and can be detected in cerebrospinal fluid, plasma and 
saliva, as well as in the media of cultured cells ( E l - A g n a f  et al., 2003, J a n g  et al., 
2010, L e f . et al., 2005). In SH-SY5Y human neuroblastoma cells overexpressing a-Syn, 
a small percentage of newly translated a-Syn was transferred into the lumen of vesicles 
and rapidly secreted from cells. This secretion was inhibited by low temperature, 
suggesting an exocytotic process ( J a n g  et al., 2010, L e e  et a l,  2005). Oxidative stress 
and proteosomal and lysosomal inhibition increase both vesicular translocation and 
release of a-Syn ( J a n g  et al., 2010).
Exosomes have been shown to be involved in the secretion of PrP5 0  from 
cultured cells and the secreted prion is able to act as a seed for prion propagation in an 
uninfected cell ( F e v r i e r  et a l, 2004). Recently it was found that a-Syn is also secreted 
via exosomes in SH-SY5Y cells ( A l v a r e z - E r v i t i  et a l, 2011, E m m a n o u e l i d o u  et a l, 
2010). These findings highlight that a-Syn is transferred between cells via exosomes 
and that transmission is enhanced under conditions associated with PD pathology, 
including aggregated a-Syn and lysosomal dysfunction (Figure 18).
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Once a-Syn leaves the donor cell, it must transit to the recipient cells. One 
possible mechanism is direct cell-to-cell transmission of a-Syn. It has recently been 
suggested that a-Syn can transfer trans-synaptically from one neuron to another at 
axonal terminals. Heat shock protein 70 (Hsp70) is associated with extracellular a-Syn 
in this paradigm, and when it is overexpressed it appears to reduce a-Syn 
oligomerization ( D a n z e r  et al., 2011). Exogenous fibrillar a-Syn, prepared from 
recombinant human protein, is internalized by differentiated human neuroblastoma cells 
( L e e  et al., 2008, L u k  et al., 2009). This uptake is slow and reaches a maximum level 
after more than 24 h. It is significantly decreased at low temperature and when 
neuroblastoma cells are transfected with a dominant-negative mutant dynamin-1 , 
suggesting an endocytosis-mediated pathway ( L e e  et al., 2008). Most of the fibrillar a- 
Syn in the neuroblastoma cells is detected in the vesicle fraction ( L e e  et al., 2008), 
which is consistent with endocytosis-mediated uptake ( A n g o t  &  B r u n d i n ,  2009).
In order to spread the pathology throughout the cells, a-Syn should internalize 
new cells and recruit the endogenous protein from host cell. This permissive templating 
or seeding activity requires that the internalized aggregates interact with and convert the 
soluble homologous proteins into aggregated species. The propensity of a-Syn 
aggregates to nucleate the aggregation of soluble endogenous proteins proposes a 
similar mechanism of pathology between P D  and prion disease ( A g u z z i  &  R a j e n d r a n ,  
2009, B r u n d i n  et a l, 2010, D u n n i n g  et al., 2011, K r a m m e r  et al., 2009).
5.7. Role of dimerization in a-Syn aggregation
The molecular mechanism underlying a-Syn transformation from its soluble 
monomeric form to the disease-associated oligomeric conformation has been a subject 
of intense research. Homodimer formation has been characterized as an essential factor 
in the aggregation pathway of numerous proteins, such as serpin, tau, and prion protein 
which are all involved in protein misfolding disorder ( C o n g d o n  et al., 2008, R o o s t a e e  
et a l, 2009, Y a m a s a k i  et al., 2008). In this regard, in vitro experiments have reported 
the existence of a dimeric state during conversion of a-Syn from soluble monomers to
W hich form of o-*ytl
Figure 18. Model of a-Syn cell-to-celi transfer
(a) Exocytosis of a-Syn from donnor cell. MVBs-mediated a-Syn release from cells 
through exocytosis. Oxidative stress and proteasomal and lysosomal inhibition induce 
a-Syn release. a-Syn can also exit from dying neurons when they release their content.
(b) Internalization of a-Syn by the recipient cell. a-Syn can enter cells via different 
mechanisms such as passive diffusion through the plasma membrane, endocytosis and 
exosome-mediated transfer. The involvement of other factors such as an unknown 
receptor or lipid rafts in a-Syn internalization is an important issue which remain 
elusive. Adapted from ( S t e i n e r  et al., 2011).
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toxic aggregates ( I w a t a  et a l, 2003). The dimerization of a-Syn induced by 
intramolecular oxidative cross-linking of tyrosine residues has been reported to induce 
the aggregation process ( K r i s h n a n  et a l, 2003). Interaction of natively unfolded a-Syn 
with membrane phospholipids results in the formation of two a-helices in the N- 
terminus ( A u l u c k  et al., 2010). Subsequently, a-Syn forms dimers and adopts a p-sheet 
secondary structure, resulting in the formation of toxic oligomers and leading to the 
permeabilization of the cell membrane ( A u l u c k  et al., 2010). However, the importance 
of dimerization in a-Syn aggregation has not yet been directly tested. In addition, it is 
not known whether or not recombinant a-Syn dimers or oligomers, which are highly 
potent to transform into amyloid fibrils, are neurotoxic in vivo.
The influence of hydrophobic interfacial area was recently emphasized as a an 
important factor for accelerating a-Syn dimerization, aggregation and amyloidogenesis 
( Z h a n g  et a l, 2008). In agreement with the importance of dimerization for a-Syn 
aggregation and pathogenesis, another study has shown that dimeric intermediates of 
wild type and PD-associated mutants of a-Syn were relevant species in protein 
aggregation and cellular toxicity ( O u t e i r o  et a l, 2008). The increased aggregation rate 
of dimerization-induced a-Syn may help misfolded proteins to evade the cellular 
clearance machinery. In this scenario, a feedback loop is generated through which a- 
Syn aggregates impair the proteasome-mediated protein degradation pathway ( Z h a n g  et 
al., 2008), resulting in a further shift in the population of a-Syn from soluble into 
cellular aggregates and amyloid inclusions which are involved in PD pathogenesis.
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6. RESEARCH OBJECTIVES
The main objective of this project is the characterization of the molecular 
mechanism of a-Syn and PrP aggregation and amyloidogenesis as well as 
determination of neurotoxic properties of aggregated species involved in PD and prion 
disease pathologies.
6.1. Protein aggregation is central to the pathology of PD and prion disease
Aggregation and amyloid fibril formation of a-Syn and prion are directly 
linked to the pathogenesis of PD and prion disease, respectively. Unfolding of both 
proteins involves substantial structural changes which is associated with a new toxic 
gain of function for the produced aggregates and oligomeric species. The mechanism of 
protein aggregation and neurotoxicity has been a subject of intense research in recent 
years. Indeed, aggregation and neurotoxicity of prion and a-Syn aggregates have been 
demonstrated in vitro and in animal models. There is accumulating evidence that prion 
and a-Syn share the same properties in terms of aggregation, neurotoxicity and 
propagation of pathology. However, the molecular mechanism of protein aggregation 
has not been defined for neither PrPc nor a-Syn. In addition, the exact nature of toxic 
species formed during PrP0  or a-Syn aggregation has not been well characterized yet. 
Prion dimers have been characterized in the aggregated material from brains of prion- 
infected animal models as well as in the crystal structures obtained from PrP . 
Similarly, there is bulk of evidence indicating the involvement of dimers during 
oligomerization of a-Syn. These results in association with the similarities between 
pathways of aggregation and propagation of pathology in PD and prion disease 
prompted us to determine whether the mechanism of aggregation initiation is also 
similar in PrP0  and a-Syn.
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6.2. Hypothesis
Dimerization is central to the initiation of aggregation and amyloidogenesis for 
both PrPc and a-Syn proteins. Since PrPc and a-Syn share the same molecular 
mechanism of aggregation, they should produce same neurotoxic species during 
oligomerization.
6.3. Specific aims
6.3.1. Effect of dimerization on the kinetics of PrPc and a-Syn aggregation
To study the importance of dimerization in aggregation and amyloid formation 
of PrPc and a-Syn we aimed to establish an in vitro autodimerizing strategy. 
Acceleration of protein aggregation has important impacts on the pathogenesis of PD 
and prion disease. Therefore, it is important to determine the effect of dimerization on 
the kinetics of aggregation and amyloidogenesis. Dimerization-induced protein 
aggregation would be characterized by CD, fluorescent probes, epifluorescence and 
electron microscope.
6.3.2. Characterization of the neurotoxicity of PrP0 and a-Syn oligomers
One major objective of this study is to precisely characterize different 
oligomeric species and intermediary structures formed in the process of 
amyloidogenesis. The impact of dimerization on the formation of aggregates will be 
also determined. Neurotoxicity of the in vitro produced oligomers and amyloid fibrils of 
PrPc and a-Syn would be examined using cell cultures and mouse model. DNA 
fragmentation assay will be used to determine cellular apoptosis and in vivo 
neurotoxicity will be characterized by immunofluorescence experiments coupled with 
confocal microscope.
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6.3.3. In vitro propagation of a-Syn and prion aggregates
The relevance of dimerization to the propagation of protein aggregates will be 
evaluated using seeding experiments and PMC A assay. To this end aggregates obtained 
from dimerization of a-Syn or PrPc will be subjected to PMCA cycles to monitor the in 
vitro propagation of the protein aggregates. These experiments would provide further 
evidence on the similarites between pathogenesis of prion disease and PD.
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RESUME
Les maladies a prion sont causees par la conversion d'une proteine cellulaire 
(PrPc) h un isoform mal replie et agrdge (PrP1168). Le mauvais repliement de PrPc 
recombinant en absence de PrPRes, facteurs cellulaires, des agents denaturant, ou au pH 
neutre n'a pas ete realise. Plusieurs d’etudes indiquent que la dimdrisation de PrP0  peut 
etre une etape principale dans le processus d'agregation. Dans un effort pour 
comprendre l'evenement moleculaire qui peut activer le mauvais repliement de PrP° en 
conditions physiologiques plus appropriees, nous avons examine si la dimdrisation 
imposee de PrP° peut induire un changement conformationnel rdminiscent de la 
conversion de PrP° en PrPRes. Nous avons utilise une strategic bien connu de 
dimdrisation inductible par lequel un PrP° chimerique a ete creee que a compose la 
domaine de dimdrisation proteine FK506-binding (Fv) et a nommd Fv-PrP. Le Fv-PrP a 
ete incubd en prdsence d'un ligand monomerique FK506 ou d'un ligand dimerisant 
AP20187. L'addition d'AP20187 mais pas de FK506 a Fv-PrP recombinant (rFv-PrP) 
dans les conditions physiologique a eu comme consequence un changement 
conformationnel rapide caracterise par une augmentation en structure de feuille-P et 
l'agrdgation simultande de la proteine. Les agregats produits etaient partiellement 
resistants k la protdinase K et ont induit la conversion du rFv-PrP soluble dans des 
expdriences de 'seeding' en serie. Comme juge par la liaison du thioflavin T et de la 
microscopie electronique, les agrdgats ont converti en fibres amyloides. Les agregats 
etaient toxiques aux cellules cultivdes tandis que le rFv-PrP soluble et les fibres 
amyloides dtaient inoffensifs. Cette etude soutient fortement la proposition que la 
dimdrisation de PrP est un evenement primaire pathologique principal dans la 
conversion de PrP° et peut lancer la pathogenie des maladies de prion.
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ABSTRACT
Prion diseases are caused by the conversion of a cellular protein (PrPc) into a 
misfolded, aggregated isoform (PrP11**). Misfolding of recombinant PrPc in the absence 
of PrP*** template, cellular factors, denaturing agents, or at neutral pH has not been 
achieved. A number of studies indicate that dimerization of PrP0  may be a key step in 
the aggregation process. In an effort to understand the molecular event that may activate 
misfolding of PrP in more relevant physiological conditions, we tested if enforced 
dimerization of PrPc may induce a conformational change reminiscent of the conversion 
of PrP° to PrP***. We used a well- described inducible dimerization strategy whereby a 
chimeric PrP° composed of a modified FK506-binding protein (Fv) fused with PrPc and 
termed Fv-PrP is incubated in the presence of a monomeric FK506 or dimerizing 
AP20187 ligand. Addition of AP20187 but not FK506 to recombinant Fv-PrP (rFv-PrP) 
in physiological-like conditions resulted in a rapid conformational change characterized 
by an increase in beta-sheet structure and simultaneous aggregation of the protein. 
Aggregates were partially resistant to proteinase K and induced the conversion of 
soluble rFv-PrP in serial seeding experiments. As judged from thioflavin T binding and 
electron microscopy, aggregates converted to amyloid fibres. Aggregates were toxic to 
cultured cells whilst soluble rFv-PrP and amyloid fibres were harmless. This study 
strongly supports the proposition that dimerization of PrP0  is a key pathological primary 
event in the conversion of PrP° and may initiate the pathogenesis of prion diseases.
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INTRODUCTION
Prion diseases or transmissible spongiform encephalopathies (TSEs) are fatal 
neurodegenerative disorders that affect both animals and humans. These diseases 
include scrapie in sheep, bovine spongiform encephalopathy ( B i e r e  et al.) in cattle and 
Creutzfeldt-Jakob Disease (CJD) in humans. In humans, these disorders can appear in 
three forms, sporadic, genetic, and iatrogenic. All forms involve modification of the 
normal prion protein (PrP°), a secreted gycosylphosphatidylinositol (GPI)-anchored 
sialoglycoprotein, into a disease-causing prion protein (PrP*68) ( P r u s i n e r ,  1998). 
Although the primary structures of PrPc and PrP1*68 have been found to be identical 
( S t a h l  et al., 1993) the two isoforms have considerably different physiochemical 
properties. PrPc is monomeric and degradable by proteinase K (PK), whereas PrPRes 
exists as insoluble aggregates that show dramatically increased resistance to digestion 
by PK ( P r u s i n e r ,  1998). Furthermore, spectroscopic data indicate that the two prion 
protein isoforms are characterized by different secondary structures; PrP is largely «■- 
helical, whereas PrP1*68 is rich in p-sheet structure ( C a u g h e y  et al., 1991, P a n  et al., 
1993). In designing strategies to prevent the propagation and the progression of TSEs, it 
is important to determine the molecular pathway leading to the aggregation of PrP .
Substantial efforts have been devoted to reconstitute de novo misfolding of 
PrPc and prion infectivity and/or toxicity. In a first approach, PrP1*68 was amplified in 
Prpitei-dependent conversion reactions experimental conditions (see ( S u p a t t a p o n e ,  
2004) and ( B a s k a k o v ,  2007) for reviews). Experiments included the use of ionic or 
non-ionic detergents, or repeated sonication steps, or shaking for a long period of time. 
In a second approach, recombinant PrP (rPrP) was mixed in a combination of low 
concentrations of guanidinium chloride (GdnHCl) ( J a c k s o n  et al., 1999, S w i e t n i c k i  et 
al., 2000) or urea and NaCl ( B a s k a k o v  et al., 2001, B o c h a r o v a  et al., 2005, 
M o r i l l a s  et a l, 2001) in acidic or neutral conditions. Recent investigations showed 
that acidic conditions alone can induce the conversion of rPrP ( C o b b  et al., 2008). 
Addition of lipids to rPrP also induces a conformational change into a form reminiscent
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of PrPRes ( W a n g  et a l, 2007). Furthermore, low concentrations of SDS induce a 
structural transition of PrP into a pathogenic conformation ( L e f f e r s  et al., 2005, 
S i m o n e a u  et a l, 2007). These approaches allowed purified PrPc or rPrP to undergo a 
transition to an oligomeric P-sheet-rich structure with essential physiochemical 
properties similar to those of PrP80*, and in some instances, to reconstitute infectivity 
( C a s t i l l a  et al., 2005, L e g n a m e  et al., 2004). Recently, thermal refolding and 
expression of PrP in form of a tandem repeat resulted in the formation of soluble 
oligomers with high P-sheet content ( R e z a e i  et al., 2005, S i m o n e a u  et a l,  2007). In 
vitro PrP conversion techniques have already contributed significant insights into the 
molecular mechanisms of prion diseases. However, an important issue remains 
unresolved: physiological circumstances mimicking in vitro conditions used to induce 
misfolding of PrPc are unlikely to occur in vivo. Thus, elucidating what molecular event 
may induce the aggregation of PrPc in physiologically relevant conditions remains an 
important challenge.
In acquired TSEs, PrP1*6* physically interacts with PrPc, and may force PrPc 
molecules to dimerize/oligomerize, and aggregate ( C H E S E B R O  etal., 2005, H o r i u c h i  &  
C a u g h e y ,  1999, M e i e r  et a l, 2003, P r u s i n e r  et al., 1990). Thus, we reasoned that 
dimerization may be a key step towards aggregation of PrP° in vivo. In favour of this 
hypothesis, several observations indicate that PrP can form dimers that could be 
intermediate states in PrP116* formation ( T o m p a  et al., 2002). Recently, we used a well- 
described chemical dimerization strategy to test this proposition. In this technology, a 
synthetic homodimerizing ligand termed AP20187 binds to and cross-links two FK506 
binding domains (Fv). A fusion protein between PrPc and Fv was engineered, and 
addition of AP20187to cultured cells expressing Fv-PrP resulted in the formation of 
extracellular deposits that are insoluble in non-ionic detergents and partially resistant to 
proteinase K ( G o g g i n  et a l, 2007). These findings demonstrated that homologous 
interactions between PrP molecules constitute a minimal and sufficient molecular event 
leading to PrP aggregation and extracellular deposition of aggregates, at least in 
cultured cells. Dimerization-induced aggregation of PrP may either be an intrinsic
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property of the protein, or require other cellular factors. In the present study, we 
addressed this issue by inducing the dimerization of purified recombinant Fv-PrP (rFv- 
PrP) in physiological-like conditions. We show that addition of AP20187 but not 
control monomeric FK506 to rFv-PrP results in spontaneous misfolding and 
aggregation as judged by an increase in turbidity, by differential centrifugation, and by 
electron microscopy. Circular dichroism experiments confirmed that AP20187 induces a 
structural conversion characterized by a decrease in a-helices and a concomitant 
increase in P-sheets. Furthermore, rFv-PrP aggregates induced the conversion of soluble 
rFv-PrP in serial seeding experiments. These results demonstrate that dimerization is a 
sufficient molecular event responsible for initiating misfolding and aggregation of PrP 
in vitro, and support the hypothesis that dimerization of PrPc is a possible initial step in 
the pathogenesis of prion diseases.
EXPERIMENTAL PROCEDURES 
Cloning, expression and purification of recombinant proteins
Recombinant human Fv-PrP (rFv-PrP) was amplified from pCEP4P-FvPrP 
( G o g g i n  et al., 2007). PCR primers were forward 5’-
ggaattccatatgaagaagcgcccgaagcctggag-3’ and reverse 5’-
cggaattctcacgatcctctctggtaataggcctg-3’. Recombinant Fv-PrP2 3 ' 124 and rFv-PrP124"231  
were generated by overlap extension PCR. For rFv-PrP2 3  124, Fv was amplified from 
pC4-FvlE (vector kindly provided by ARIAD Pharmaceuticals; 
www.ariad.com/regulatidnkits) using PCR primers forward 5’- 
actatacatacacatatggcttctagaggagtgcaggtggagactatc-3’ and reverse 5’-
ggcttcgggcgcttcttgcatgcgtagtctggtacgtcg-3’. PrP23 124 was amplified from pCEP4|3-PrP 
( G o g g i n  et al., 2007), using PCR primers forward 5’-
ccagactacgcatgcaagaagcgcccgaagcctggagg-3’ and reverse 5’-
cagtactaggaattcttacactgccccagctgctgcagcacc-3’. Fv-PrP2 3  124 was generated by using the 
products of these two PCR as primers for the overlap extension. For rFv-PrP124'231, Fv 
was amplified from pC4-FvlE using PCR primers forward 5’-
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actatacatacacatatggcttctagaggagtgcaggtggagactatc-3’ and reverse 5’- 
gccgccaaggccccccactgcgtagtctggtacg-3’. PrP124-231 was amplified from pCEP4P-PrP, 
using PCR primers forward 5’-cgtaccagactacgcagtggggggccttggeggctac-3’ and reverse 
5’-taggaattctcacgatcctctctggtaataggcctgagattccctctcg-3’. rFv-PrP124'231 was generated by 
using the products of these two PCR as primers for the overlap extension. In order to 
generate recombinant mouse Fv-PrP (rMoFv-PrP), Fv was amplified from pC4-FvlE 
using PCR primers forward 5’-phospho-gggtctagaggagtgcaggtggagactatc-3’ and reverse 
5’-phospho-gggtgcgtagtctggtacgtcgtacgg-3\ The PCR product was inserted in the 
natural Smal site of mouse Pmp at bpl 16. MoFv-PrP was amplified using PCR primers 
forward 5’-ggaattccatatgaaaaagcggccaaagcctggag-3’ and reverse 5’- 
cggaattctcaggatcttctcccgtcgtaataggc-3’. Recombinant human PrP (rHuPrP) was 
amplified from pCEP4P-PrP using PCR primers forward 5’- 
attctagctagccaccaccaccaccaccactgcaagaagcgcc-3’ and reverse 5’-
gcggatcctcacgatcctctctggtaataggcctg-3’. The PCR products were inserted between the 
Ndel and EcoRI sites in pET28a(+), creating NH2-6 xHis-tag constructs. PCR 
amplification fidelity was confirmed by sequencing. Constructs were over-expressed in 
BL-21 (DE3)pLys S cells and inclusion bodies were purified ( Z a h n  et al., 1997). 
Purification of recombinant proteins from the inclusion bodies was performed using the 
artificial chaperone-assisted method ( D a u g h e r t y  et al., 1998). Inclusion bodies were 
resuspended in buffer D1 containing 6  M GdnHCl, 100 mM Na2HPC>4 , 10 mM 
TrisHCl, 10 mM reduced glutathione , 1 mM Tris(2-carboxy-ethyl)phosphine (TCEP), 
pH 8.0. Soluble protein fraction obtained after harvesting (15,600 x g, 45 min) was 
added to 20 ml of Ni-NTA resin followed by incubation for 3 h at 4°C. Buffer D1 was 
gradually substituted by buffer D2 (4 mM GdnHCl, 100 mM Na2HP0 4 , 10 mM 
Tris HCl, 5 mM reduced glutathione, 0.5 mM TCEP, pH 8.0). GdnHCl was then 
replaced by 14 mM cetrimonium bromide in buffer D2 and samples were incubated at 
4°C for 2 h. Buffer D2 was exchanged by buffer R (100 mM NaH2P0 4 , 10 mM 
Tris HCl, 0.5 mM TCEP, 5 mM p-cyclodextrin, pH 8.0) followed by overnight 
incubation at 4°C. After a washing step with buffer R devoid of P-cyclodextrin (Buffer 
W), the protein was eluted with the same buffer containing 500 mM imidazole and 100
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mM GdnHCl (buffer E ) .  The eluted fractions were concentrated ( R o o s t a e e  et al., 
2008) in buffer W. All buffers contained 30 mM imidazole, unless indicated otherwise.
Assessment of in vitro aggregation
Recombinant proteins (0.2 mg/ml) were incubated in the presence or absence 
of increasing concentrations of AP20187 or FK506 at 37°C in 0.5 ml of 25 mM sodium 
phosphate buffer pH 7.4. After 30 min, the apparent OD, which is proportional to 
turbidity, was measured at 340 nm using a Beckman model DU 70, multisample 
UV/Vis spectrometer. After recordings, samples including AP20187 were transferred to 
fresh tubes, spun at 15,600 x g for 15 min, and the absorbance of supernatant was 
recorded at 340 nm.
Aggregation was also assessed by differential centrifugation. Recombinant 
proteins (0 . 2  mg/ml) were incubated in the absence or in the presence of increasing 
concentrations of AP20187 in a 0.5 ml of a buffer containing 10 mM Tris-HCl and 100 
mM Na2HPC>4 , pH 7.4. After 30 min at 37°C, samples were centrifuged at 15,600 x g 
for 15 min. Supernatants containing soluble proteins were collected in fresh tubes and 
proteins precipitated with TCA, and pellets were solubilized in 30 pi SDS loading 
buffer (0.5% SDS (w/v), 1.25% p-mercaptoethanol (v/v), 4% glycerol (v/v), 0.01% 
bromphenol blue (w/v), 15 mM Tris-HCl, pH 6 .8 ). Pellets containing aggregated 
proteins were directly solubilized in 30 pi SDS loading buffer. A 10 pi aliquot of each 
sample was analyzed in 12% SDS-PAGE and proteins stained with Coomassie blue.
Circular dichroism (CD) spectroscopy
CD measurements were carried out as previously described ( L a v i g n e  et al., 
1995) using a protein concentration of 6  pM in a 25 mM sodium phosphate buffer at pH 
7.4 (PBS) and at 37°C. The secondary structure changes of rFv-PrP were evaluated by 
monitoring the ellipticity in the far-UV region (190-250 nm). In some experiments, CD
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data were collected at various incubation time intervals after addition of AP20187. 
Three consecutive scans were accumulated and the average spectra were stored. Protein 
thermal denaturation curves were determined by monitoring the CD values at 222 nm, 
with increasing temperature from 10°C to 90°C. The temperature dependence of the 
mean residue ellipticity (0 ) at 2 2 2  nm was fitted using an in-house non-linear least- 
squares fitting program ( L a v i g n e  et al., 1998). In order to obtain the thermodynamic 
parameters (T°, AHU°(T°), ASU(T°) and AG„ (T)) describing the stability of rFv-PrP 
structural species, thermal denaturation curves of rFv-PrP were simulated assuming a 
two-state unfolding mechanism ( L a v i g n e  et a l, 1995, L a v i g n e  et a l, 1998, R o o s t a e e  
et a l, 2008). These experiments were performed in triplicates.
Data analysis
The temperature dependence of mean residue ellipticity (0) at 222 nm 
obtained from thermal denaturation profiles were fitted using an in-house non-linear 
least-squares fitting program assuming a two-state unfolding reaction as given below
0(7M1-Pu(D)-0n(7)+Pu(7>©u(D (D
where 0n (T) and ®u(T) are the temperature dependence of the mean residue ellipticity 
of the macroscopic folded and unfolded states, respectively. They were both assumed to 
be linear, i.e. ©n(7) = ©n(0) -  d®^(T)/dTT and ©u(7) = ©u(0) -  d@\j(T)/dT-T, where 
©n(0) and ©u(0) are the mean residue ellipticities at 0°C for the folded and unfolded 
states, respectively; correspondingly d®u(T)/dT and d©u(7)/dT are the constant slopes 
of ©n(T) and ©u(T)- Pu(T), the population of the unfolded state, is given by:
exp(-AG ((T) / RT)P (t ) = — ^ ------— (2 )
l+exp(-AG (T)/RT)
where the temperature dependence of the free energy of unfolding (AG„(7)) is described 
by the equation (3):
-T in ,I r jy  e
I
r j to
T \
* g u(T) = a h ; \  1 - —  l+A CPJ T - D
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where 7° is the melting temperature, AHu° is the apparent enthalpy of unfolding at 7° 
and ACp,u is the temperature-independent (Gomez et al., 1995) heat capacity of 
unfolding. In the present study, ACP,„ was considered constant and equal to 1 
kcalmol-K ' 1 (1 kcal -4 .184 kJ).
Thioflavin T (ThT) assay
The kinetics of amyloid fibril formation was monitored by a benzothiazole 
dye ThT-binding assay ( N a i k i  et al., 1989). Briefly, 5 pM AP20187 was added to 50 
pM rFv-PrP in a physiological buffer (PB buffer), ( G o d t  &  M a u g h a n ,  1988), 
containing 10 mM K3P04, 1 mM KC1, 50 mM CH3COOH, 5 mM KH3PO4 , 5 mM 
Na2HP0 4, pH 7.4, followed by incubation at 37°C. Aliquots of 30 pi were withdrawn 
and diluted to a final concentration of 5 pM rFv-PrP in PBS buffer (pH 8 ) containing 10 
pM ThT. ThT fluorescence emission at 482 nm (450 nm excitation) was measured on 
an Hitachi F-2500 spectrofluorometer. For seeding experiments, freshly prepared 
seeded amyloid fibrils obtained after 48 h of incubation in the presence of AP20187 
were sonicated on ice to disrupt large aggregates ( K u n d u  et al., 2003), and 2% (w/w) 
fibrillar material was added to 50 pM rFv-PrP.
Proteinase K sensitivity
Analysis of PK resistance was performed by incubating 10 pg/ml of each 
protein for 15 min in the presence of various concentrations of PK at 37°C in PB buffer. 
The samples were then precipitated with four volumes of methanol, resuspended in the 
loading buffer, and analyzed by western blotting with 3F4 (Chemicon) or EP1802Y 
(Abeam) antibodies.
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Electron microscopy of rFv-PrP samples
Fifty pM rFv-PrP was incubated with 5 pM AP20187 for 2 h or 48 h at 37°C. 
A 10 pi aliquot of protein preparation was applied to formar- and carbon-coated grids. 
The excess fluid was drained with filter paper and the sample was stained for 1 min 
with 2% uranyl acetate. The grid was air-dried and examined in a Hitachi H-2500 
electron microscope at 80 kV at a magnification of 15-75000.
Dimerization-induced seeding reactions
In a total reaction volume of 100 pi, 50 pM of rFv-PrP was aggregated by 
addition of 5 pM AP20187 in a buffer including 130 mM NaCl, 50 mM Na2HPC>4 , pH 
7.4 at 37°C. From the reactions aliquots were withdrawn after 1 h of incubation and 
used in seeding experiments after dilution 20 times in the same buffer containing 10 pM 
rFv-PrP in the absence of AP20187. After dilution, samples were subjected to protein 
misfolding amplification cycles with shaking/incubation periods ( A t a r a s h i  et al., 
2008). Each cycle included 2 min shaking and 30 min incubation at 37°C. PK digestion 
of the samples was performed using 2pg/ml PK. Proteins were precipitated with four 
volumes of cold methanol and analysed by western blotting. The following 
modifications were introduced for rFv-MoPrP. Aliquots were withdrawn after 5 h of 
incubation with AP20187, and shaking and incubation times were 5 min and 60 min, 
respectively. For the experiment in figure 10, rPrP was aggregated with 0.1% SDS and 
periodic sonication as previously described ( A t a r a s h i  et al., 2007)
In vitro toxicity experiments
For toxicity monitoring, N2a cells were seeded at a density of 0.5 x 106  cells 
per wells in a 6 -well plate. After one day in culture, cells were incubated in different 
conditions for 72 h. In order to keep steady culture medium concentrations, the proteins 
were diluted in 2 x culture medium and the proper volume of water and vehicle solution
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were added to get a final lx  concentration. rFv-PrP aggregates were obtained by 
incubating freshly prepared 1 mM rFv-PrP with 100 pM AP20187 for 30 min. 
AP20187-treated rFv-PrP was directly added to cells at a final concentration of 10 pM. 
Staurosporine was used at a concentration of 100 nM to induce apoptosis in control 
experiments ( B e l m o k h t a r  et al., 2001). Control aggregates of StAR protein 
( R o o s t a e e  et al., 2008) were obtained with 2M urea at pH 5.0 and added to cells in the 
same concentration as rFv-PrP.
RESULTS 
Dimerization-induced aggregation of rFv-PrP
To test whether dimerization of PrP induces a conformational change, rFv- 
PrP was expressed and purified as described in Experimental Procedures. SDS-PAGE 
analysis showed that the 38-kDa rFv-PrP protein was the predominant polypeptide in 
the purified fraction (Figure. 1A, left panel). The identity of the protein was also 
confirmed by immunoblotting analysis, using a monospecific antibody (Figure. 1A, 
right panel).
Recombinant Fv-PrP was incubated in the presence of increasing concentration 
of the dimerizing ligand AP20187 and the turbidity associated with the formation of 
aggregated proteins was measured at 340 nm. A large increase in absorbance was 
observed upon addition of AP20187, and maximal aggregation was achieved at 1.4 jxM 
AP20187 (Figure. IB, filled circles). Furthermore, all absorbance was lost after 
centrifugation of the samples in a table top centrifuge set at 15,600 x g (Figure. IB, 
empty circles). Addition of FK506, a monovalent ligand unable to induce the 
dimerization of Fv domains did not induce any change in absorbance, indicating that 
dimerization is essential for the aggregation of rFv-PrP (Figure. IB, filled triangles). 
Aggregation of rFv-PrP was confirmed by SDS-PAGE and Coomassie staining (Figure. 
1C). In the absence of AP20187, rFv-PrP was detected in the supernatant after
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centrifugation at 15,600 x g. Addition of increasing concentrations of AP20187 induced 
the transfer of the protein from supernatant to pellet, whilst FK506 did not modify the 
distribution of rFv-PrP (Figure. 1C).
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Figure 1. Expression and purification of rFv-PrP, and detection of rFv-PrP 
aggregates by light scattering and Coomassie
A. rFv-PrP was produced in E.Coli cells, BL2 1 (DE3>pLys S as described in 
Experimental Procedures. A 2 pg of rFv-PrP was subjected to the SDS-PAGE analysis 
(left panel). Immunoblotting assay was performed using 3F4 antibody (right panel). B. 
Light scattering: rFv-PrP (0.2 mg/ml, final volume 0.5 ml) was incubated in the 
presence of increasing concentrations of AP20187 (•) or FK506 (o) ligands at 37°C. 
Optical density resulting from light scattering of rFv-PrP aggregates or soluble proteins 
were measured at 340 nm by UV/visible spectroscopy. Samples including AP20187 
were centrifuged and the absorbance of supernatant is represented (▼). Values are 
expressed as the mean ± S.E.M. of O.D. at 340 nm from three independent experiments 
(p<0.5). C. Coomassie blue staining: 50 pM of rFv-PrP was incubated in the presence 
of the indicated concentrations of AP20187 or FK506 at 37°C for 30 min. After 
centrifugation at 15,600 x g for 15 min supernatants were separated and precipitated by 
TCA. Aggregated rFv-PrP pellets and precipitated supernatant were solubilised in SDS 
loading buffer and a 10 pi aliquot from each sample was subjected to a 12% SDS- 
PAGE analysis.
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Changes in the secondary structure of rFv-PrP
The dramatic propensity of rFv-PrP to undergo dimerization-induced 
aggregation prompted us to examine whether AP20187 induces a structural change 
characterized by modifications in the content of a-helices and P-sheets. Figure 3A 
shows the far UV CD spectra for rFv-PrP in PBS, pH 7.4 at a protein concentration of 6  
pM. In the absence of AP20187, the spectrum of rFv-PrP displayed a double minimum 
at 222 and 208 nm, characteristic of a-helical structure. Remarkably, upon the addition 
of AP20187, we observed a concentration-dependent decrease in negative ellipticity, 
concomitant with a change in the shape of the spectrum to one characteristic of P-sheet 
structure. The continuous helical destabilization can be monitored by an isodichroic 
point near 203 nm (Lu et a l, 1991), which was recorded after an increasing 
concentration of dimerizing ligand (Figure. 2A, arrow). The percentages of protein 
secondary structure from CD spectra using the K2d program confirmed the structural 
changes and indicated similar proportions of a-helix, P-sheet, and disordered structures 
after treatment with 3 pM AP20187 (Figure. 2B). Importantly, the values obtained were 
consistent with values obtained for brain-derived PrP1*68 and after in vitro conversion of 
PrPc by protein misfolding cyclic amplification (Table 1 and ( C a s t i l l a  et al., 2005)). 
The spectra and values (Figure. 2; Table 1) show a still relatively high content of a- 
helical structure after AP20187 treatment, as expected for disease-associated misfolded 
prion protein ( M a y  et al., 2004). A low content or lack of a-helical structure is 
considered a drawback for many in vitro PrP refolding/misfolding assays in which the 
misfolded PrP1*65 form is almost entirely organized in an aggregated P sheet structure 
( M a y  et al., 2004). The addition of FK506 did not change the secondary structure of 
rFv-PrP (not shown).
Dimerization increases the conformational stability of rFv-PrP
In order to gain more insights into the mechanism of PrP dimerization and its 
aggregation, the stability of rFv-PrP in the monomeric and aggregated states was 
studied by temperature-induced denaturation monitored by CD spectroscopy. In this
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Figure 2. Titration of rFv-PrP with AP20187 monitored by CD
Titration of rFv-PrP with dimerizing ligand AP20187 (□, 0 pM; o, 1.5 pM; ■, 2 pM; e, 
3 fiM) was carried out at a protein concentration of 6  fiM in 25 mM PBS pH 7.4 at 
37°C. The secondary structure changes were monitored by circular dichroism in a 0.1- 
cm pathlength quartz cell. Three consecutive scans in the far-UV (190-250 nm) were 
accumulated and the average spectra were stored. Arrow represents the isodichroic 
point.
Secondary rFv-PrP a Brain PMCA
structure |»|.pRes b PfpRes*
- +
AP20187 AP20187
a-Helix 56 34 36 36
p-Sheet 18 30 31 32
Random 26 36 33 32
a This study; values are derived from Figure 3 (3 pM AP20187). b From Ref. 17; 
PMCA, protein misfolding cyclic amplification.
Table 1. Pecentage of the secondary structure of rFv-PrP before and after 
dimerization
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context, changes in heat-induced conformational stability of rFv-PrP were 
determined at 222 nm ([®]2 2 2) over a range of 10-90°C different times after addition of 
AP20187.
The unfolding profiles of rFv-PrP were associated with a single and 
cooperative transition (Figure 3A). Using an in-house non-linear least-squares fitting 
program, temperature-denaturation curves {[0 ] 2 2 2  (T)} were fitted to eqn ( 1 ). to obtain 
T°, AHU°(T°), ASU°(T°) and AGU°(T°). All of the thermodynamic parameters were 
measured from the equations described in the Experimental Procedures. Thermal 
denaturation of rFv-PrP initially revealed a midpoint of thermal transition (Tm) of 70°C 
(Figure 3A, filled circles), in accordance with values published in the literature for rPrP 
( C o r d e i r o  et a l, 2005, S W I E T N I C K I  et a l, 1998). The addition of AP20187 resulted in a 
slight decrease of the Tm value to 6 8 .6 °C (Figure 3A, empty circles). This can be 
assumed as the initial step of the binding where AP20187 docks into the Fv domain 
which in turn increases the dynamics of binding site and a global destability in rFv-PrP 
structure. However, the stability of rFv-PrP was restored in a time- dependent manner 
with an increase in Tm after 1 h (Figure 3A, filled triangles). Maximum stability was 
observed 24 h following chemical dimerization of rFv-PrP with a Tm value of 79.8°C 
(Figure 3A, empty triangles; Table 2). A comparison of stability curves revealed that 
dimerization of rFv-PrP favoured spontaneous transformation of the protein into more 
stable conformations (Figure 3B). As depicted in Table 2, at 37°C the free energy of 
unfolding of the aggregated states reached a maximum value [AG„° (37°C) = 7.1 ± 0.2 
kcal.mol'1] when compared with that of the native soluble rFv-PrP [AGU° (37°C) = 4.9 ±
0.1 kcal.mol1], with a AAG„° (37°C) = 2.2 ± 0.1 kcal.mol1. To analyze the nature of 
this favorable structural transformation, variation in enthalpy and entropy of unfolding 
were determined as a function of temperature (Figure 3B). A comparison of AHu° 
(37°C) of rFv-PrP unfolding during the aggregation indicated that less favorable 
(enthalpic) interactions are broken during the structural transformation (Table 2). 
However, the variation in entropy 7AASU° (37°C) of unfolding of rFv-PrP caused by the 
dimerization-induced aggregation was calculated to be 12.2 ± 0.3 kcal.mol' 1 after 24 h. 
That is, the unfolding of the aggregated rFv-PrP is accompanied with a reduction of 
favorable (less positive) entropy. This behavior could be the result of the exposure of
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Figure 3. Thermal unfolding of rFv-PrP
A. Thermal denaturations of 6  pM soluble rFv-PrP in PBS, pH 7.4, were monitored by 
circular dichroism. Curves represent simulation of molar ellipticity points, (©2 2 2 ). 
obtained from thermal denaturation experiments. Temperature dependence of the 
unfolding of rFv-PrP was determined at different time intervals after AP20187- 
mediated dimerization: 0 h (•); 0.1 h (o); 1 h (▼); 24 h (V). B. Stability curves of rFv- 
PrP at physiological pH. The stability curves were calculated from the simulated 
unfolding profiles shown in A. Solid line, 0 h; dotted line, 0.1 h; dash dotted line 1 h; 
dash line, 24 h. The thermodynamic parameters calculated from stability curves are 
listed in Table 2.
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Time
after
addition
of
AP20187
Tin M u°
(37°C)
TASU°
(37°C)
AG„°(37°C)
h °C kcal.moi1
0 70.1 ± 37.4 ± 32.5 ± 4.9 ±0.1
0.3 0 . 6 0.5
0 . 1 6 8 . 6  ± 36.8 ± 32.6 ± 4.2 ± 0.6
0.7 0.3 0.9
1 71.2 ± 35.2 ± 29.1 ± 6.1 ±0.3
0.9 0 . 8 1 . 1
24 79.8 ± 27.4 ± 20.3 ± 7.1 ±0.2
0 . 2 0.4 0 . 2
Table 2. Thermodynamic parameters of temperature-induced denaturation of rFv- 
PrP
Parameters were determined from data shown in Figure 3B as described in 
Experimental Procedures. Data represent the mean and S.D. of three independent 
experiments.
83
more buried hydrophobic surfaces upon chemical dimerization and structural 
transformation of the protein.
Dimerization-induced amyloid formation of rFv-PrP and self-seeded conversion
To further characterize the nature of dimerization-induced rFv-PrP aggregates, 
we used the ThT assay. ThT specifically binds to amyloid fibrils ( N a i k i  et a l, 1989). 
The structure of rFv-PrP was very stable and no ThT binding occurred for over 60 h of 
incubation at 37°C (Figure 4A, empty squares). The addition of AP20187, but not 
monomeric FK506 to rFv-PrP resulted in a time-dependent increase in ThT binding 
(Figure 4A, filled triangles and filled squares, respectively). The kinetic curves for the 
assembly of amyloid structures were characterized by a lag phase of 4 h that was 
completely eliminated after addition of a small amount (2 % wt/wt) of the preformed 
rFv-PrP amyloid to monomeric rFv-PrP (Figure 4A, compare filled triangles with empty 
and filled circles). These results indicate that the conformational conversion of rFv-PrP 
is a self-seeded reaction that requires dimerization-induced oligomeric nuclei. In a 
positive control experiment, 0.1 mM GdnHCl and 1 M Urea were added to rFv-PrP to 
induce the formation of amyloids (Figure 4A, empty triangles).
Recombinant Fv-PrP fibres showed a bright fluorescence characteristic of 
amyloids after excitation by ultraviolet light (Figure 4B). In contrast, FK506-treated 
rFv-PrP did not show any specific staining (Figure 4C). The morphology of rFv-PrP 
fibres was further studied by electron microscopy. The micrographs of the protein 
incubated for 2 h in the presence of AP20187 showed amorphous aggregates of 
irregular shape (Figure 5A). After 48 h of incubation, numerous fibrils of about 15-20 
nm in diameter and of variable length were observed (Figure 5B). The diameter of these 
fibres is consistent with values previously obtained after conversion of rPrP in 
denaturing conditions ( B a s k a k o v  et a l, 2002, S w i e t n i c k i  et al, 2000). Aggregates or 
fibres were never observed in the presence of FK506 (Figure 5C).
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Figure 4. rFv-PrP fibrilization monitored by ThT-binding fluorescence assay. A. 
Fifty fiM rFv-PrP was incubated in the absence (□), or in the presence of 5 pM 
AP20187 (▼) or 5 pM FK506 (■) in the standard physiological buffer. In the seeded 
reactions, 2% wt/wt of preformed seeds were incubated with rFv-PrP (o) or rFv- 
PrP/AP20187 (•). The formation of amyloid fibrils was also induced in physiological 
buffer containing 100 mM GdnHCl and 1 M urea (A). All reactions were performed at 
pH 7.4 at a temperature of 37°C. B & C. ThT fluorescence of rFv-PrP observed in a 
fluorescence microscope after excitation with UV light. rFv-PrP was incubated for 48 h 
in the presence of 3 pM AP20187 (B) or 3 pM FK506 (C).
85
Figure 5. Morphology of rFv-PrP amyloid fibrils
A-D. Electron micrographs of negatively stained rFv-PrP taken after 2 h (A) or 48 h (B 
& C) of incubation in physiological buffer at 37°C in the presence of AP20187, or 48 h 
in the presence of FK506 (D). Note the presence of amyloid fibres after 48 h (B & C). 
C. Higher magnification of section indicated by a black box in B. The bar represents 
1 0 0  nm.
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Dimerization-induced aggregates and amyloids are slightly resistant to proteinase 
K digestion
Next we sought to investigate the extent to which AP20187-treated rFv-PrP is 
resistant to proteinase K (PK) digestion. In these experiments, aggregates and amyloids 
were produced after incubation of rFv-PrP with 3 pM AP20187 for 1 h and 48 h, 
respectively. Untreated (not shown) or FK506-treated rFv-PrP was fully degraded in a 
15 min incubation at 37°C in the presence of as little as 0.5 pg/ml of PK (Figure 6 A, left 
panel). In contrast, rFv-PrP incubated with AP20187 was slightly resistant to PK, and a 
number of fragments persisted at 2 pg/ml of PK (Figure 6 A, middle panel). A 
concentration of 8  pg/ml was required to completely proteolyse amyloid fibres (Figure 
6 A, right panel). These results were not specific to the human protein since the mouse 
protein (rFv-MoPrP) also acquired some resistance to PK treatment after incubation 
with AP20187 (Fig 6 B).
The C-terminal structured domain is responsible for dimerization-induced 
aggregation of PrP
In order to test which domain of PrP is involved in the aggregation of the 
protein after dimerization, we engineered two recombinant proteins, rFv-PrP2 3 ' 124  
representing the N-terminal unstructured domain between residues 23 and 124, and rFv- 
prp 124-231 representing the folded C-terminal domain between residues 124 and 231. 
Similar to rFv-PrP, these two truncated molecules were also fused to Fv. rFv-PrP2 3 ' 124  
was slightly insoluble since some protein was recovered in the pellet in the absence of 
any ligand after centrifugation at 15,600 x g (Fig 7A). Addition of AP20187 or FK506 
did not result in a significant increase of the protein in the pellet fraction, indicating that 
dimerization of rFv-PrP2 3 ' 12 4 does not induce its aggregation. In contrast, addition of 
AP20187 but not FK506 to rFv-PrP124-231 triggered the transfer of the protein from the 
soluble to the insoluble fraction (Fig 7A). In accordance to these results, aggregates
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formed after dimerization of rFv-PrP124' 231 were slightly resistant to PK treatment (Fig 
7B). Incubation of rFv-PrP2 3 124 with AP20187 did not modify the resistance of the 
protein to PK treatment. Interestingly, rFv-PrP124 231 was more sensitive to PK than rFv- 
PrP (compare Figure 6 A and 7B), suggesting that the N-terminal domain of PrP is
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Figure 6. Differential resistance of the rFv-PrP species to proteinase K digestion
A. rFv-PrP (2pg) was incubated in PB at 37°C in the presence of FK506 for 48 h, or in 
the presence of AP20187 for 1 h or 48 h. Proteins were then subjected to PK digestion 
at various concentrations of PK ranging from 50 ng to 3.2 pg in a total volume of 200 
pi. Western blot analysis was performed using 3F4 antibody. The position of rFv-PrP 
and PK-resistant (PK-res.) fragments is indicated. B. rFv-MoPrP (2pg) was incubated in 
PB at 37°C in the presence of FK506 or AP20187 for 48 h. Proteins were then subjected 
to PK digestion at various concentrations of PK ranging from 50 ng to 3.2 pg in a total 
volume of 200 pi. Western blot analysis was performed using EP1802Y antibody.
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Figure 7. Aggregation of truncated mutants of rFv-PrP
A. Coomassie blue staining: dimerization of 50 pM of rFv-PrP23' 124 or rFv-PrP124' 231  
was induced using the indicated concentrations of AP20187 at 37°C for 30 min. After 
centrifugation at 15,600 x g for 15 min supernatants were separated and precipitated by 
TCA. Pellets and precipitated supernatant were solubilised in SDS loading buffer and a 
10 pi aliquot from each sample was subjected to a 12% SDS-PAGE analysis. B. 
Differential resistance of rFv-PrP2 3 ' 124 and rFv-PrP124*231 to proteinase K digestion. 
Recombinant proteins (2pg) were incubated in PB at 37°C in the presence of FK506 or 
AP20187 for 48 h. Proteins were then subjected to PK digestion at various 
concentrations of PK ranging from 50 ng to 250 ng in a total volume of 200 pi. Western 
blot analysis was performed using 3F4 (rFv-PrP2 3  124) or EP1802Y (rFv-PrP124-23’) 
antibodies.
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important to acquire full resistance to PK. All together, these results show that the C- 
terminal domain of PrP is essential for dimerization-mediated aggregation of PrP.
Recombinant Fv-PrP conversion by shaking
PrpRes-seeded conversion of rPrP is an efficient method to demonstrate the 
presence and propagation of PrP1*65 ( A t a r a s h i  et al., 2007, A t a r a s h i  et a l, 2008). 
Since dimerization-induced rFv-PrP aggregates have seeding activity in amyloid 
formation assays (Figure 4A), we tested if they also display seeding activity in 
misfolding cyclic amplification assays using the quaking-induced conversion method 
recently described ( A t a r a s h i  et al., 2008). rFv-PrP aggregates were diluted 20 times 
into a buffer containing soluble rFv-PrP, and the reaction mixture submitted to quaking- 
induced conversion. The generation of aggregates was determined by western blotting 
after PK digestion (Figure 8 A). The conversion of rFv-PrP was observed through at 
least 5 serial reactions. The concentration of AP20187 present in the initial innoculum 
after the dilutions are not sufficient to account for the conversion of rFv-PrP during the 
30 min long quaking reactions (see Figure IB). Recombinant Fv-PrP incubated in the 
presence of monovalent FK506 did not sustain amplification of PK-resistant aggregates 
(Figure 8 A, right panel). The low levels of PK-resistant rFv-PrP resulted from shaking 
of the samples since no PK-resistant rFv-PrP was observed in the absence of shaking 
(Figure 8 A, right panel, shaking cycle 0; see also Figure 6 A, left panel). Similarly, 
dimerization-induced rFv-MoPrP aggregates had also seeding activity as demonstrated 
in shaking-induced conversion experiments (Fig 8 B).
Conversion of PrP with rFv-PrP aggregates
One strategy to test if AP20187-mediated aggregation of rFv-PrP is relevant to 
the conformational conversion of PrP was to investigate if rFv-PrP aggregates are able 
to induce the conversion of recombinant PrP (rPrP). rFv-PrP aggregates were diluted 20 
times into a buffer containing soluble rPrP, and the reaction mixture submitted to
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Figure 8. Quaking reactions seeded with rFv-PrP or rFv-MoPrP aggregates
A. rFv-PrP was incubated in the presence of 5 pM AP20187 orFK506 for 1 h. Samples 
were diluted 20 times into freshly prepared soluble rFv-PrP and submitted to quaking 
reactions as described in Experimental Procedures. Dilutions and quaking reactions 
were repeated 5 times. Proteins were then subjected to 2 pg / ml PK digestion and 
western blot analysis using 3F4 antibody. The position of rFv-PrP and PK-resistant 
(PK-res.) fragments is indicated. The concentration of AP20187 and FK506 remaining 
in each reaction is also indicated. B. rFv-MoPrP was incubated for 5 h in the presence 
of 5 pM AP20187. Samples were submitted to 5 cycles of quaking reactions as 
described in A. Proteins were then subjected to 2 pg / ml PK digestion and western blot 
analysis using EP1802Y antibody.
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quaking-induced conversion. The generation of aggregates was determined by western 
blotting after PK digestion at a concentration of 2 jig/ml (Figure 9A). This concentration 
of PK allowed the detection of aggregated rFv-PrP in the first shaking cycle (Fig 9A). A 
concentration of 10 pg/ml of PK was otherwise required to completely digest rPrP 
aggregates seeded by rFv-PrP aggregates (Fig 9B), and soluble rPrP was completely 
degraded with 2 pg/ml PK (Figure 9C). The conversion of rPrP with aggregated Fv-PrP 
was observed through at least 6  serial reactions (Figure 9A). In a reverse experiment, 
aggregated rPrP was also able to convert soluble rFv-PrP in shaking reactions (Figure 
9D).
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Figure 9. Conversion of rPrP by rFv-PrP aggregates
A. rFv-PrP was incubated in the presence of 5 pM AP20187 for 1 h. Samples were 
diluted 20 times into freshly prepared soluble rPrP and submitted to quaking reactions
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as described in Experimental Procedures. Dilutions and quaking reactions were repeated 
5 times. Proteins were then subjected to 2 pg / ml PK digestion and western blot 
analysis using 3F4 antibody. The position of PK-resistant rFv-PrP and rPrP fragments is 
indicated. Note that PK-resistant rFv-PrP fragments are too diluted to be detected after 
the second quaking cycle. B. Sample from shaking cycle 5 obtained as described in A 
was treated with increasing concentrations of PK as indicated, followed by western blot 
with 3F4 antibodies. C. Purified soluble rPrP was untreated (lane 1) or treated with 2 
pg/ml PK, precipitated with methanol and analyzed by western blotting with 3F4 
antibodies. D. rPrP was aggregated and the sample was diluted 20 times into freshly 
prepared soluble rFv-PrP and submitted to quaking reactions as described in A. Note 
that most of PK-resistant rPrP fragments are not detected after the first dilution and are 
completely undetectable after the second quaking cycle.
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Aggregates but not fibrils are toxic to cultured cells
The toxicity of dimerization-induced aggregates was tested in N2a cells by the 
intemucleosomal DNA fragmentation assay. Aggregates and amyloid fibres were 
produced as described above. Exposure of cells to 10 pM rFv-PrP aggregates for 72 h 
resulted in clear DNA fragmentation, similar to cells exposed to the apoptosis inducer 
staurosporine (Figure 10). In contrast, amyloid fibres were completely innocuous, 
demonstrating that only non-amyloid PrP aggregates are toxic species. FK506-treated 
rFv-PrP was also not toxic to N2a cells. Aggregates from the steroidogenic acute 
regulatory protein (StAR) were innocuous, indicating that toxicity is specifically 
associated with PrP aggregates.
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Figure 10. In vitro toxicity of rFv-PrP aggregates
DNA fragmentation assay was performed on N2a cells incubated for 72 h with 
staurosporine (1), 10 pM rFv-PrP aggregates (2), 10 pM rFv-PrP amyloids (3), 10 pM 
FK506-treated rFv-PrP (4). As an external control, N2a cells were incubated with 10 
pM of steroidogenic acute regulatory protein (StAR) aggregates (5).
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DISCUSSION
Misfolding of PrPc is the central pathogenic event in TSEs, yet what triggers 
de novo conformational change and aggregation of the protein in physiological 
conditions (e.g. no sonication, no chaotropic or denaturing agent, neutral pH) and in the 
absence of PrP* 68 remains unknown. The most important Ending of this study is the 
recognition of dimerization as a minimal and sufficient mechanism leading to 
spontaneous aggregation of PrP in physiological conditions. Furthermore, dimerization- 
induced aggregation is an intrinsic property of PrP since it occurs in vitro using the 
purified recombinant protein.
Several lines of evidence indicate that dimerization-induced misfolding of PrPc 
may be relevant to the aggregation of the protein in prion diseases. First, our Endings 
are consistent with previous reports based on theoretical and experimental data 
suggesting that dimerization has an important role in conformational change of PrPc 
(reviewed in ( T o m p a  et al., 2002)). We have directly tested and confirmed this 
hypothesis by using a conditional dimerization strategy. Most importantly, aggregates 
obtained after dimerization of rFv-PrP display seeded activity in amyloid fibrils 
formation and quaking conversion assays. Second, the proposition that dimerization 
may be a key event in PrP aggregation implies that PrP dimers should exist in both 
physiological and pathological conditions. Indeed, the presence of PrP dimers has been 
detected in non-infected hamster and mouse brains ( B e n d h e i m  &  B o l t o n ,  1986), and 
in murine neuroblastoma cell line expressing hamster PrP ( P r i o l a  et al., 1995). Dimers 
were also detected in Creutzfeldt-Jakob infectious material disaggregated in gentle 
conditions ( S k l a v i a d i s  et al., 1989), and in infected hamster brains ( P r i o l a  et al., 
1995). Third, monomeric rPrP is able to spontaneously dimerize during its 
crystallization process ( K n a u s  et al., 2001). The structure of the dimer suggested that 
dimerization may constitute an important step in the conversion PrPc —» PrP1*68. Finally, 
an in vitro study on the mechanism of PrP assembly into amyloid demonstrated that the 
precursor exists in a monomer-dimer equilibrium ( S t o h r  et al., 2008). The contact sites 
in the dimer were identified to residues 90-106 and 152-156.
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What may trigger the dimerization of PrP0  in prion diseases? In TSEs acquired 
by infection, PrP* 65 interacts with and could force the dimerization/oligomerization of 
PrPc molecules ( A b a l o s  et al., 2008, M e i e r  et al., 2003, S o l f o r o s i  et al., 2007). In 
TSEs non acquired by infection, dimerization of PrPc may be triggered either by an 
unknown ligand (Ho et al., 2005), or by the concentration of the protein in a restricted 
environment.
Our thermodynamic data indicate that the population of rFv-PrP dimers are 
more stable than that of the soluble monomers. A progressive increase in the entropy of 
reaction (Table 2 ) is a consequence of the disruption of a hierarchy of different kinds of 
intermolecular interactions (hydrogen bonds, electrostatic, dispersion forces and 
disulfide bridges) at the monomer-monomer interface. This evolution of internal 
dynamics in association with strong hydrophobic forces helps the system to cross the 
energy barriers according to the energy landscape model ( D o b s o n ,  2 0 0 3 ) .  This can 
result in the formation of a stable ‘seed’ which serves as a template for other soluble 
monomers. A global structural transformation in population of soluble rFv-PrP 
monomers shifts the equilibrium towards the massive rFv-PrP aggregation and 
subsequent amyloid fibril formation.
It is noteworthy that dimerization-induced aggregates form ThT-positive 
structures with typical amyloid morphology after 48 h of incubation. Previous reports 
describing the production of amyloid fibres from rPrP are all associated with the use of 
denaturants, elevated temperatures, or a combination of phospholipids bicelles and 
elevated temperature ( B o c h a r o v a  et al., 2005, B o c h a r o v a  et al., 2006, L u h r s  et al., 
2006). Our observation indicates that dimerization-induced aggregates are competent to 
form amyloids and demonstrate that it is possible to achieve the generation of PrP 
amyloid fibres in vitro in physiological-like conditions.
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Another interesting finding in this study is that rFv-PrP aggregates but not 
amyloids are cytotoxic. This result confirms previous evidence that small aggregates 
rather than amyloids are the toxic species in prion diseases and in other 
neurodegenerative diseases ( C a u g h e y  e ta l ,  1991, H a a s s  &  S e l k o e ,  2007, S i m o n e a u  
et al., 2007) and underscores the relevance of dimerization in prion diseases.
From our results, it is tempting to speculate that dimerization of PrPc in vivo 
would be a noxious event. This hypothesis is comforted by the observation that enforced 
dimerization of PrP° using cross-linking antibodies results in neuronal toxicity in mice 
( S o l f o r o s i  et al., 2 0 0 4 ) .  In that study, the presence of PrP aggregates was not 
investigated. However, in contrast to chemical dimerization, it is likely that cross- 
linking antibody-mediated dimerization may interfere with further conformational 
changes and aggregation.
The present study establishes dimerization of PrPc as a potential toxic 
mechanism in TSEs. Future therapeutic strategies may be aimed at preventing the 
contact between PrP° monomers.
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RESUME
Les maladies k prions, ou encephalopathies spongiformes transmissibles 
(TSEs), sont des ddsordres neurodegeneratifs mortels touchant humains et animaux, et 
provoques par le changement conformationnel d'une glycoproteine cerebrale normale 
(protdine prion, PrPc) k un isoforme infectieuse (PrPSc). Pendant la pathogenese des 
TSEs, des agrdgats et des fibres amyloides de la proteine prion sont formes. Cependant, 
le mecanisme exact de l'agrdgation et de la neurotoxicite des agregats de prion est 
toujours inconnu. Dans cette etude, nous avons examine l'effet de la dimdrisation sur 
l'agregation et la neurotoxicitd des espdces agrdgees produites k partir de protdine prion 
recombinante. Pour cela, nous avons produit une PrP recombinante chimdrique qui 
contient un domaine de dimdrisation (Fv) et qui a etd nominee Fv-MoPrP. Un ligand 
dimdrisant AP20187 a dtd employd pour induire la dimdrisation de Fv-MoPrP. L'analyse 
de la structure secondaire de Fv-MoPrP en presence d'AP20187 par dichroisme 
circulaire a demontre une perte progressive de structure hdlicale due k l'agrdgation de la 
protdine et k la formation de feuillets-p. Cependant, Fv-MoPrP soluble en absence 
d'AP20187 ou en prdsence d'un ligand monovalent FK506 possedait une structure 
hdlicale stable. Les agrdgats de Fv-MoPrP dimdrisd ont montrd une affmitd elevee pour 
la liaison k la sonde fluorescence ANS tandis qu'en absence d'AP20187, les monomeres 
de Fv-MoPrP n'ont pas montrd une liaison significative a l'ANS. Des analyses par 
microscopie k epifluorescence et par microscopie dlectronique ont ddmontrd qu’en 
conditions physiologiques, la dimdrisation de Fv-MoPrP a induit une formation rapide 
d'agregats globulaires et de fibres amyloides. L'injection sterdotaxique subcorticale de 
protdines recombinantes dans le cerveau de souris a prouvd que les agrdgats globulaires 
mais pas les protdines monomdriques ni les fibres amyloides dtaient neurotoxiques. Ces 
rdsultats suggdrent un role important de la dimdrisation de la protdine prion dans les 
processus d’agregation et de neurotoxicite retrouvds dans la pathologie des maladies k 
prions.
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ABSTRACT
Prion diseases, or transmissible spongiform encephalopaties (TSEs), are fatal 
neurodegenerative disorders of humans and animals caused by conformational 
conversion of a normal host glycoprotein (PrPc) into an infectious isoform (PrPSc). 
Formation of amyloid fibrils and protein aggregates occurs during the pathogenesis of 
prion disease. However, the exact mechanism of prion aggregation and neurotoxicity is 
still unknown. In this study, we examined the effect of dimerization on aggregation and 
neurotoxicity of aggregated species produced from recombinant prion protein. 
Therefore, a chimeric recombinant PrPc was designed which contained a dimerizing 
domain (Fv and termed Fv-MoPrP. A dimerizing ligand AP20187 was used to induce 
Fv-MoPrP dimerization. Secondary structure analysis of Fv-MoPrP in the presence of 
AP20187 by circular dichroism demonstrated a progressive loss of helical structure due 
to protein aggregation and P-Sheet formation. However, soluble Fv-MoPrP in the 
absence of dimerizing ligand or in the presence of a monovalent ligand FK506 revealed 
a stable helical structure. Dimerized Fv-MoPrP aggregates showed a high affinity to 
bind to ANS fluorescence whereas in the absence of AP20187, Fv-MoPrP monomers 
did not show any significant ANS binding activity. In the physiological conditions, 
dimerization of Fv-MoPrP induced a rapid formation of globular aggregates and 
amyloid fibrils as judged by epifluorescence and electron microscopy. Subcortical 
stereotaxic injection of recombinant proteins in the mouse brain showed that globular 
aggregates but not monomeric proteins or amyloid fibrils were neurotoxic. These results 
suggest an important role for prion dimerization in protein aggregation and 
neurotoxicity of prion disease pathology.
INTRODUCTION
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Transmissible spongiform encephalopathies (TSEs) or prion diseases, are fatal 
neurodegenerative diseases of mammals ( A g u z z i  &  H e i k e n w a l d e r ,  2006). TSEs have 
been known as humans diseases for decades, and include Kuru, Familial Creutzfeldt- 
Jakob disease (fCJD), sporadic CJD (sCJD), and more recently variant CJD (vCJD). In 
animals, TSEs include bovine spongiform encephalopathy in cattle, scrapie in sheep 
and goats and chronic wasting disease in elk and deer. In addition, TSEs have been 
detected in other animals such as cats and mink. The transmissible agent in TSEs is 
exclusively composed of protein and no genomic nucleic acid has been associated with 
the molecular pathology of prion diseases ( P r u s i n e r ,  1997). The infectious agent of 
TSEs was defined in 1982 by Stanley B Prusiner ( P r u s i n e r ,  1982) as Prion 
(proteinaceous infectious). Therefore, prion has been defined as an ‘infectious’ protein 
with the capacity to induce conversion of a normal host protein termed PrP , or simply 
PrP, into a misfolded isoform termed PrPSc ( A g u z z i  &  H a a s s ,  2003). PrPc is a 
membrane glycoprotein which is expressed mainly in cells of the lymphoreticular tissue 
and central nervous system (CNS). PrPc and PrP8® are two isoforms with identical 
amino acid sequences but differ in their conformational properties ( B a s l e r  et al., 
1986). The structure of PrPc from different species has been revealed by nuclear 
magnetic resonance (NMR) ( H O R N E M A N N  et al., 2004, R l E K  et al., 1996, Z a h n  et al., 
2000). The structure of PrPc has been mainly composed of a-helical content and little 
P-sheet structure, whereas PrPSc is composed exclusively of P-sheet content ( P a n  et al., 
1993, S m i r n o v a s  et al., 2011). Limited proteolysis of PrPSc with proteinase K (PK) 
produces PrP27'30, which retains infectivity. However, PrPc is very sensitive to PK 
digestion and is completely hydrolyzed under the same experimental conditions 
( B u t l e r  et al., 1988). The characteristic hallmark of prion disease is accumulation of 
PrP5 0 in the CNS of the affected host ( P r u s i n e r ,  1997). Therefore, it is generally 
accepted that transmission of TSEs depends only on a single protease-resistant protein 
component, PrP5* ( A g u z z i  &  C a l e l l a ,  2009).
One important characteristics of prion is the ability to propagate within cells 
and tissues and the infection is associated with neurotoxicity manifested by brain tissue
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damage. However, relationship between prion conversion, generation of neurotoxic 
species, prion propagation and clinical onset has remained to be determined. Recently, it 
has been proposed that prion toxicity and infectivity are two distinct processes in the 
pathogenesis of prion disease ( S a n d b e r g  et a l,  2011). According to this model, 
interaction of infectious PrPSc with PrPc monomers can convert PrPC molecules to 
neurotoxic entities. There is much evidence to hypothesize that prion infectivity and 
neurotoxicity occur in two distinguished phases. When transgenic mice expressing PrPc 
without the GPI anchor are infected with PrP50, protease-resistant PrP10* amyloid 
plaques are deposited but there is no manifestation of pathological symptom in the 
infected mice ( C H E S E B R O  et al., 2005). However, there are some cases of prion disease 
where PrP5 0 is not detectable in the clinical studies. This occurs in some cases of fatal 
familial insomnia ( G a m b e t t i  et al., 1995), scrapie-like disorders in mice 
overexpressing mutant PrP transgenes ( T e l l i n g  et a l,  1996), wild-type mice inoculated 
with PrPSc ( L a s m e z a s  et a l, 1997, M a n u e l i d i s  et al., 1997) and in prion-infected mice 
expressing a PI OIL mutant variant of the prion protein ( M a n s o n  et a l,  1999). Other 
studies have shown that PrP fragment including the hydrophobic domain sequence of 
PrPc (residues 106-126) is toxic to neuronal cultures ( B a h a d i  et al., 2003, B r o w n  et 
a l, 1996, F o r l o n i  et al., 1993, H a i k  et al., 2000). N-terminally truncated PrP can also 
induce neurotoxicity when the expression of the wild type PrPc is absent in cells 
( S h m e r u n g  et a l, 1998). Based on these results, it can be proposed that amyloid 
structures of PrP50 are not the toxic species in prion disease and that under certain 
conditions, PrP° can adopt a conformation that can induce cellular toxicity ( S i m o n e a u  
et al., 2007).
There is growing evidence that the toxic species in neurodegenerative diseases 
are soluble oligomers and protofibril structures and not mature fibrils. This hypothesis is 
confirmed by several studies in which different types of aggregates were produced in 
vitro from recombinant PrP ( K a y e d  et al., 2003, W a l s h  et a l, 2002, W h a l e n  et al., 
2005) as well as some other disease-causing proteins ( B u c c i a n t i n i  et a l,  2002, K a y e d  
et a l, 2003, N O V I T S K A Y A  et al., 2006, W A L S H  et a l ,  2002, W H A L E N  et a l,  2005) and
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their toxicity to cultured cells were evaluated. The experiments showed that P-oligomers 
and smaller pre-fibrillar structures induce greater toxicity levels compared to mature 
amyloid fibrils.
It has been shown that soluble AP dimers and oligomers extracted from 
Alzheimer's disease brains have the potential to impair synapse structure and function 
and that AP dimer can act as smallest synaptotoxic unit ( S h a n k a r  et a l,  2 0 0 8 ) .  Some 
laboratories have produced and characterized smaller annular oligomeric species of 
synthetic AP and have designated these ADDLs ( L a m b e r t  et a l, 1 9 9 8 ) .  ADDL-like 
oligomeric structures, which their presence has been associated with memory loss, have 
been isolated from post-mortem AD brains ( G o n g  et al., 2003). These neurotoxic 
prefibrillar intermediate aggregated structures are formed during amyloidogenesis 
pathway and the endpoint products such as amyloid fibrils and plaques may have other 
distinct biological activities which remain to be determined (Figure 1 A).
In vitro and in vivo studies have been done to characterize the neurotoxic 
species involved in prion pathology. It has been reported that annular and pre-fibrillar P- 
Sheet-rich aggregates made of recombinant prion in acidic and denaturing conditions 
(Figure IB) are highly toxic to cell cultures ( S a n g h e r a  et al., 2 0 0 8 ) .  Another study 
showed that prion annular aggregates and protofibrils (Figure 1C) obtained from 
oligomerization of thermally unfolded bovine PrPc or a dimer of prion composed of two 
covalently bound PrPc molecules are neurotoxic when injected to the mice brains 
( S l M O N E A U  et al., 2 0 0 7 ) .
Although intriguing, these results are all based on preparations and 
characterizations of prion neurotoxic species in non-physiological conditions such as 
high temperature unfolding of PrP° or the use of denaturants and acidic conditions
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Figure 1. Formation of oligomeric pre-fibrillar aggregates in Alzheimer's and 
prion diseases
(A) AP annular and globular aggregates, which are produced during formation of 
tangles and plaques in Alzheimer's disease, are responsible for neurotoxicity, synaptic 
dysfunction and cell death. (B) Morphology of Prion oligomers which are toxic to cell 
cultres ( S A N G H E R A  et a l, 2 0 0 8 ) .  ( C )  Morphology of bovine PrP aggregates which are 
neurotoxic after injection to the mice brain ( S e m o n e a u  et al., 2 0 0 7 ) .
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( S A N G H E R A  et al., 2008, S l M O N E A U  et al., 2007). In vitro PrP conversion techniques 
have already contributed to give significant insights into the molecular mechanisms of 
prion diseases. However, an important issue to be answered is: in vitro conditions used
unlikely to occur in vivo.
W e  h a v e  p r e v i o u s l y  u s e d  a  w e l l - k n o w n  d i m e r i z i n g  s t r a t e g y  ( F i g u r e  2 )  t o  s t u d y  
t h e  m e c h a n i s m  o f  p r i o n  a g g r e g a t i o n  a n d  a m y l o i d o g e n e s i s  i n  p h y s i o l o g i c a l l y  r e l e v a n t  
c o n d i t i o n s  ( G o g g i n  et al., 2 0 0 7 ,  R o o s t a e e  et al., 2 0 0 9 ) .  F v - M o P r P ,  a  c h i m e r i c  f o r m  o f
termed AP20187, has been produced in the laboratory and its biological characteristics 
have been well studied. Addition of AP20187 to cultured cells expressing Fv-MoPrP 
results in the formation of extracellular deposits that are insoluble in non-ionic 
detergents and partially resistant to proteinase K ( G o g g i n  et al., 2007). In vitro, 
dimerization of Fv-MoPrP accelerates the formation of partially proteinase K-resistant 
aggregates and amyloid fibrils. These aggregates contain a high P-Sheet content 
characteristic of PrP8® ( R o o s t a e e  et al., 2009).
to recapitulate the physiological circumstances that induce misfolding of PrPc are
PrPc harboring a dimerizing Fv domain capable of binding to a dimerizing ligand
+
m
+
AP20187
Figure 2. Design of in vitro dimerizing system
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In this study we took advantage of dimerizing system to study the formation of 
toxic species involved in prion pathology, in physiological conditions. Dimerization of 
Fv-MoPrP results in the formation of pre-fibrillar oligomeric species which show high 
affinity to bind to ANS florescence probe. These protein species which are formed in 
the early phases of prion aggregation show a quick loss of helical structure, consistent 
with a fast formation of p-Sheet conformation associated with Fv-MoPrP dimerization. 
These oligomers were highly neurotoxic when injected into the mice brain. The current 
work provides, for the first time, evidence on the neurotoxicity of prion oligomers 
produced in a physiologically relevant condition.
MATERIALS AND METHODS 
Cloning of Mouse FvPrP (Fv-MoPrP)
To generate recombinant mouse Fv-MoPrP, Fv was amplified from pC4-FvlE 
using PCR primers forward 5'-phospho-gggtctagaggagtgcaggtggagactatc-3' and reverse 
5'-phospho- gggtgcgtagtctgg tacgtcgtacgg-3'. The PCR product was inserted in the 
natural Smal site of mouse Pmp at bp 116. Mouse Fv-MoPrP was amplified using PCR 
primers forward 5 ggaattccatatgaaa aagcggccaaagcctg gag-3' and reverse 5’- 
cggaattctcaggatcttctcccgtcgtaataggc-3'. Recombinant human PrP was amplified from 
pCEP4-PrP using PCR primers forward 5-
attctagctagccaccaccaccaccaccactgcaagaagcgcc-3 and reverse 5'-
gcggatcctcacgatcctctctggtaataggcctg-3'. The PCR products were inserted between the 
Ndel and EcoRI sites in pET28a vector, creating NH2-His6 tag constructs. PCR 
amplification fidelity was confirmed by sequencing.
Expression and purification of Fv-MoPrP
Freshly transformed overnight culture of E. coli BL21(DE3) cells (Stratagene) 
containing the respective plasmid for expression of prion protein was added at 37°C to 2 
1 of Luria broth (LB) medium plus ampicillin (100 ug/ml). At OD600 = 0.5, expression 
was induced with isopropyl (3-D-galactopyranoside (IPTG) to a final concentration of 1
I l l
mM. Cells were harvested by centrifugation at 6000 rpm, lysed in buffer [50 mM 
Tris/HCl (pH 8 ), lOOmM sodium chloride and 1 mM EDTA] containing PMSF (0.1 
mM final) and lysozyme (20 pg ml- 1  final) and then treated with sodium deoxycholate 
(1 mg ml- 1  final) and DNase (5 pg ml- 1  final). Bacteria were spun at 15000 rpm for lh  
and the pellet was kept at -80X1!. Samples underwent three consecutive freez-thaw 
cycles and centrifuged at 15000 rpm for 30 min. Inclusion bodies were resuspended in 
100 ml denaturing buffer buffer G (6 M GdmCl, 10 mM Tris-HCl, 100 mM Na2P0 4 , 10 
mM reduced glutathione, pH 8.0). After sonication and centrifugation, the soluble 
protein fraction was added to 30 ml of nickel-nitrilotriacetic acid (NTA) agarose resin 
(Qiagen) and stirred for 10 min. The resin was poured into a column and washed with 
120 ml buffer G, and to the immobilized histidine tail-containing fusion protein we 
applied a 200 ml GdmCl gradient of buffer G to buffer B (10 mM Tris-HCl, 100 mM 
Na2P0 4 , pH 8.0). Protein impurities devoid of histidine tails were removed from the 
agarose resin with 75 ml of 50 mM imidazole in buffer B. The protein was eluted with 
buffer E (10 mM Tris, 100 mM Na2 P0 4 , 500 mM imidazole, pH 5.8). After washing the 
resin with 30 ml of buffer G, oxidative refolding and imidazole elution were repeated to 
obtain a second batch of. soluble prion protein. Histidine tail-fused Fv-MoPrP was 
dialysed against buffer D (10 mM Na2 P0 4 , pH 5.8), and afterwards against a 
physiological buffer containing 10 mM K3PO4 , 1 mM KC1, 50 mM acetic acid, 5 mM 
KH3PO4  and 5 mM Na2HPC>4 (pH 7.4), using Millipore ultracentrifugation filters 
(Amicon Canada).
Dimerization-induced aggregation of Fv-MoPrP in physiological conditions
All reactions were performed in 1.5 ml tubes in a total volume of 0.5 ml. Fifty 
pM rFv-MoPrP was incubated in the absence , or in the presence of 1 pM AP20187 in a 
buffer containing 10 mM K3PO4 , 1 mM KC1, 50 mM acetic acid, 5 mM KH3PO4  and 5 
mM Na2HPC>4 (pH 7.4). Samples were subjected to Shaking (200rpm) at 37 C. As the 
negative control parallel incubations were performed including Fv-MoPrP and a 
monovalent ligand FK506. From this reactions, aliquots were withdrawn at different
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time intervals and were either structurally analysed by circular dichroism, electron 
microscopy and ANS binding assay or were used for in vivo injections.
Circular dichroism (CD) spectroscopy
CD measurements were performed at 25 C using a Jasco J-810 
spectropolarimeter. Ellipticity is reported as mean residue ellipticity ([0]) in deg cm2  
dmole' 1 and calculated from the following equation: [0 ] = [0 ]obs(mrw)/ 1 0 /c, where 
[0 ]obs is the ellipticity measured in degrees, mrw is the mean residue weight 
(molecular mass divided by the number of amino acid residues, c is the peptide 
concentration in grams per milliliter and I is the optical path length of the cell in 
centimeters. CD spectra were the average of three consecutive scans obtained by 
collecting data at 0.1 nm intervals from 250 to 190 nm. Peptide concentrations were 
determined by amino acid analysis. To study the effect of dimerization on the 
conformational transformation of Fv-MoPrP. Aliqoutes were taken every 4h from 
aggregation reactions mentioned above and proteins were diluted to a final 
concentration of 6  pM in a 25 mM sodium phosphate buffer at pH 7.4. To represent a 
time course of helical changes in Fv-MoPrP after dimerization, the average points at 
222 nm were collected and plotted against the time. En each acquisition, the CD spectra 
of a 25 mM sodium phosphate buffer containing appropriate concentration of AP20187 
(blank) was subtracted from the spectra obtained for protein sample.
Electron microscopy of Fv-MoPrP samples
Fifty mM Fv-MoPrP was incubated with 1 pM AP20187 for 8  h or 48 h at 
37°C with shaking (200 rpm). A 10 pi aliquot of protein preparation was applied to 
formar- and carbon-coated grids. The excess fluid was drained with filter paper and the 
sample was stained for 1 min with 2% uranyl acetate. The grid was air-dried and 
examined in a Hitachi H- 2500 electron microscope at 80 kV at a magnification of 15- 
75000.
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Thioflavin T (ThT) staining of Fv-MoPrP amyloid fibrils
For ThT staining, lpl aliquots from dimerization/aggregation assays (0 h , 8  
h,48 h) were withdrawn and diluted into 50 pi PBS buffer (pH 8.0) containing 50 pM 
ThT. Samples were incubated for 1 h at 371 .  ThT fluorescence of rFv-MoPrP observed 
in a fluorescence microscope after excitation with UV light ( R o o s t a e e  et al., 2009).
8-anilino-l-naphthalenesulfonate or ANS binding assay
ANS binding assay for prion oligomerization was done in time course and also 
concentration-dependent manner. For time course studies, 20 pi aliquots were 
withdrawn from aggregating reactions every 4h and were diluted into 20 mM potassium 
phosphate buffer, pH 7.0, to give a final protein concentration of lpM. Aliquots of ANS 
from a stock solution in 20 mM phosphate buffer, pH 7.0, were subsequently added to 
the protein samples, to a final ANS concentration of 50 pM. ANS (100 pM) was also 
titrated with 0-3 pM increasing concentrations of Fv-MoPrP samples taken after 8 h 
from aggregating reactions. Binding of ANS was evaluated by measuring the 
fluorescence enhancement of ANS upon excitation at a wavelength of 380 nm. The 
emission spectra were integrated from 400 to 600 nm and values collected at 470 nm 
were plotted against the time or protein concentration.
In vivo Neurotoxicity Experiments
A group of 36 WT C57BL/6 mice were injected intracerebrally with 2 pi of 1 
mg/ml of Fv-MoPrP preparations (soluble, aggregates, amyloids), or the same volume 
of buffer. Soluble proteins were taken before induction of dimerization and aggregates 
and amyloids were obtained from samples aggregated 8  h and 48 h after dimerization, 
respectively. Coordinates for the injection site were 1.50 mm posterior and 1.75 mm 
ventral to the bregma and 2 . 0 0  mm lateral to the midline. 2  pi physiological buffer 
containing 10 mM K3PO4 , 1 mM KC1, 50 mM acetic acid, 5 mM KH3PO4  and 5 mM 
Na2HPC>4 (pH 7.4), or 2 pi protein samples (40 pM) were injected at a rate of 0.4 
pl/min. At 48 h post-injection, animals were euthanized by cervical dislocation,
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according to the Animal Ethics Committee of the Universite de Sherbrooke. Brains 
were fixed in 4% paraformaldehyde in Phosphate-Buffered saline containing 4% 
sucrose. Brain sections adjacent to the injection site were tested for apoptosis using 
ApopTag BrdU kit (Promega, Madison, WI, USA) and apoptotic cells were observed by 
confocal microscopy. Brain nuclei were stained with Hoechst Three independent 
experiments were performed.
Confocal microscopy
For confocal analysis, brain sections were examined with a scanning confocal 
microscope (FV1000, Olympus, Tokyo, Japan) 40X objective (Olympus). Specimens 
were laser-excited at 488 nm (TUNEL-positive signals) and 405 nm (Hoechst). In order 
to avoid cross-talk between the fluorescence emitted by different dyes, images were 
acquired sequentially. Serial horizontal optical sections of 320 X 320 pixels were taken 
from cells adjacent to the injection site and hippocampus CA2-CA3 region and focal 
planes were stacked for optimal detection. Identical settings of the instrument were used 
for all photos. For illustration purposes, each dye was pseudocolored (FluoView 
software, Olympus).
RESULTS
Time-dependent conformational transformation of Fv-MoPrP induced by 
dimerization
In the previous work we designed an in vitro autodimerizing system containing 
PrPc containing a dimerizing Fv domain capable of binding to a divalent ligand termed 
AP20187. In vitro studies showed that in the presence of the increasing concentrations 
of AP20187, human rFv-MoPrP displays a fast a-helix —* J3-sheet conformational 
transformation ( R O O S T A E E  et al., 2009). Indeed in that study we characterized the 
instant effect of AP20187 concentration on the secondary structure changes of Fv- 
MoPrP.
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In the current work a lower concentration of AP20187 was used to verify the 
aggregation of Fv-MoPrP independent of the ligand concentration. Using this condition 
we can also diminish the possibility of structural changes of Fv domain caused by 
higher AP20187 concentrations. Therefore, aggregation of 50 pM Fv-MoPrP was 
induced with a low concentration of AP20187 (1 pM) and reactions were let to proceed 
for 48 hours. These conditions have two advantages: (1) limited number of initial 
dimers provide aggregate nuclei which can gradually seed the aggregation of soluble 
Fv-MoPrP, (2) secondary structural changes of proteins can be characterized in a 
controlled time course manner.
Secondary structure analysis of Fv-MoPrP was performed by circular 
dichroism spectroscopy on the samples obtained from aggregating experiments. Figure 
3A shows the far UV CD spectra for Fv-MoPrP in PBS, pH 7.4 at a protein 
concentration of 6  pM. In the absence of AP20187 the spectrum of Fv-MoPrP displayed 
a double minimum at 2 2 2  and 208 nm (with a mean residue ellipticity at 2 2 2  nm, ©2 2 2 . 
of -17.30 x 103 deg cm2 drool'1) typical for a a-helix-rich protein. As shown in Figure 
3A, 4 h after addition of AP20187 there is a substantial change in the secondary 
structure of Fv-MoPrP. Molar ellipticity of Fv-MoPrP spectra at 208 (corresponding to 
helical structure) decreases from -18.84 x 103 to -14.44 x 103 deg cm2  dm ol1 (Figure 
3A). After 8  h there is a significant decrease in helical structure at 208 nm and 222 nm 
from -18.84 x 103 and -17.30 x 103 deg cm2 dmol' 1 to -7.819° x 103 and -14.21 x 103  
deg cm2 dmol'1, respectively. This means that in the presence of lower concentrations 
of AP20187, there is a gradual decrease in the a-helical content of Fv-MoPrP. This 
decrease in the helical structure of Fv-MoPrP reaches the maximum after 48 hours 
where molar ellipticities corresponding to 208 nm and 2 2 2  nm wavelengths decreases to 
5.610 x 103 and 10.91 x 103 deg cm2 dmol'1, respectively. These results indicate that the 
observed structural transformation of Fv-MoPrP occurs even at low concentrations of 
AP20187.
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For a more detailed characterization of the secondary structural changes of Fv- 
MoPrP, time course experiments were carried out. For kinetic studies, samples were 
withdrawn every four hours after dimerization, their CD spectra were obtained and 
molar ellipticity points recorded at 222 nm were plotted against the time (Figure 3B). In 
the absence of AP20187, Fv-MoPrP shows a stable helical structure in physiological 
buffer and after 48 h shaking at 37 C, a slight decrease in the helical content of the 
protein was observed. When Fv-MoPrP was incubated with a monovalent ligand 
FK506, helical changes were in the same range as protein in the absence of ligand. This 
indicates that the presence of Fv domain or a monovalent ligand does not have any 
significant effect on the structural transformation of recombinant Fv-MoPrP. However, 
in the presence of lpM AP20187, substantial changes in helical conformation of Fv- 
MoPrP were recorded (Figure 3B). Analysis of time course curves clearly shows that 
the loss of helical structure occurs very fast within 1 0  h after induction of dimerization.
CD spectra analysis of Fv-MoPrP demonstrate that despite substantial loss of 
helical structure after protein aggregation, there is still relatively low content of a- 
helical structure after AP20187 treatment, as expected for disease-associated misfolded 
prion protein ( M a y  et al., 2004). A low content or lack of a-helical structure is 
considered a drawback for many in vitro PrP refolding/misfolding assays in which the, 
misfolded PrPRes form is almost entirely organized in an aggregated P-sheet structure 
( M a y  et al., 2004, S m i r n o v a s  et a l, 2011).
Dimerization of Fv-MoPrP induces the formation of aggregates and amyloid fibrils
Previous studies have demonstrated that the precursor state of the amyloid 
fibrils exist in a monomer-dimer equilibrium of partially denatured, a-helical PrP 
(Stohr  et al., 2008). These precursors can convert into several intermediate structures 
and amyloid fibrils. Based on the substantial decrease in helical structure of the 
recombinant Fv-MoPrP about 8  h after dimerization and the minimum [ @ ] 2 2 2  obtained 
after 48 h we decided to analyse the structure of these P-Sheet-rich protein species 
formed at these time frames ( 8  and 48 h).
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Figure 3. CD spectroscopy of Fv-MoPrP
A 6  pM soluble or aggregated Fv-MoPrP was analysed by CD. (A) CD spectra of 
soloble Fv-MoPrP or samples withdrawn 4, 8  and 48 h from aggregation reactions. (B) 
CD spectra of Fv-MoPrP recorded at 222 nm ([0 ]2 2 2) and plotted against the time.
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Electron micrographs of Fv-MoPrP preparations are shown in Figure 4. In the 
absence of AP20187, when Fv-MoPrP is incubated with FK506, after 8  h there is no 
considerable structure formed under this experimental condition. Even after 48 h only 
some dispersed aggregates without any defined ultrastructure can be observed in the 
samples of Fv-MoPrP which have not been dimerized (Figure 4, bottom). However, in 
the dimerizing incubations where AP20187 is included in the aggregation reactions, two 
different phases of aggregation and amyloid fibril formation could be distinguished. In 
the presence of AP20187, Fv-MoPrP proteins form several intermediate aggregated 
structures such as small amorphous structures and annular and globular and prefibrillar 
assemblies (Figure 4. top, arrows). The morphology of prion aggregates reported by 
electron microscopy in our experimental conditions are similar to the previously 
reported granular protofibrils and annular prion aggregates produced in the acidic 
conditions or in the high temperature unfolding protocols (Sanghera  et al., 2008, 
SlMONEAU et al., 2007).
When aggregation reactions were let to proceed in the physiological conditions 
up to 48 h, amyloid fibrils were formed from Fv-MoPrP in the dimerizing conditions 
(Figure 4, Top). After 48 h of incubation, amorphous aggregates and amyloid fibrils of 
about 15-20 nm in diameter and of variable length were detected. The diameter of these 
fibres was consistent with values previously obtained after conversion of rPrP in 
denaturing conditions (Baskakov  et al., 2002, Sw ietnicki et a l, 2000)
Pre-fibrillar aggregates and amyloid fibrile induced by dimerization of Fv-MoPrP 
are stained by ThT
One of the characteristics of amyoid fibrils is their high reactivity with ThT 
which is a fluorescent dye used extensively to study the kinetics of amyloidogenesis 
(Baskakov  et al., 2002). Therefore, we decided to use ThT to visualize the amyloid 
formation process in the aggregating reactions containing Fv-MoPrP plus AP20187.
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Figure 4. Morphology of Fv-MoPrP aggregates
Electron micrographs of negatively stained moFv- PrP taken after 8  h or 48 h of 
incubation in physiological buffer at 37°C in the presence of AP20187 (top) or FK506 
(bottom). Note the presence globular intermediate protofibrils and amyloid fibres 
formed 8  h and 48 h, respectively, following the dimerization of Fv-MoPrP. The bar 
represents 100 nm. Arrows: black, annular aggregates; red, graanular aggregates; blue, 
pre-fibrillar amorphous structures.
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Figure 5 represents fluorescent microscope photos taken to show the process of 
amyloid fibrils formation induced by the Fv-MoPrP dimerization. In negative control 
including Fv-MoPrP before dimerization, no ThT fluorescence is observed (Figure 5A). 
Eight hour after dimerization (Figure 5B), granular protofibrils are clearly stained with 
ThT.
A
0  h
B
8 h
C
48  h
Figure 5. ThT staining of Fv-MoPrP amyloid fibrils
(A) Fv-MoPrP before dimerization (0 h). (B) Granular pre-fibrillar structures formed 8 h 
after dimerization. (C) Amyloid fibrils with ordered ultrastructures formed 48 h 
following dimerization. Samples were analysed with epifluorescence microscope.
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We further characterized the propensity of annular and globular pre-fibrillar 
aggregates to convert into amyloid fibrils. To date, there is least in vitro evidence on the 
formation of neurotoxic protofibrils in a pathway which normally results in the 
formation of mature amyloids. Indeed, previous protocols have produced either globular 
aggregates or amyloid fibrils in parallel assays and analysed their structures and 
biological functions. As shown in Figure 5C, globular intermediate structures formed 8  
h after dimerization are transformed into amyloid fibrils after 48 h in a progressive 
manner. ThT saturation in some regions demonstrates the formation of highly structured 
amyloids which react readily with ThT. These results show that dimerization of Fv- 
MoPrP can initiate the formation of pre-fibrillar aggregates which are able to convert 
into mature amyloid fibrils.
Binding of ANS to dimerized Fv-MoPrP aggregates
Kinetics of Fv-MoPrP oligomerization was determined by ANS fluorescent 
binding assays. ANS is a dye whose special properties and quantum yield are highly 
sensitive to polarity and viscosity. Therefore, ANS binds to solvent-exposed 
hydrophobic clusters, and thereby generates a significant increase in its fluorescence 
emission intensity and a blue shift of its maximum emission wavelength (Bo lo g n esi et 
al., 2010). ANS has a high affinity for protofibrils and intermediate toxic oligomeric 
species and to less extents it binds also to amyloid fibrils (Bolognesi et al., 2010, 
Cam pioni et al., 2010).
As shown in Figure 6 , Fv-MoPrP in the presence or absence of FK506, shows 
a very low affinity for binding to ANS even after 48 h shaking at 37 °C. In these 
conditions, only a small portion of moFvPrP may form intermediary oligomeric 
structures which possess few hydrophobic sites for ANS binding. However, when 
reactions start with dimerization, a substantial increase in the ANS fluorescence 
emission is recorded within 4 to 20 h (Figure 6 ).
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Figure 6 . Kinetics of Fv-MoPrP aggregation monitored by ANS fluorescence
(Top) A 50pM Fv-MoPrP was incubated with and without lpM AP20187 or with 1 |xM 
FK506 for the indicated times at 3 7 1 .  At the end of incubation time, ljxM Fv-MoPrP 
was incubated with 50 pM ANS. The obtained fluorescent emission intensities of ANS 
were plotted against the time of aggregation assay. (Bottom) ANS was titrated with the 
indicated concentrations of 8 h aggregated or soluble Fv-MoPrP, or Fv-MoPrP in the 
presence of FK506. The obtained fluorescence intensities were plotted against protein 
concentrations.
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Kinetically, four different phases are distinguishable during 48 h of Fv-MoPrP 
aggregation: (1) a fast increase in ANS fluorescence which represents rapid generation 
of oligomers and intermediary aggregated structures induced by dimerization (Figure 6 , 
0-4 h); (2) a linear phase recorded 4 to 12 h of aggregation which shows high binding 
affinity of ANS for the hydrophobic oligomers formed in this time frame (Figure 6 , 4- 
12 h); (3) 12 to 20 h after dimerization, kinetics of Fv-MoPrP aggregation shows a 
slower rate and (4) the affinity for ANS binding still diminishes as aggregation 
approaches the end of incubation time (Figure 6 , 20-48 h).
High affinity of Fv-MoPrP aggregates for ANS binding is in agreement with 
the formation of intermediary granular structures induced by protein dimerization which 
were observed by electron and fluorescence microscopes. It is known that ANS binds 
tightly to such oligomeric structures (Bo log nesi et al., 2010, Ca m pio n i et al., 2010). 
Therefore, we rationalized that if aggregates with hydrophobic intermediate granular 
structures are formed after protein dimerization, the increasing concentration of these 
aggregates should increase the fluorescence intensity of ANS in a linear manner. 
Indeed, it was the case when a constant concentration of ANS was titrated with the 
increasing concentrations of Fv-MoPrP. Fv-MoPrP in the presence or absence of FK506 
after 8  h aggregation does not show a significant binding affinity to ANS (Figure 6 , 
bottom), consistent with a low fluorescence intensity observed at this time point (Figure 
6 , top). However, aggregates obtained 8  h after Fv-MoPrP dimerization display a high 
affinity for ANS binding which linearly increases with the protein concentration.
Neurotoxicity of recombinant Fv-MoPrP aggregates
Our results demonstrate that dimerization of the recombinant Fv-MoPrP can 
induce and accelerate the formation of oligomeric structures and amyloid fibrils of 
different size and morphologies. It is known that structural flexibility and hydrophobic 
exposure are important determinants of the ability of oligomeric assemblies to induce 
cellular toxicity. In fact, pre-fibrillar amyloids and intermediate aggregates have been
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known as neurotoxic species in many neurodegenerative disorders such as Alzheimer's 
disease (Lasagna-Reeves etal., 2010).
We have previously shown that protein aggregates formed by dimerization of 
prion are toxic to cell cultures (Roostaee et al., 2009). In this study we attempted to 
characterize the in vivo neurotoxicity of dimerized oligomers and amyloids of Fv- 
MoPrP. To investigate the neurotoxicity of different forms of Fv-MoPrP in vivo, 
stereotaxic subcortical injections of soluble, oligomeric or fibrillar preparations of Fv- 
MoPrP were carried out in the right hemispheres of wild type C57BL/6 mice. The site 
of injection which is illustrated in Figure 7A is located above the CA2 region of the 
hippocampus. The effect of Fv-MoPrP preparations on neuronal toxicity was 
determined 24 h post-injection. The whole brains were sectioned and screened for 
neurotoxicity by deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) to 
confirm the presence of apoptosis phenomenon caused by neurotoxic effect of the 
injected materials. Therefore, the neuronal cells of brains were labeled by ApopTag 
BrdU that binds to DNA breaks, a hallmark of apoptosis. Nuclei of brain cells were 
stained by Hoechst and brain sections were analysed by confocal microscopy.
As seen in Figure 8 C, Fv-MoPrP in the absence of AP20187 does not induce 
any toxicity when injected into the mice brain. However, neurons exposed to the Fv- 
MoPrP granular oligomeric structures exhibit intense BrdU labeling (Figure 8 A). The 
level of Brdu labeling in the samples injected with amyloid fibrils were very low or
Figure 7. Schematic representation of a coronal section of a mouse brain with 
arrow indicating the injection site of the Fv-MoPrP preparations
Figure 8. Neurotoxicity of Fv-MoPrP oligomers
Fv-MoPrP aggregation was induced as indicated and injected into the brain of wild-type 
C57BL/6 mice. Apoptotic cells adjacent to the injection site were detected by TUNEL assay 
(red channel) followed by confocal microscopy. Nuclei are stained with Hoechst (cyan channel). 
Bar, 20 pm.
126
absent (Figure 8 B), indicating that mature amyloids were not neurotoxic, at least 24h 
post-injection. These results show that in vivo, granular oligomeric structures of the 
dimerized Fv-MoPrP are highly neurotoxic whereas the resulting mature amyloid fibrils 
have no any toxic effect in the mice brain, consistent with previous in vivo results 
(SlMONEAU et al., 2007).
DISCUSSION
A detailed characterization of prion aggregation and amyloidogenesis is 
essential to comprehend the molecular mechanisms of neurotoxicity and pathology 
spread in prion disease. A very important challenge in understanding the mechanism of 
prion pathology, and in the subsequent design of intervention strategies, has been the 
initiation of protein polymerization and the correlation of aggregate formation with 
biological effects, such as neurotoxicity and amyloidogenesis. In this study we show 
that prion dimerization is essential both for the production of toxic protofibrillar 
oligomeric species and for the formation of mature amyloid fibrils. Also, we show a 
biological pathway through which prion dimerization induces the formation of toxic 
oligomers which can further transform into harmless amyloid fibrils.
Structure of p-Sheet-rich gligomers and amyloid fibrils induced by Fv-MoPrP 
dimerization
Previous studies on toxicity of prions have focused on short synthetic peptides 
of PrP including residues 106-126 (Brow n  et a l, 1996, Ettaiche  et al., 2000). Some 
studies have characterized the toxicity of the full-length (N ovitskaya  et al., 2006, 
Sanghera  et a l, 2008, SlMONEAU et a l, 2007) and structured C-terminal domain of 
PrP (Kazlauskaite  et al., 2005). These studies have determined the toxic effects of 
PrP in the mice brain and cultured cells and have provided important insights into the 
understanding of certain aspects of prion pathology. However, there is a lack a 
comprehensive description of the mechanistic issue in terms of prion structural changes 
during the production of toxic species. In these studies there is lack of conditions to 
recapitulate the exact biological events occur during prion aggregation and
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neurotoxicity in the physiological context. Moreover, in these works protein oligomers 
or amyloid fibrils are prepared in different ways and there is no consistency between the 
preparation of oligomeric intermediates and amyloid fibrils. The aggregates and 
amyloid fibrils are usually obtained by different methods under completely non- 
physiological conditions such as high temperature unfolding or the use of acids and 
denaturants. However, protofibrillar aggregates and amyloid fibrils are produced in the 
same amyloidogenesis process which except a few cases, happens in the physiological 
conditions during the pathogenesis of prion disease.
Using a controlled dimerizing strategy we developed an in vitro assay through 
which P-Sheet-rich oligomers and amyloid fibrils are subsequently produced in a 
physiological-like conditions. In vitro formation of prion amyloids is a slow process 
which may take up to 7 days but in the presence of PrP80 seeds, amyloidogenesis is 
accelerated and occurs only within 24 h (STOHR et a l, 2008). In these studies lower 
concentrations of SDS is used to induce the formation of pre-fibrillar states composed 
of prion dimers and soluble oligomers (Jansen  et al., 2001) which transform into 
amyloids when PrP5 0 is present (Sto h r  et al., 2008). Other studies have produced (3- 
oligomers and amyloid fibrils under acidic and neutral conditions (Ba sk a k o v  et a l, 
2002). Our dimerization strategy excludes the need of acids, SDS or PrP8 0 seeds for the 
oligomerization and amyloidogenesis process. In this system, prion dimers can act as 
seeds to nucleate the aggregation and p-Sheet formation of soluble proteins (Figure 9). 
The resulted structures are granular protofibrils (Figure 5B) which can spontaneously 
transform into mature amyloid fibrils (Figure 5C) without the need of any additional 
factor (Figure 9).
Hydrophobic globular aggregates are highly neurotoxic
Recently, we showed that introduction of in vitro produced dimerized human 
Fv-MoPrP aggregates could induce toxicity and cell death (Roostaee et a l, 2009). 
These aggregates showed PK-resistance properties compatible to PrP80 that confirms the 
relevance of the dimerizing system to the aggregation pathway which finally results in
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PrPSc formation (Goggin  et al., 2007, R o o staee  et al., 2009). In the current work we 
extend these findings to in vivo experiments and also to biochemical characterization of 
the toxic aggregates.
In the current work, we provide experimental information on the structural 
features of oligomers produced under dimerizing conditions and the relationship 
between the structure of aggregates and cellular toxicity. One important feature of the 
synthetic Fv-MoPrP aggregates is their ability to bind tightly to ANS molecule (Figure 
6 A). We found a correlation between the neurotoxicity of dimerized aggregates (Figure 
8 A) and the level of aggregate binding to ANS which represents the degree of 
hydrophobicity of aggregates. Therefore, the structural differences between toxic and 
non-toxic protein species results from different degrees of the presence of hydrophobic 
residues within their structures. The neurotoxicity is associated with the level of solvent 
exposure as well as structural flexibility of these hydrophobic clusters.
The structural properties of protofibrils and mature amyloid fibrils of the 
amyloid-P peptide (AP4 0), the peptide that implicates in the pathology of Alzheimer's 
disease, have been studied by hydrogen/deuterium (H/D) exchange (Kh e t er pa l  &  
W etzel , 2006). These data indicate that AP4 0  protofibrils contain 12 highly protected 
backbone amide protons after 2 days of exchange time. However, the structure of AP4 0  
amyloid fibrils retains 2 2  protected backbone amide protons in the sequence forming the 
structural core of amyloids, over similar exchange time. Moreover, in the case of fibrils, 
the N- and C-termini of AP4 0  as well as some of the residues flanking the amyloid core 
regions are also protected from H/D exchange (K h eterpa l  & We tz el , 2006). NMR 
studies have shown that AP4 0  have a rigid structural core which may diminish the 
exposure of hydrophobic regions, explaining why mature AP40 fibrils less toxic than 
protofibrils (Rah im i et al., 2008). The structural relationship between hydrophobic 
cores of protofibrils and mature fibrils proposes an on-pathway role for protofibrils in 
amyloid fibril assembly, a mechanism also supported with the dimerization-induced 
amyloidogenesis of Fv-MoPrP (Figure 9).
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Figure 9. Spontaneous formation of pre>fibrilar amyloids and mature amyloid 
fibrils induced by dimerization
Dimerization induces a-helix to |3-sheet structural transformation of the prion protein. 
The newly formed P-sheet dimers can act as seeds to nucleate the aggregation of soluble 
proteins. The growing seeds can then polymerize into small units of aggregates such as 
granular oligomers and protofibril structures. The final step in amyloidogenesis is the 
conversion of protofibrils and oligomeric structures into mature amyloid fibrils.
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According to the dimerization model, pre-fibrillar aggregates are induced after dimer 
formation and these protofibrils have a high degree of hydrophobicity as they bind 
efficiently with ANS probe. These aggregates are potential precursors of amyloid fibrils 
and therefore, transform into highly structured amyloids in the physiological conditions. 
The amyloids are not neurotoxic probably due to the rigidity of their structural cores, 
less exposed hydrophobic regions as well as the morphological differences they display 
with their precursors globular aggregates.
The exposure of hydrophobic regions of protein oligomers to the solvent may 
influence biological properties of proteins such as interaction with membrane lipids. 
Some studies have shown a correlation between the size and surface hydrophobicity of 
A|340 aggregates and their ability to interact with and decrease the model membrane 
fluidity ( K r e m e r  et al., 2 0 0 0 ) .  These results suggest that the exposure of hydrophobic 
surfaces to the solvent determines the ability of oligomeric species to interact with cell 
membranes.
Dimers are central to oligomerization and neurotoxicity
Oligomeric protofibrils and mature amyloid fibrils produced in this study were 
differing by their kinetics of formations and also by their size and morphologies. The 
kinetics of amyloidogenesis composed of two phases: first, formation of dimers as 
oligomeric units with potential to act as a seed to nucleate the aggregation of soluble 
proteins, thereby producing neurotoxic protofibrils. This process is very fast and could 
occur within 8  h of dimerization. At this step, the hydrophobicity and morphology of 
synthetic Fv-MoPrP are two determinants of the level of neurotoxicity. Second, 
formation of mature amyloid fibrils from protofibril structure which is long and usually 
takes up to 48 h. In the studies done on the pathology of Alzheimer's disease, dimeric 
forms of Ap peptide were isolated from the core of amyloid plaques ( R o h e r  et al., 
1993), cerebrospinal fluid (CSF) ( V i g o - P e l f r e y  et al., 1993) and from human cortical 
homogenates ( E n y a  et al., 1999). Based on peptide packing program and molecular 
dynamic (MD) simulations, a recent study has characterized the structure of neurotoxic
131
globulomers formed from Ap peptide during the pathogenesis of Alzheimer's disease 
( Y u  &  Z h e n g ,  2 0 1 1 ) .  According to this model, Ap oligomers (globulomers) are packed 
by array of dimer subunits with a hydrophobic core made of C-terminal residues of 
proteins. Therefore, dimers can be the initiative building blocks of AP oligomers and 
amyloid fibrils in the pathology of Alzheimer's disease. Similarly, we propose that 
packing of two prion molecules into a dimer can create a central unit for the formation 
higher ordered oligomeric structures which are stabilized through the hydrophobic 
interactions. This proposition confirms the similarities between pathway of aggregation 
as well as the mechanism of production of neurotoxic species by AP peptide and prion 
protein.
CONCLUSION
In this study, we demonstrated the importance of controlled dimerization of 
prion as a powerful tool for studying the mechanism of prion oligomerization and 
toxicity. In addition, by adjusting the concentration of AP20187 we could control the 
kinetics of prion aggregation and amyloidogenesis. This method can provide valuable 
information on the molecular mechanism of prion aggregation and facilitates detailed 
analysis of oligomeric forms of prion with different morphologies and kinetics of 
formation.
Based on the dimerizing approach, we can also pinpoint the important 
similarities between the aggregation mechanisms of prion protein and AP peptide. In 
both prion and AP pathology, protein misfolding and aggregation can start with 
dimerization. The dimeric structures constitute seeding sites to induce further 
aggregation of soluble population of the proteins. The outcome of this process is the 
formation of highly hydrophobic structures. It would be also interesting to design 
transgenic mice with the ability to produce prion dimers and determine if there is prion 
pathology. Indeed, in vivo demonstration that prion dimerization could initiate prion 
pathology which is under investigation in the laboratory, would provide new insights 
into the mechanism of prion disease. Based on these information, it would be tempting 
to propose prion dimer cores as new therapeutic targets.
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RESUME
Contexte: L'agregation de la proteine a-synucleine (a-Syn), la formation de fibres 
amyloi'des et la neurodegdnerescence progressive sont les caracteristiques 
neuropathologiques de la maladie de Parkinson (1). Toutefois, un mecanisme detaille 
d'agregation/fibrillogenese de l’a-Syn et la nature exacte des especes oligomeriques 
toxiques produites au cours du processus de formation de fibres amyloi'des sont encore 
inconnus.
Rdsultats: Dans cette etude, la vitesse d'agregation de l’a-Syn a ete comparee pour l'a- 
Syn recombinante sauvage (WT) et une proteine homologue chimerique 
structurellement pertinente, contenant le domaine de dimerisation inductible Fv (a- 
SynFv), capable de former des dimeres en presence d'un ligand divalent (AP20187). En 
presence d'AP20187, nous rapportons un changement conformationnel rapide de 
'random coil' en feuillet-P de l’a-SynFv en moins de 24 h, tandis que le type sauvage de 
I’a-Syn a montre 24 h de retard, atteignant une structure en feuillet-p aprds 48 h. 
L’utilisation des sondes fluorescentes Thioflavin T (ThT) et ANS demontre une 
formation acceleree d'oligomdres/amyloi'des k partir des dimdres de l’a-SynFv, compard 
k l'oligomerisation plus lente de l’a-Syn WT ou de l’a-SynFv sans AP20187. Une fois 
injecte dans le cerveau des souris, les agregats pre-fibrillaires de l’a-SynFv et de l’a-Syn 
ont ete internalises par les cellules et ont induit de la neurotoxicite dans l'hippocampe 
des souris. Des fibres amyloi'des non toxiques, formees a partir des agregats 
recombinants toxiques, ont ete amplifiees avec succds par la mdthode d'amplification 
cyclique d'agregats protdique (PMCA), foumissant la premidre preuve de la propagation 
in vitro d'agrdgats synthetiques de l’a-Syn.
Conclusions: En rdsumd, nous montrons que la dimdrisation est importante pour 
l'agrdgation et la transition conformationnelle de l’a-Syn. En outre, les mdcanismes 
d'agregation de l’a-Syn et la formation d'agrdgats toxiques sont semblables h ceux 
observes lors de la pathologie des maladies k prions. Une caractdrisation ddtaillde du 
mdcanisme d'agregation de l’a-Syn et de sa toxicitd est cruciale pour comprendre la 
pathologie de la maladie de Parkinson au niveau moldculaire.
141
ABSTRACT
Background: Aggregation of the a-Synuclein (a-Syn) protein, amyloid fibril formation 
and progressive neurodegeneration are the neuropathological hallmarks of Parkinson's 
Disease. However, a detailed mechanism of a-Syn aggregation/fibrillogenesis and the 
exact nature of toxic oligomeric species produced during amyloid formation process are 
still unknown.
Results: In this study, the rates of a-Syn aggregation were compared for the 
recombinant wild-type (WT) a-Syn and a structurally relevant chimeric homologous 
protein containing an inducible Fv dimerizing domain (a-SynFv), capable to form dimers 
in the presence of a divalent ligand (AP20187). In the presence of AP20187, we report a 
rapid random coil into p-sheet conformational transformation of a-SynFv within 24 h, 
whereas WT a-Syn showed 24 h delay to achieve P-sheet structure after 48 h. 
Fluorescence ANS and ThT binding experiments demonstrate an accelerated 
oligomer/amyloid formation of dimerized a-SynFv, comparing to the slower 
oligomerization and amyloidogenesis of WT a-Syn or a-SynFv without dimerizer 
AP20187. Both a-SynFv and a-Syn pre-fibrillar aggregates internalized cells and 
induced neurotoxicity when injected into the hippocampus of wild-type mice. These 
recombinant toxic aggregates further converted into non-toxic amyloids which were 
successfully amplified by protein misfolding cyclic amplification method, providing the 
first evidence for the in vitro propagation of synthetic a-Syn aggregates.
Conclusions: Together, we show that dimerization is important for a-Syn 
conformational transition and aggregation. In addition, mechanisms of a-Syn 
aggregation, amyloidogenesis and formation of toxic aggregates are similar to the 
pathology of prion disease. A detailed characterization of the mechanism of a-Syn 
aggregation/amyloidogenesis and toxicity is crucial to comprehend Parkinson's disease 
pathology at the molecular level.
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BACKGROUND
Parkinson’s Disease (Barsottin i et al.) is an age-related deterioration of 
dopaminergic neurons in the substantia nigra and other brain regions. The pathological 
hallmark of PD is the cytoplasmic deposition of amyloid-like aggregates termed Lewy 
Bodies , the fibrous inclusions which contain the protein a-Synuclein (a-Syn) [1-3]. a- 
Syn is a soluble, natively unfolded protein containing 140 a.a. which is expressed in the 
central nervous system including the cerebral cortex, hippocampus, amygdala, and 
olfactory bulb [4, 5]. Although it is known that a-Syn is concentrated in presynaptic 
nerve terminals and appears to be associated with vesicular structures, its exact 
biological function is still uncertain [6, 7]. Overexpression of the wild-type a-Syn or 
mutant variants (A30P, A53T, E46K) in several model organisms results in cytoplasmic 
inclusion formation followed by neurodegeneration [8,9].
PD belongs to a larger category of neurodegenerative diseases called protein 
misfolding disorders. The diagnostic feature common to protein misfolding disorders 
involves the deposition of insoluble protein aggregates and amyloid fibrils caused by 
accumulation of homologous proteins which are abnormally folded into P-sheet 
structures [10, 11]. There is growing evidence that the pathogenic species causing 
cellular toxicity and neurodegeneration are non-fibrillar dimers and oligomeric 
assemblies [12-15]. Expression of a-Syn soluble oligomers with reduced fibrillization 
propensity induced neurotoxicity in worms, flies and mammalian neurons [16]. These 
pre-fibrillar aggregate species are readily formed in vitro from a-Syn mutants such as 
A30P and A53T, which are associated with neurotoxicity and early-onset PD [17, 18]. 
In Alzheimer’s disease and transmissible spongiform encephalopathies, cytotoxicity of 
Amyloid-p oligomers and prion protein, respectively, is significantly more pronounced 
for rapidly formed pre-fibrillar aggregates than for highly-organized amyloid structures 
[19, 20]. The exact biological function of amyloid inclusions is still under debate. 
Recent experimental data indicate the capacity of a-Syn amyloids to transfer between 
cells, both in cultured cells and in transgenic mice [21]. Interaction of a-Syn fibrils 
either with recombinant or cell-expressed a-Syn converts soluble homologous proteins 
into a misfolded state through a nucleation-dependent polymerization process [22, 23]. 
These results suggest that the mechanism underlying propagation of a-Syn fibrils is
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reminiscent of those by which tau aggregates and prions spread and transmit the 
pathology through the brain tissue in Alzheimer’s and prion diseases, respectively [24].
The molecular mechanism underlying a-Syn transformation from its soluble 
monomeric form to the disease-associated oligomeric conformation has been a subject 
of intense research. Homodimer formation has been characterized as an essential factor 
in the aggregation pathway of numerous proteins, such as serpin, tau, and prion protein 
which are all involved in protein misfolding disorders [14, 25, 26]. In this regard, in 
vitro experiments have reported the existence of a dimeric state during conversion of a- 
Syn from soluble monomers to toxic aggregates [27]. The dimerization of a-Syn 
induced by intramolecular oxidative cross-linking of tyrosine residues has been reported 
to induce the aggregation process [28]. Substitution of cystein for tyrosine residues has 
been shown to induce a-Syn aggregation and in vitro toxicity [29]. Interaction of a-Syn 
with membrane phospholipids which results in the formation of P-sheet dimers and 
oligomers is considered to be a potential cytotoxic event, leading to the 
permeabilization of the cell membrane [30]. However, the importance of dimerization in 
a-Syn aggregation has not yet been directly tested. In addition, it is not known whether 
or not recombinant a-Syn dimers or oligomers, which are highly potent to transform 
into amyloid fibrils, are neurotoxic in vivo.
Here, we directly tested the hypothesis that dimerization of a-Syn is a key 
molecular step in the aggregation of a-Syn. We engineered a fusion protein between a- 
Syn and an FK506 binding domain (Fv). In the presence of AP20187, a divalent ligand 
that binds Fv, two protein molecules containing an Fv module are forced to interact and 
to dimerize. This strategy allows a fine regulation of induced dimeric interactions 
between Fv-containing proteins [14, 31-34]. We demonstrate that dimerization is the 
central mechanism of aggregation and fibrillogenesis of a-Syn. Recombinant dimerized 
oligomeric species, but not structured insoluble amyloids, were neurotoxic when 
injected to the brains of mice, consistent with the toxicity of cell-expressed a-Syn 
mutants with the propensity to form intermediate aggregates [16]. The a-Syn oligomers 
proceeded to form stable amyloids which could be amplified in vitro through the protein 
misfolding cyclic amplification (PMCA) method [35]. These results suggest that
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dimerization initiates a-Syn aggregation and provide direct evidence for the in vivo 
toxicity of a-Syn soluble prefibrillar aggregates.
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RESULTS
Dimerization accelerates a-Syn aggregation and amyloidogenesis
Based on an inducible dimerizing system [14], we aimed to characterize the 
role of dimerization in a-Syn aggregation and fibrillogenesis. An Fv dimerizing domain 
was fused to the C-terminal of a-Syn, thereby creating a-SynFv with the capacity to 
homodimerize in the presence of AP20187. Analysis of the circular dichroism spectrum 
of freshly purified recombinant a-SynFv or a-Syn in the absence of AP20187 reveals a 
random coil structure with minimum molar ellipticity at 198 nm (Figure. SI, 
Figure. 1 A), consistent with a-Syn native secondary structure [36]. Both a-SynFv and a- 
Syn showed a conformational transition from random coil to P-Sheet with a minimum at 
216 nm within 48 h (Figure. 1A,B) [36]. However, in the presence of AP20187, this 
transition was accelerated and occurred within 24 h. The secondary structure 
transformation of a-Syn involved the formation of helical structures as manifested by a 
negative peak with minimum ellipticity at 208 nm after 24h incubation (Figure. IB), 
consistent with recent demonstration of the existence of helical intermediates during a- 
Syn aggregation [37].
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Figure 1. Circular dichroic spectra of «-SynFv and a-Syn
(A) Circular dichroic spectra of a-SynFv. a-SynFv was incubated at different times in 
the absence (-AP20187) or in the presence (+AP20187) of dimerizer at 37 °C with 
agitation. (B) Circular dichroic spectra of a-Syn. a-Syn was incubated different times as 
indicated in (A). Both a-SynFv and a-Syn displayed structural transition from random 
coil to P-sheet conformation.
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Soluble recombinant a-Syn converts into aggregated amyloids after 2-3 days of 
incubation with agitation at 37°C [36]; however, under static conditions, a prolonged 
incubation time (> 30 days) is needed for a-Syn to assemble into amyloid fibrils [17]. 
Thus, we examined whether induced a-Syn dimerization could increase the rate of 
amyloidogenesis under static or dynamic conditions. Electron micrographs of a-Syn 
preparations showed amyloid fibril formation in both stationary and agitating 
incubations with no detectable difference between the morphology of a-SynFv or a-Syn 
fibrils under any experimental condition (Figure. 2). Amyloid fibrils were clearly 
detected after dimerization of a-SynFv following 48 h of agitation or two weeks without 
agitation. However, very few a-Syn fibrils were detected after 48 h of agitation, while 
under static conditions, a-Syn required 3 weeks incubation to form detectable fibrils 
(Figure. 2). The kinetics of amyloid formation was then monitored by Thioflavin T 
(ThT) fluorescence. ThT exhibits a characteristic increase in fluorescence emission 
upon interaction with ordered p-sheet structures [38]. In the incubations including a- 
SynFv plus AP20187, maximum fluorescence intensity was observed within 30h. Fibril 
quantification of a-Syn, in the presence or absence of AP20187, showed a longer lag 
phase and highest ThT emission achieved after 60h (Figure. 3A). When 1% a-Syn 
aggregates or a-SynFv dimerized aggregates were incubated with soluble a-Syn and a- 
SynFv, respectively, both proteins displayed the same capacity to trigger fibril formation 
(Figure. 3A). However, a-SynFv had a lower efficiency to polymerize into fibrils in the 
absence of dimerizing conditions (Figure. 3A). These results also exclude any 
possibility that AP20187 or Fv domain could increase the rate of fibril formation by a- 
Syn constructs.
Kinetics of early aggregation of a-Syn was determined by the change in 8- 
anilino-l-naphthalenesulfonate (ANS) fluorescence intensity, due to the presence of a 
higher number of exposed hydrophobic sites, a key characteristic of early aggregates 
and oligomeric intermediate species [39]. ANS-binding experiments revealed the rapid 
formation of a-Syn pre-fibrillar aggregates within 2h of dimerization induced by 
AP20187, whereas assembly of a-Syn monomers into oligomers was associated with a 
significant (>2h) delay (Figure. 3B).
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Figure 2. Electron micrographs of a-SynFv and a-Syn protein preparations
a-Syn and a-SynFv were incubated at 37°C in different conditions as indicated. Scale bar, 100 nm
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Figure 3. Aggregation of a-Syn proteins monitored by ThT and ANS fluorescence
(A) Amyloidogenesis of a-SynFv and a-Syn incubated at 37°C with agitation in different 
conditions was monitored with ThT over 80 h incubation time. (B) Protein 
oligomerization that caused exposure of hydrophobic regions was monitored with ANS 
during 0-24 h incubation time.
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Accelerated formation of neurotoxic oligomers induced by a-Syn dimerization
The demonstration that dimerized a-SynFv displayed a higher capacity for 
ANS-binding over 24 h of aggregation compared to a-Syn (Figure. 3B) suggested that 
dimerization could accelerate the formation of toxic oligomeric species [40]. To verify 
this hypothesis, neurotoxicity of aggregates and amyloid fibrils formed by a-Syn or a- 
SynFv was determined by subcortical inoculation of proteins into the right hippocampus 
of wild-type C57BL/6 mice [41]. The susceptibility of mice to a-Syn-induced 
neurotoxicity was determined by monitoring hippocampal cells for apoptosis 48 h post­
injection by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
assay. Neuronal cells were identified by immunofluorescence with an antibody against 
the neuronal marker NeuN. Formation of toxic aggregates was highly dependent on the 
oligomerization state of a-Syn. Following agitating incubations, both dimerized a-SynFv 
and a-Syn transformed into highly neurotoxic oligomers within 10 h and 24 h, 
respectively, and caused severe apoptosis in hippocampal neurons (Figure. 4A, S2A). 
The protein toxic species were morphologically higher-ordered aggregates of 
heterogeneous size, such as annular and amorphous protofibrillar oligomers (Figure.4B, 
S2B), with a high capacity to bind ANS (Figure. 3B). In contrast to the oligomers, 
neither soluble a-Syn or a-SynFv proteins nor insoluble amyloid fibrils were neurotoxic 
in our experiments (Figure. 4A, S2A, S3A). AlexaFluor 633-labeled oligomers and 
amyloid fibrils were clearly visible in the cytoplasm of neurons (Figure. 4B, S2C,D, 
S5B). Therefore, dimerization of a-Syn enhances the formation rate of toxic oligomers 
which can further transform into insoluble amyloid fibrils lacking neurotoxic activity.
In Vitro amplification of a-Syn fibrils
In PD pathology, topographical progression of a-Syn aggregated amyloids or 
Lewy Bodies includes stereotypical spread of Lewy Body formation from the lower 
brainstem and anterior olfactory structures into the limbic system, neocortex and other 
brain areas [42]. Recent data reported cell-to-cell transmission of a-Syn aggregates both 
in cultured cells and in transgenic mice [21]. These data strongly suggest that a-Syn
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a-Syn aggregates 
(24 h, agitation)
Soluble a-Syn 
(24 h, no agitation)
Hoechst
NeuN
TUNEL
Figure 4. In vivo neurotoxicity of synthetic o-Syn oligomers.
(A) a-Syn protein was treated as indicated and injected into the brain of wild-type 
C57BL/6 mice. Apoptotic neurons of the hippocampal region adjacent to the injection 
site were detected by TUNEL assay (green channel) followed by confocal microscopy. 
Hippocampus in the injected hemisphere is shown in a dotted box. The neuronal marker 
NeuN is detected by immunofluorescence (red channel). Nuclei are stained with 
Hoechst (blue channel). Scale bar, 500 pm. (B) Electron micrographs of toxic a-Syn 
oligomers obtained after incubation at 37 °C for 24 h. Scale bar, 25 nm. (C) Synthetic a- 
Syn aggregates were labeled with Alexa Fluor 633 prior to injection and detected by 
confocal microscopy (aggregates, yellow channel; NeuN, red channel; nucleus, blue 
channel). Scale bar, 10 pm.
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aggregates can polymerize by recruitment of soluble homologous proteins and fragment 
to generate new seeds which retain the capacity to nucleate newly synthesized soluble 
monomers, thereby propagating protein aggregates through the nervous system, in a 
mechanism similar to prion propagation [23, 43]. To test if a-Syn aggregates were able 
to propagate in vitro by recruiting and enforcing the aggregation of soluble a-Syn, a 
characteristic that has been already demonstrated for the prion protein, we generated a 
modified in vitro conversion assay similar to the PMCA protocol which has been used 
to convert cellular prion protein into infectious prion aggregates [35]. In addition, 
PMCA was applied to a-SynFv to determine if dimerized a-Syn aggregates could also 
display self-propagating activity. Each cycle of PMCA was composed of two phases 
(Figure. 5A). During the first phase, a-Syn and a-SynFv aggregates were diluted 20 
times with soluble homologous protein and incubated 12 h with constant agitation to 
induce the formation of amyloids. This dilution factor was selected based on the 
observation that seeding with 5% aggregates resulted in maximum ThT binding within 
12 h (Fig S4A). Formation of large polymers in the samples incubated for 12 h was 
determined by centrifugation and SDS-PAGE analysis. The obtained results confirmed 
that both a-Syn and a-SynFv were predominantly insoluble at the end of a 12 h 
polymerization phase (Figure. S4B). During the second phase of PMCA, a-Syn and a- 
SynFv amyloids were sonicated in order to fractionate fibril polymers and multiply seeds 
for subsequent polymerization [44]. Centrifugation and analysis of proteins in 
supernatant and pellet fractions by SDS-PAGE confirmed the amplification of insoluble 
aggregates by PMCA (Figure. 5B). Densitometric analysis of the proteins in three 
independent experiments definitively established that both a-Syn and a-SynFv 
aggregates were efficiently amplified through PMCA using our protocol (Figure. S5). 
High molecular weight SDS-resistant species including dimers were formed during the 
PMCA and could be detected by western blot (Figure. S6). The conversion of soluble a- 
Syn and a-SynFv into aggregated states and higher molecular weight species was 
observed through at least five serial reactions (Figure. 5B, S6). In a parallel experiment, 
samples were immediately centrifuged after 1/20 dilution of sonicated aggregates 
instead of being submitted to a 12 h polymerization phase (Figure. 5C). No significant 
levels of insoluble proteins used to seed the reaction were detected, indicating that
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insoluble fractions detected after the PMCA cycles were essentially formed from 
soluble monomers during the polymerization phase. In control assays where proteins 
were subjected to polymerization in a static phase for 12 h, no amplification of protein 
aggregates was recorded, indicating the requirement of agitation for an efficient 
conversion (Figure. 5D). The dilution factor for the initial seeds used to start PMCA 
was estimated to be 3.2 X lO"6 in the fifth cycle. This concentration of seeds was 
insufficient to account for the conversion of soluble proteins in PMCA cycles, 
demonstrating that de novo generated a-Syn and a-SynFv aggregates also gained their 
own seeding activity, as shown by agitation-induced conversion experiments (Figure. 
5B).
PROTEIN MISFOLDING CYCLIC AMPLIFICATION 
OF a-SYNUCLEIN AGGREGATES
B
1 cycle
First phase: elongation
1. a-Syn aggregates:soluble a-Syn 1:20
2.6  x (30 sec sonication/10 min shaking at 37*C)
3. Incubation 10 h at 37*C
Second phase: fractionation of aggregates 
6 x (30 sec sonication/10 min shaking at 37°C)
»a-Syn*' + AP20187 
i a-Syn
Dilution: 1/20 1/20 1/20 1/20
PMCA cycle: 1 2 3 4 5
I 1 I--- 1 I-------1 I---- 1 I---1
S P S  P S  P S  P S  P
a-Syn
_  Fv a-Syn
AP20187
D
a-Syn
S P 
Syn ( 9
Fv —
1/20
a-Syn ( tf j |
a-Syn
Fv
2 3 4
PMCA cycles
Figure 5. PMCA reactions seeded with a-Syn or a-SynFv aggregates
(A) Illustration of PMCA method used to amplify a-Syn or a-SynFv aggregates in the 
presence of homologous soluble proteins. (B) a-Syn aggregates or a-SynFv aggregates 
induced by AP20187 were diluted 20 times into freshly prepared soluble proteins of the 
same species. Supernatant (S, soluble) and pellet (P, insoluble) fractions recovered from
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centrifugation of protein samples withdrawn at the end of each PMCA cycle were 
analyzed by SDS-PAGE and Coomassie blue staining. This result is representative of 
three independent experiments. (C) Densitometric analysis of PMCA reactions with a- 
Syn and a-SynFv in three independent experiments. (D) a-Syn or a-SynFv aggregates 
were diluted 1/20 into soluble homologous proteins and immediately centrifuged. The 
absence of detectable protein in the pellet fraction indicates the lack of amplification of
f?vaggregates. (E) a-Syn or a-Syn aggregates were submitted to two PMCA cycles with 
incubations performed under stationary conditions.
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DISCUSSION
A detailed characterization of a-Syn aggregation and amyloidogenesis is 
essential to comprehend the molecular mechanisms of neurotoxicity and pathology 
spread in PD. A critical challenge in understanding the mechanism of a-Syn pathology, 
and in the subsequent design of intervention strategies, has been the initiation of protein 
polymerization and the correlation of aggregate formation with biological effects, such 
as neurotoxicity, amyloid formation and propagation. In this study we describe the 
importance of dimerization in initiation and acceleration of a-Syn aggregation and 
neurotoxicity. Under physiological-like conditions, toxic aggregates can transform into 
non-toxic amyloid fibrils which are amplified in vitro in the presence of homologous 
soluble proteins, thereby generating de novo amyloids. The results discussed herein can 
open new insights into the mechanism of a-Syn oligomerization which is directly linked 
to the pathology of PD.
Importance of dimerization in formation of a-Syn toxic aggregates and amyloid 
fibrils
Homodimerization of amyloid-forming proteins such as prion protein, amyloid-0 
and serpin has been characterized as a primary factor involved in aggregation and 
pathogenesis of prion encephalopathies, Alzheimer’s disease and serpinopathies, 
respectively [14, 26, 45]. Here, we extend these observations to a-Syn, as well, since a- 
Syn dimerization induces a conformational change to a 0-sheet rich structure (Figure. 
1). This results in a considerable increase in the rate of a-Syn aggregation and 
amyloidogenesis (Figure. 2 and 3A). In comparison to a-Syn, accelerated aggregation of 
a-SynFv was associated with the increased binding of ANS (Figure. 3B), suggesting that 
dimerization of a-Syn induced protein aggregation through increase in surface 
hydrophobicity within the amino acid side chains of aggregating proteins [40]. The 
influence of hydrophobic interfacial area was recently emphasized as a new factor for 
accelerating a-Syn aggregation and amyloidogenesis [46]. In agreement with the 
importance of dimerization for a-Syn aggregation and pathogenesis, another study has 
shown that dimeric intermediates of WT and PD-associated mutants of a-Syn were
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relevant species in protein aggregation and cellular toxicity [47] [48]. The increased 
aggregation rate of dimerization-induced a-Syn may help misfolded proteins to evade 
the cellular clearance machinery. In this scenario, a feedback loop is generated through 
which a-Syn aggregates impair the proteasome-mediated protein degradation pathway 
[48], resulting in a further shift in the population of a-Syn from soluble into cellular 
aggregates and amyloid inclusions which are involved in PD pathogenesis.
Acceleration of protein aggregation and formation of prefibrillar oligomers have 
been proposed to be associated with PD-related neurotoxicity [16,18], however, there is 
a lack of direct in vivo evidence on the neurotoxicity of a-Syn oligomers and 
protofibrils. In this study we show that synthetic a-Syn aggregates, which can further 
transform into amyloid fibrils, are potent neurotoxic species. In addition, dimerization 
of a-Syn can significantly accelerate the formation of toxic oligomeric species and 
amyloid fibrils with no toxic activity (Figure. 4). The most toxic oligomers have 
spherical or amorphous ultrastructures (Figure. 4), which show a high degree of 
hydrophobicity (Figure. 3B). Recent results on HypF-N, a bacterial protein not associated 
with any amyloid disease, indicate that hydrophobicity of oligomeric assemblies is a major 
determinant of membrane interaction and cytotoxicity of aggregate oligomers [40]. These 
observations are consistent with the theory that hydrophobicity of protofibril 
intermediates aids penetration of the membrane lipid bilayer in order to form pore-like 
structures which disrupt normal cellular physiology and cause neurotoxicity [49]. 
Further research is required to evaluate this proposal and other mechanistic issues 
concerning neurotoxicity, as well as the exact biological activity of a-Syn aggregates.
Prion-like amplification of a-Syn amyloids.
Propagation of cellular prion protein misfolding occurs via transmission of its 
scrapie isoform throughout cells and tissues. Emerging studies of protein misfolding 
disorders suggest that the molecular mechanism underlying transmission of protein 
aggregation in Alzheimer’s, Huntington’s and Parkinson’s diseases is similar to prion 
diseases [11, 50]. The mechanism of prion amplification has been recapitulated in vitro
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using the PMCA assay which promotes the formation of infectious prions via a self- 
propagating cycle in a cell-free system. In the current work, we developed a modified 
PMCA assay (Figure. 5A) to investigate whether a-Syn amyloid fibrils could display 
the same replication capacity as prion amyloids. Our results demonstrate that similar to 
prion protein, fragmentation of a-Syn aggregates can provide new nucleation sites to 
induce conformational conversion of newly added a-Syn soluble monomers (Figure. 
5B). This in vitro propagation pattern of a-Syn strongly supports a prion-like 
mechanism for transmission of a-Syn aggregates at the molecular level [11, 51]. 
Formation of a-Syn aggregates has been recently characterized in vivo in grafted human 
fetal mesencephalic neurons implanted in the brain of a patient with PD [50]. Therefore, 
our demonstration of the in vitro replication of a-Syn amyloid aggregates in the absence 
of cellular factors provides evidence for the existence of a self-propagation system by 
which Lewy Body formation eventually spreads throughout the nervous system.
Could a-Syn dimers be a therapeutic target?
The phenomenon of protein dimerization has been observed during aggregation 
and amyloidogenesis of a-Syn. The A30P and A53T mutants, which are linked to 
familial PD, display a faster rate of protein aggregation and show a great propensity to 
self-interact and form dimeric structures [17, 28, 47, 48, 52]. Here, we directly show 
that a-Syn dimerization accelerates formation of neurotoxic intermediate aggregate 
species and amyloid fibrils both of which are associated with PD pathology. Therefore, 
compounds that prevent or slow down the dimerization rate of a-Syn can block or 
hinder protein aggregation which otherwise would be followed by a rapid accumulation 
and deposition of neurotoxic oligomers and amyloid inclusions. This information could 
be used to evaluate transgenic animal models with accelerated PD pathology caused by 
a-Syn dimerization. The prion-like mechanism of a-Syn propagation in vitro through a 
seeding-aggregation process provides further evidence for the existence of a common 
aggregation pathway for prion and a-Syn. However, extensive research is still required 
to indentify in vivo factors, such as uptake or release of a-Syn by cells, involved in cell-
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to-cell transfer of protein aggregates with seeding activity during pathology spread 
throughout the nervous system [53].
CONCLUSIONS
By using a combination of in vitro and in vivo approaches, we propose a 
mechanistic link between a-Syn dimerization and aggregation with consequent 
neurotoxicity. Indeed, this study provides direct evidence on the impact of dimerization 
on the a-Syn oligomerization and amyloidogenesis rates. Acceleration of 
oligomerization can subsequently induce the formation of neurotoxic aggregates and 
amyloid fibrils which can be propagated in vitro in a prion-like manner. The important 
finding that both a-Syn and a-SynFv synthetic aggregates can induce neurotoxicity 
confirms the literature data and provides new experimental tools for studying a direct 
cause and effect relationship between the aggregation of a-Syn and formation of 
neurotoxic species. Finding the precise correlation between different oligomeric 
structures and neurotoxicity in PD pathogenesis is essential to comprehend the 
molecular mechanism of pathology. In this context, characterization of the globular 
aggregates as neurotoxic species is an important step toward understanding the 
pathology of PD at the molecular level. In addition, propagation of a-Syn amyloids by 
the PMCA method excludes the possibility of the involvement of other cellular factors 
and states that a-Syn propagation happens through an autocatalytic mechanism similar 
to the prion protein. The important characteristics of a-Syn amplification in vitro 
provides a direct evaluation of the in vivo theories on the propagation of a-Syn 
aggregates and amyloid fibrils.
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METHODS
Cloning of a-Syn constructs
Total RNA was extracted from HeLa cells using the Trizol reagent (Invitrogen), 
according to manufacturer's instructions. a-Syn and a-Syn-Fv constructs were generated 
using PCR primers listed in Table SI. a-Syn cDNA was produced using a-Syn-Fw and 
a-Syn-Rv PCR primers specific to the 3’ and 5’ untranslated region of a-Syn mRNA. 
The full-length C-terminally 6 xHis-tagged recombinant a-Syn was amplified from a- 
Syn cDNA using the a-Syn-His-Fw and a-Syn-His-Rv primer pair. a-Syn cDNA was 
also used as a template to produce 6 xHis-tagged recombinant a-SynFv by overlap 
extension PCR, using a-SynFv-Rv, a-SynFv-Fw and Fv-His-Rv primers. Fv was 
amplified from pC4-FvlE (vector kindly provided by ARIAD Pharmaceuticals; 
www.ariad.com/regulationkits). To avoid cysteine misincorporation at codon 136 in 
bacterially expressed a-Syn constructs and artefactual autodimerization [54], site- 
directed mutagenesis of codon 136 (Y136-TAC to Y136-TAT) was done using a-Syn- 
Fwyi36-tat/ a .Syn-RvY136TAT and a-Syn-Fv-FwY ,3 6  TAT/a-Syn-Fv-RvY 1 3 6  TAT primer 
pairs to generate a-Syn and a-SynFv final constructs, respectively. PCR amplification 
fidelity was confirmed by sequencing and constructs were inserted into PET-21b 
vectors using Ndel and Hindm cloning sites.
Expression and Purification of a-Syn and a-SynFv
Constructs were overexpressed in BL21(DE3)pLysS cells at 25 °C with slow shaking, 
using 0.1 mM EPTG (isopropyl P-D-thiogalactoside) for 10 h. The bacterial pellets were 
lysed in 300 mM NaCl, 50 mM NaH2PC>4 (pH 8.0), 1 mM PMSF, 0.1 mM TCEP [tris- 
(2 -carboxyethyl)phosphine] and 1 mg/ml lysozyme, followed by either drawing- 
expelling of the lysates through a 2 1 -gauge-needle or a brief sonication followed by 
centrifugation for 45 min at 20000 g. Purification of the protein from supernatant was 
carried out using nickel-affinity chromatography according to the manufacturer’s 
protocol (Qiagen). Proteins were eluted in a buffer consisting of 125 mM NaCl, 300 
mM imidazole, 0.1 mM TCEP, 25 mM NaH2P0 4  (pH 7.4). This buffer was then 
exchanged for a physiological buffer [55] consisting of 50 mM K3PO4 , 2 mM KC1, 70
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mM CH3COOH, 9 mM KH3PO4  and 5 mM Na2HP04  (pH 7.4), using Millipore 
ultracentrifugation filters (Amicon Canada). The concentration of proteins was 
estimated by the absorbance at 280 nm, considering molar absorption coefficients of 
15392 M_1 cm_1  and 28660 M_1 cm_1 for 6 xHis-tagged a-Syn and a-SynFv, 
respectively. The recombinant proteins were detected by SDS-PAGE and western blot 
using monoclonal antibody (EP1646Y) to a-Syn.
Amyloid Assembly Experiments
a-SynFv (5.7 mg/ml) and a-Syn (3.0 mg/ml) in the presence or absence of 10 pM 
AP20187 (divalent ligand) or 10 pM FK506 (monovalent ligand) were used in the 
amyloid assembly preparations. Samples were incubated in 0,5 ml physiological buffer 
supplemented with 0,02% NaN3 (pH 7.4) in microtubes with or without agitation at 300 
rpm at 37°C. Aliquots were withdrawn at different time intervals from samples 
incubated in agitation or static conditions, and were analyzed by biochemical and 
biophysical methods (see below).
Circular Dichroism Spectroscopy
tyv
Circular dichroism measurements were done as described before [56]. a-Syn and a- 
Syn were taken from amyloid assembly incubations and diluted to 20 pM in phosphate 
buffer (25 pM Na2 HP04). Samples were transferred into 0.1 cm light-path quartz 
cuvettes and far UV spectra (190-250 nm) were recorded on a Jasco J-810 CD 
spectrophotometer at 25°C. Three consecutive scans were accumulated and the average 
spectra were recorded. Raw data were converted to molar ellipticity and plotted as a 
function of wavelength.
Thioflavin T and 8-anilino-l-naphthalenesulfonate binding
Thioflavin T binding to a-Syn and a-Syn-Fv amyloid samples withdrawn from amyloid 
assembly experiments at the indicated time points was evaluated as described before 
[14]. Binding of 8 -anilino-l-naphthalenesulfonate to a-Syn and a-SynFv was evaluated 
by measuring the fluorescence enhancement of 8 -anilino-l-naphthalenesulfonate (50 
pM) in the presence of 85 pM protein preparation upon excitation at a wavelength of
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380 nm. The emission spectra were integrated from 400 to 600 nm. Values are 
expressed as the mean ± S.E.M. of maximum fluorescence intensity from three 
independent experiments.
Electron Microscopy
A 10 pL sample from amyloid assembly preparations was taken for EM analysis. 
Samples included a-SynFv or a-Syn amyloids after 10 h, 24 h and 48 h agitation at 37°C. 
Aliquots were also withdrawn after 1, 2 and 3 weeks from stationary incubations. 
Protein samples were applied to formar- and carbon-coated grids. The excess fluid was 
drained with filter paper and the samples were stained for 1 min with 2% uranyl acetate. 
The grid was air-dried and examined in a Hitachi H-2500 electron microscope at 80 kV 
at a magnification of 15-75000.
In vivo Neurotoxicity Experiments.
Inocula were protein aliquots withdrawn from amyloid assembly experiments after 10 h, 
24 h, and 48 h shaking at 37°C. Male WT C57BIV6 mice were anesthesized with 
ketamine/xylazine (lml/kg, 87/13) and positioned on a stereotaxic frame. Coordinates 
for the injection site were 1.50 mm posterior and 1.75 mm ventral to the bregma and 
2.00 mm lateral to the midline. 2 pi physiological buffer or 2 pi protein samples (40 
pM) were injected at a rate of 0.4 pl/min. After 48 h, mice were anesthetized using 
isoflurane followed by euthanasia by cervical dislocation, according to the Animal 
Ethics Committee of the Universite de Sherbrooke.
Detection of apoptotic cells.
To detect apoptotic cells, brain sections adjacent to the injection site were tested by 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay using 
Dead End Fluorometric TUNEL System (Promega), according to the manufacturer’s 
protocol. Nuclei were also stained with Hoechst. For confocal analysis, brain sections 
were examined with a scanning confocal microscope (FV1000, Olympus, Tokyo, Japan) 
coupled to an inverted microscope with a 63X oil immersion objective (Olympus). 
Specimens were laser-excited at 488 nm (TUNEL-positive signals) and 405 nm
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(Hoechst). In order to avoid cross-talk between the fluorescence emitted by Hoechst 
(405) and Alexa 488, images were acquired sequentially. Serial horizontal optical 
sections of 320 X 320 pixels were taken at 1.0 pm intervals through the entire thickness 
of the tissue (optical resolution: lateral 0.18 pm; axial 0.25 pm). Identical settings of the 
instrument were used for all photos. For illustration purposes, images were 
pseudocolored according to their original fluorochromes, merged (FluoView software, 
Olympus), then cropped and assembled (Adobe Photoshop software, Adobe Systems, 
Mountain View, CA).
Detection of recombinant a-syn species in neuronal cells
The Alexa 633-labeled inocula were injected in the mice brain as described. Brain 
nuclei were stained with Hoechst and neuronal cells were identified by 
immunofluorescence using NeuN antibody. Brain sections were examined with a 
scanning confocal microscope with a 60X oil immersion objective (Olympus). 
Specimens were laser-excited at 633 nm to detect Alexa-labeled a-syn and a-SynFv 
preparations, 568 nm (NeuN) and 405 nm (Hoechst). In order to avoid cross-talk 
between the fluorescence emitted by different dyes, images were acquired sequentially. 
Serial horizontal optical sections of 320 X 320 pixels were taken from CA2-CA3 
hyppocampal neurons and focal planes were stacked for optimal a-syn detection. 
Identical settings of the instrument were used for all photos. For illustration purposes, 
each dye was pseudocolored (FluoView software, Olympus).
Protein misfolding cyclic amplification (PMCA) of a-Syn
PMCA reactions were prepared in 1.7 ml ultraclear microtubes as 300 pi solutions 
containing physiological buffer (pH 7.4). In the first cycle, 22.5 pi aliquots from 48 h 
fibril assembly experiments of a-Syn1^  or a-Syn were added to 300 pM soluble a-Syn1^  
and a-Syn in physiological buffer solutions, respectively, to give a fibril/protein ratio of 
1:20. In the elongation step, reactions were initiated by incubating samples at 37°C with 
shaking (300 rpm) for 1 h during which 6X periodic sonication/incubation cycles (30s 
sonication followed by 10 min shaking) were performed to prepare homogeneous 
aggregate seeds. This step was followed by incubation of samples for 10 h with constant
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shaking (37°C) to elongate amyloid fibrils. After 10 h incubation, newly formed 
amyloids were subjected to periodic sonication/incubation cycles for 1 h (as described 
above) to fractionate amyloid fibrils in order to provide a solution of amyloid seeds. 
Fractionated amyloids were then diluted 1/20 in physiological buffer containing 300 pM 
soluble proteins and identical elongation and fractionation cycles were applied to 
complete the PMCA round. These cycles were consecutively repeated at least five times 
and at the end of each PMCA round, 50 pi aliquots were withdrawn centrifuged at 20 
000 g for 1 h to separate insoluble amyloids from the supernatant. Proteins from the 
supernatant fractions were precipitated with four volumes of methanol. 2 pg of protein 
from each pellet or supernatant were subjected to SDS-PAGE analysis and Coomassie 
blue staining and band densities were analyzed with AlphaEaseFC software (Alpha 
Innotech)
. To verify the importance of shaking in the efficiency of PMCA, control cycles were 
performed in static conditions. To confirm the importance of elongation, after 1/20 
dilution of amyloid seeds, samples were spun as described and both soluble and 
insoluble fractions were stored at -20 °C until SDS-PAGE analysis.
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Coomassie Western blot
Figure. SI. Expression and purification of a-Syn and a-SynFv
Recombinant proteins were produced in BL21(DE3)pLysS Escherichia coli cells, as 
described under “Materials and Methods”. 2 pg of recombinant proteins was subjected 
to the SDS-PAGE and Coomassie blue staining (left panel). Purity of the proteins was 
estimated to be superior to 95%. Identity of the proteins was confirmed by 
immunoblotting using monoclonal anti-a-Syn EP1646Y antibody (right panel).
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Figure. S2. In vivo neurotoxicity of synthetic a-SynFv oligomers
(A) a-SynFv protein was treated in the absence (soluble) or in the presence of 10 jjM  
AP20187 (aggregates and amyloids) as indicated, and injected into the brain of wild- 
type C57BL/6 mice. Apoptotic neurons of the hippocampal region adjacent to the 
injection site were detected by TUNEL assay (green channel) followed by confocal 
microscopy. Hippocampus in the injected hemisphere is shown in a dotted box. The 
neuronal marker NeuN is detected by immunofluorescence (red channel). Nuclei are 
stained with Hoechst (blue channel). Scale bar, 500 pm. (B) Electron micrographs of 
toxic a-SynFv oligomers obtained after incubation at 37 °C for 10 h. Scale bar, 25 nm.
(C) Synthetic a-SynFv aggregates were labeled with Alexa Fluor 633 and detected by 
confocal microscopy (aggregates, yellow channel; NeuN, red channel; Nucleus, Blue 
channel). Scale bar, 10 pm. (D) Synthetic a-SynFv amyloids were labeled with Alexa 
Fluor 633 and detected by confocal microscopy (aggregates, yellow channel; NeuN, red 
channel; nucleus, blue channel). Scale bar, 10 pm.
Figure. S3. Absence of in vivo neurotoxicity of synthetic a-Syn amyloids
(A) a-Syn protein was treated as indicated, and injected into the brain of wild-type 
C57BI76 mice. Apoptotic neurons of the hippocampal region adjacent to the injection 
site were detected by TUNEL assay (green channel) followed by confocal microscopy. 
Hippocampus in the injected hemisphere is shown in a dashed box. The neuronal 
marker NeuN is detected by immunofluorescence (red channel). Nuclei are stained with 
Hoechst (blue channel). Scale bar, 500 pm. (B) Synthetic a-Syn amyloids were labeled 
with Alexa Fluor 633 and detected by confocal microscopy (aggregates, yellow channel; 
NeuN, red channel; nucleus, blue channel). Scale bar, 10 pm.
Figure. S4. Acceleration of a-Syn amyloid formation in seeding incubations
(A) 200 pM of freshly prepared recombinant a-Syn or a-SynFv was incubated with 2% 
or 5% homologous amyloid seeds with agitation at 37°C for 80 h. a-SynFv seeds were 
produced in the presence of AP20187. a-Syn seeds were obtained by agitating a-Syn for 
48 h at 37°C. (B) Aliquots withdrawn at 4 h intervals from the incubations including 5% 
seed were analyzed by centrifugation, SDS-PAGE and Coomassie blue staining.
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Figure. S5. Densitometric analysis of PMCA reactions with a-Syn and a-Syn in 
three independent experiments
a-Syn aggregates or a-SynFv aggregates induced by AP20187 were diluted 20 times 
into freshly prepared soluble proteins of the same species. Supernatant (S, soluble) and 
pellet (P, insoluble) fractions recovered from centrifugation of 3 pg protein samples 
withdrawn at the end of each PMCA cycle were analyzed by SDS-PAGE and 
Coomassie blue staining.
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Dilution: 1/20 1/20 1/201/20 1/20 1/201/201/20
PMCA cycle: 1 2 3 4 5  1 2 3 4 5
SOS-resistant 
oligomeric species
Figure. S6. SDS-resistant a-Syn and a-SynFv species after PMCA in pellet fractions
At the end of each PMCA cycles using purified recombinant proteins (Figure. 5), 
proteins in the pellet were analyzed by western blot using monoclonal anti-a-Syn 
EP1646Y antibody.
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DISCUSSION
1. The advantages of dimerization strategy
To gain more insights into biological events underlying pathogenesis of prion 
and Parkinson's diseases, we decided to characterize the mechanism of protein 
aggregation at the molecular level. Characterization of the protein dimers involved in 
the pathology of several neurodegenerative disorders (Kna u s  et al., 2001, O u teiro  et 
al., 2008, Shankar  et al., 2008) prompted us to examine the effect of dimerization on 
the PrPc and a-Syn aggregation and amyloidogenesis. To this end, we designed a 
dimerizing strategy by inserting a Fv dimerizing motif into the sequence of PrPc and a- 
Syn proteins to give Fv-PrP and a-SynFv, respectively. Fv-PrP and a-SynFv display the 
same secondary structural elements as PrPc and a-Syn, demonstrating that addition of 
Fv domain has no effect on the secondary structures of PrPc and a-Syn proteins. Also, 
we have demonstrated that the presence of Fv domain does not change biological 
activity of PrPc (Goggin  et al., 2007). This ensures that the Fv domain would not 
interfere with biological features of the fused proteins such as aggregation and 
amyloidogenesis. The dimerization system has been designed to work perfectly in the 
physiological conditions in the absence of acids or denaturants. The ligand that cross 
links two Fv domains is termed AP20187 which is a synthetic version of naturally 
occurring ligand FK506. This system uses minimal components to induce aggregation 
of the Fv-containing proteins in the physiologically relevant conditions. The rate of 
protein aggregation can be easily controlled by differing AP20187 concentrations or by 
changing the time of incubation. The advantage of this system is that we can study the 
formation kinetics of different oligomeric forms of proteins in a controlled manner. In 
the case of prion, dimerization system would allow to confirm the protein only 
hypothesis which proposes that prion infection is composed of only prion protein and no 
other biological factor is involved in the infectious. *
Many studies have tried to convert PrPc —► PrP80 in vitro using non- 
physiological conditions. In vitro conversion assays are either done in the presence of
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PrP80 or are carried out in the absence of PrP80 template in the conditions that usually 
include recombinant PrPc. First attempt for cell-free conversion of prion was made by 
Kocisko et al., where the conversion of 35S-labelled recombinant Syrian hamster (SHa) 
PrPc expressed in tissue culture cells was tried in the presence of excess (50X) quantities 
of PrP8'  (Kocisko  et al., 1994). However, due to high PrPSc concentration in the assay, 
it would be hard to characterize de novo formation or infectious prion independent of 
the initial concentration of PrP80 used in the assay. The use of chaotropic agent urea to 
induce conversion of a fragment of recombinant mouse PrP (MoPrP(89-230)) excluded 
the necessity of the presence of PrP80 in a cell-free conversion assay (Leg n a m e  et al., 
2004). In a following work, conversion of several fragments of recombinant PrP was 
done in the presence of different concentrations of urea to give amyloids with different 
conformational stabilities. The amyloid fibrils produced in these assays were inoculated 
into mice brain and caused a prion-like disorder (Colby  et al., 2009). However, the 
presence of denaturants such as urea questions the biological significance of this 
conversion assay. Another study have used acidic conditions including GdnHCl and 
urea to generate recombinant PrP amyloids. This was followed by annealing of 
amyloids in 5% brain homogenate or in albumin with cycles of incubation at 80X1! 
(Makarava  et al., 2010). The problem concerning this assay is that presence of 
denaturants and heat (80 C) are not likely to happen in the physiological circumstances.
Several in vitro assays have been developed to study the mechanism of 
aggregation and amyloidogenesis of different proteins such as Ap peptide and a-Syn. 
Amyloidogenesis of a-Syn and its disease-associated mutant (A30P) has been achieved 
in vitro in the physiological-like conditions (Y onetan i et al., 2009). Nevertheless, this 
assay could not defined the oligomeric intermediate structures form during amyloid 
formation of a-Syn. Moreover, only the presence of a-Syn aggregate seeds could 
accelerate the amyloidogenesis process, which otherwise, in the absence of a-Syn seed, 
amyloidogenesis is a slow process and may take up to one week in the shaking 
conditions. Some in vitro assays have been established to characterize the intermediate 
structures of a-Syn which are formed during the amyloidogenesis process. In these 
conditions, high protein concentration is used in the acidic buffer with high temperature
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and agitating to decrease the net charge and to increase the hydrophobicity of a-Syn 
environment (U versky  et al., 2001). However, high temperature and low pH are non- 
physiological and provide only a useful model by increasing the concentration of 
aggregate intermediates which are essential for the amyloidogenesis pathway. 
Fibrillation of a-Syn is a slow process and usually involves a lag phase during which 
formation of aggregates and amyloid seeds occur very slowly. Under certain conditions 
such as macromolecular crowding, amyloid formation by a-Syn is accelerated. These 
conditions include the presence of certain metals and pesticides, polyanions, polycations 
and low concentrations of organic solvents (M u n ish k in a  et al, 2009). A recent study 
have used SDS to convert a-Syn where SDS molecules make micelles with a-Syn 
molecules and this micelle act as an aggregation unit which rapidly grows in the size 
(Geehm et al., 2010).
All these methods have some success in elucidating the pathway of a-Syn 
aggregation and amyloidogenesis. However, some protocols use conditions which do 
not mimic the physiological circumstances, and those methods which are done in 
physiological conditions suffer from efficiency in achieving rapid and efficient 
amyloidogenesis in the in vitro experiments.
Our dimerization technology, therefore, provides a unique tool to characterize 
aggregation and amyloidogenesis of both a-Syn and prion proteins in a physiological- 
like condition. Moreover, this system allows us to determine the commonalities 
between the mechanism of pathology in prion disease and PD (An g o t  et al., 2010) in 
terms of the initiation of aggregation of a-Syn and prion and the formation of 
oligomeric toxic structures. We propose that a-Syn aggregation is initiated by 
dimerization similar to prion protein. To verify this hypothesis, we studied the 
propensity of a-Syn for aggregation and amyloid formation in the dimerizing 
conditions. In this system we used minimal components to study a-Syn aggregation and 
amyloidogenesis. The physiological buffer used for dimerization reaction is appropriate 
for the intracellular proteins and is composed of principal cytosolic constituents in frog 
skeletal muscle (Godt  & M au ghan , 1988).
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2. Dimerization Is central to prion aggregation
In this study, we show that in vitro dimerization of prion is a molecular event 
sufficient to induce aggregation of the prion protein. Many evidences indicate that prion 
dimerization can contribute to the pathogenesis of the prion disease by inducing protein 
aggregation and amyloid formation. Our results are in agreement with theoretical and 
experimental data confirming an important role for dimerization in the conformational 
transition of PrPc to PrP80 (Tom pa  et al., 2002). Supporting evidence for the role of 
dimerization in pathogenesis of prion disease is the existence of PrP dimers in murine 
neuroblastoma cells as well as in non-infected hamster and mouse brains. Antibodies 
designed against PrP80, which normally has a molecular weight of 27-30 kD, recognize 
a 54 kDa in the non-infected brain homogenates of mice and hamster (B en d h eim  &  
Bolton , 1986). This 54 kDa protein which is a prion dimer could be a precursor for 
PrP8® formation. Expression of hamster PrPc (HaPrP) in murine neuroblastoma cells 
produces a 60 kDa fragment and peptide mapping analysis shows that this 60kDa 
polypeptide is composed of HaPrP. Therefore, this fragment is a prion dimer which can 
act as intermediate for aggregation of PrP80 (Prio la  et al., 1995). This is consistent 
with a theory that presence of prion dimers can provide replication sites for propagation 
of PrP80 (Jarrett  & La n sbury , 1993).
Prion dimers have been also detected in vivo in the infectious material obtained 
from brain of CJD patients after disaggregation in detergents (Sklaviadis et al., 1989) 
and in the brain of the prion-infected hamsters (Pr io la  et al., 1995). In addition, prion 
dimers have been shown to be in an equilibrium with monomers in a non-infected 
bovine brain (M eyer  et al., 2000). In our experimental condition, the presence of 
AP20187 is sufficient to induce a shift of prion population from monomeric to 
aggregate state and amyloid fibrils. The monomer-dimer equilibrium (M ey er  et al.,
2000) can be also shifted if a ligand or a protein could facilitate the interaction of two 
prion monomers. Formation of stable dimers can shift the equilibrium towards the
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addition of monomers to the stable dimers, resulting in polymerization of proteins into 
aggregates and amyloid fibrils.
Our dimerization model is also consistent with the theories on the prion 
conversion. According to the heterodimerization model prion conversion requires 
physical interaction between PrPc and PrPSc in the form of dimers (Pr u sin e r , 1991). 
Because in the normal condition spontaneous conversion of PrPc to PrP80 is prevented 
by a high energy barrier. In this condition, transformation of PrP0 to PrPSc occurs only 
when stable dimers are formed in the population of monomer-dimer equilibrium 
(Meyer  et al., 2000). Formation of this stable dimer not only induces PrPc —*■ PrP80 
conversion but also provide a seed to induce further polymerization of soluble PrPc 
molecules.
Another theory concerning the heterodimerization model is based on the 
involvement of protein X in the prion conversion. This theory proposes that cellular 
factors such as chaperones or other hypothetic proteins (protein X) may facilitate PrPc 
—* PrP8c conversion. The interaction between protein X and an energetically active 
intermediate form PrPc (PrP*) induces the formation of protein X-PrP* complex. This 
complex then binds to one PrP80 molecule to facilitate structural transformation of PrPc. 
In our dimerization conditions, AP20187 brings two Fv-PrP monomers in a close 
proximity and facilitate their interactions. When two monomers are stabilized through 
intermolecular interactions, a stable dimer is formed though a process which is 
energetically favorable. When steady state is reached, dimers interact with and recruit 
new Fv-PrP monomers to form aggregates which are stable insoluble structures. Light 
scattering experiments indicate that formation of Fv-PrP aggregates is dependent upon 
AP20187 concentration, indicating that there is a linear correlation between dimer 
formation and assembly of higher ordered aggregated structures.
We have characterized the kinetics of structural changes of Fv-PrP using lower 
AP20187 concentrations. Our results indicate that dimerization induces a rapid 
secondary structure changes of Fv-PrP where decrease in the a-helical structure of Fv-
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PrP is linear. Secondary structural analysis also show that conformational changes of 
Fv-PrP following dimerization includes substantial gain of fl-Sheet content. Mass 
spectrometry analysis of hydrogen-deuterium exchange experiments reveal that 
conversion of prion involves residues 80-90 to the C-terminal of PrPc. Recent finding 
demonstrate that PrPSc is composed of p-Sheet structure with some short turns/loops and 
no a-helical conformation is observed in PrP80 (Sm irnovas et al, 2011). Recombinant 
PrPc has been converted to the P-Sheet conformation in the conditions involving acidic 
pH, mildly denaturing conditions, and the presence of certain ions (MAm & Su r e w ic z ,
2001). However, to the best of our knowledge, a-helix —* P-Sheet conformational 
transition of PrPc has never been obtained in the physiological conditions. We 
demonstrate that dimerization is a sufficient mechanism to induce such conformational 
changes of PrPc in a physiological-like environment.
Our results state that a minimal concentration of dimeric structures is 
sufficient to commence the pathway of protein aggregation. This finding is consistent 
with the theory of nucleation-polymerization of prion propagation (W eissm a n n , 1996). 
According to this theory, spontaneous conversion of PrPc to PrPSc does not occur in 
thermodynamic equilibrium between PrP° and PrPSc because the conversion is 
thermodynamically controlled and the equilibrium always stabilizes the PrPc state. 
Converted PrP8*1 is stabilized only when it interacts with aggregated seeds of PrPSc 
(Soto  & Sabo rio , 2001). This is due to unstable nature of PrPSc monomer which is 
stabilized only upon aggregation with other PrP80 molecules. PrP80 aggregates promote 
the conversion of PrP0 by binding to the monomeric PrP80 and displacing the 
equilibrium toward formation of the pathological conformer. When two prion molecules 
dimerize, they provide a stable seed which can interact with other aggregated molecules 
or soluble monomers, thereby creating a nucleus for polymerization of PrPc molecules 
into oligomeric species. This nucleation-polymerization reaction requires the formation 
of stable dimer cores capable of replicating the aggregation by recruitment of 
monomeric proteins.
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2.1. Conformational stability of prion increases by dimerization
We have determined the conformational stability of Fv-PrP against thermal 
unfolding before and after protein dimerization by CD. The midpoint of the thermal 
denaturation profile (T1/2) of Fv-PrP was calculated to be 70.1 °C before dimerization. 
Previous studies on the thermal stability of PrPc have reported T\n of 68.41  (Co rd eiro  
et al., 2005). This slight difference in the T\a  of Fv-PrP and the reported T\n for PrPc 
may be due to the differences in the experimental conditions or the presence of Fv 
domain in Fv-PrP structure. The Tm  of Fv-PrP aggregation decreases to 68.6 °C after 
dimerization. Destabilization of Fv-PrP after dimerization is due to structural 
fluctuations of amino acid side chains in the interface of two momers which are 
dimerized by AP20187. At this step, protein unfolding is favored by a more negative 
AGU° (Figure 2) resulted from an increase in the dynamics of binding site which 
transiently destabilizes proteins.
0 3o<
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Figure 1. Effect of dimerization on thermodynamics of Fv-PrP unfolding
Schematic representation of changes in AGU° of Fv-PrP as a function of protein 
unfolding. Thermal denaturation of dimerized Fv-PrP includes a transition step. A, AG„° 
of unfolding of Fv-PrP before addition of AP20187; B, unfolding AGU" of Fv-PrP 
measured within 10 min of the addition of AP20187. This step represents the formation 
of less stable transient intermediary structures; C, formation of the stable dimeric and 
oligomeric species 1 h after a transition in which dimerization of Fv-PrP has been 
established; D, 24 h after dimerization aggregates with high thermal stability are formed 
which display the highest AG„.
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Following this transition, thermal stability of the dimerized Fv-PrP increases as a 
function of time and maximum stability achieves after 24 h (Figure 2). One study have 
shown an increased conformational stability of PrPc in acidic pH (Sw ietn ic k i et al., 
1997). However, in our experimental conditions, stability of Fv-PrP achieves in a 
physiological environment. A pronounced change in the entropy of Fv-PrP unfolding 
(AHU) demonstrates that hydrophobic interactions significantly contribute to the stability 
of Fv-PrP dimers and aggregates.
2.2. Dimerization accelerates aggregation and amyloidogenesis of Fv-PrP
Spontaneous conversion of prion is a slow process and has never been shown 
in physiological conditions. It usually involves a very slow lag phase in which aggregate 
seeds are formed. The lag phase is followed by a rapid linear phase during which 
polymerization of prion into amyloid fibrils occurs with a subsequent steady state. 
Therefore, amyloidogenesis of prion usually involves a sigmoidal curve (Sun et al., 
2007). However, a rapid and linear growth of amyloid fibrils occurs when amyloid 
seeds are present (COLBY et al., 2007). We show that the lag time of amyloid formation 
significantly decreases when prion conversion proceeds through dimerization. In 
addition, consistent with a literature data (C olby  et al., 2007), amyloid formation of 
Fv-PrP is accelerated in the presence of fibril seeds. Notably, seeding reactions involved 
dimerization display the fastest rate of amyloidogenesis. These results confirm that 
dimers of Fv-PrP provide nucleation sites which interact with soluble proteins and 
convert them to the aggregated species without the need of acidic pH, denaturants or 
amyloid seeds.
2.3. Formation of pre-flbrillar aggregates and amyloid fibrils induced by 
dimerization
The dimerization strategy permits to directly characterize the formation of 
prion aggregates and amyloid fibrils in the same molecular pathway. One study have 
shown that formation of the prion P-Sheet oligomeric structures happens at highly
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acidic conditions, whereas, amyloid assemblies are formed under slightly acidic or 
neutral buffers (Bocharova  et al., 2005). In this study, preparation of P-Sheet and 
amyloid fibrils is done in parallel experiments but the dimerization condition allows to 
characterize all aggregated species in the same assay. Annealing of recombinant prion 
amyloids at high temperature and in the presence of Triton X-100 results in the 
rearrangement of amyloid fibril structure. In these conditions intermediary structures 
are characterized which display a high P-Sheet content with an extended PK-resistant 
core (Bocharova  et al., 2006). These results can be challenged by the fact the due to 
their highly stable structures, amyloid fibrils are thermodynamically favored 
conformations and in the normal conditions amyloid formation is likely to be an 
irreversible process (N iraula  et al., 2004).
The conformational transition from PrPc to PrP11®5 also occurs at pH 5.0 in 
bicellar solutions containing equimolar mixtures of dihexanoyl-phosphocholine and 
dimyristoyl-phospholipids, and a small percentage of negatively charged dimyristoyl- 
phosphoserine (Luhrs et al., 2006). In this conditions P-Sheet-rich structures are 
induced which further transform into amyloid fibrils. However, the exact molecular 
species formed during amyloid fibril formation was not characterized. We show that 
dimerization of Fv-PrP induces the formation of different molecular species during 
amyloigogenesis process. Electron and fluorescence microscopy characterizes the 
formation of pre-fibrillar oligomeric structures during amyloid fibril assembly. The 
protofibrils display annular and granular structures with a high P-Sheet content. The 
formation of pre-fibrillar aggregates with the same structures has been reported for 
several proteins involved in PMDs such as a-Syn (Co n w a y  et al., 2000, V olles  &  
Lansbury , 2003), lysozyme (Ma lisauskas et al., 2005) and Ap peptide (H a rtley  et 
al., 1999, W alsh  et al., 2002). These protofibrils are either produced during pathway of 
amyloidogenesis or are formed as a result of off-pathway products from proteins 
aggregated in alternative pathways. One example of these alternative pathways is the 
formation of protofibrillar oligmers of PrP° in the acidic condition. However, formation 
of mature amyloid fibrils requires another mechanistic process as it happens in the 
physiological conditions (Bocharova  et al., 2005). The formation of different
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molecular species of aggregating products such as oligomers and amyloid fibrils is 
highly dependent upon experimental conditions (Ba skak ov  et al., 2002, N ov itsk a y a  
et al., 2006). Our dimerization strategy is unique in that both oligomeric species and 
amyloid fibrils are characterized during same kinetic pathway under the physiological 
conditions. The oligomeric structures are hydrophobic assemblies with high affinity for 
ANS binding, indicating the flexibility of these oligomers in their structural cores. ANS 
binds to the oligomeric structures and molten globule proteins in which the buried 
hydrophobic regions are exposed due to the dynamic nature of these protein species 
(Ceru  & Zerovnik , 2008). Dimerization of prion requires structural changes to 
increase the dynamics of protein-protein interaction, consistent with a lower thermal 
stability of Fv-PrP observed shortly after dimerization. After equilibrium is achieved, 
higher ordered hydrophobic structures are formed which are thermally more stable than 
the initial dimers. These structures are in an on-pathway in the amyloidogenesis and are 
transformed into mature amyloids with a high thermal stability.
Our studies on the proteins harboring mutations revealed that the C-terminal 
domain of Fv-PrP encompassing amino acids 124-231 (Fv-PrP124231) is essential for 
aggregation and that the N-terminal region of Fv-PrP contributes to the formation of 
PK-resistant aggregates. Profiles of PK digestion assays show that Fv-PrP is more 
resistant to PK than Fv-PrP124'231 which lacks the N-terminal of PrPc. The N-terminal of 
PrPc can induce formation of higher ordered aggregates with more stable oligomeric 
structures (Frankenfeeld et a l, 2005). Thus, It stabilizes the conformationally 
transformed globular C-terminal of the prion protein. Further research is needed to 
characterize the exact role of N-terminal of PrPc in the oligomerization of the prion 
protein. The C-terminal domain of the prion protein including amino acids 121-231 can 
adopt oligomeric conformations with p-Sheet structure at acidic pH (H o rn em a n n  &  
G lockshuber , 1998). We show that assembly of Fv-PrP124-231 into PK-resistant 
structures does not require acidic conditions and is possible in the physiological 
environment when protein dimerization is involved in aggregating reactions. However, 
Fv-PrP124'231 is more sensitive to PK digestion and has less propensity for aggregation 
comparing to the full length Fv-PrP. The internal hydrophobic domain of PrPc (113-
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133) is important for the prion dimerization (Ram bo ld  et al., 2008). Therefore, lesser 
potential of Fv-PrP124'231 for oligomerization can be attributed to the deletion of a part of 
hydrophobic domain (113-124) which results in a deficient ability of Fv-PrP124231 to 
undergo dimerization.
2.4. In vitro amplification of the recombinant Fv-PrP aggregates
The relevance of dimerizing assay to the pathology of prion disease is 
demonstrated by PMCA reactions. In this context, prion aggregates are theoretically 
infectious if they are amplified through PMCA cycles and production of aggregates at 
the end of each cycle is considered as propagation of PrP1*6® (Ata ra sh i et a l, 2008). 
Importantly, the seeds used to induce the aggregation of soluble Fv-PrP are generated 
from the dimerized aggregates of the recombinant Fv-PrP protein. This is the first 
PMCA assay in which both soluble proteins and aggregate seeds have recombinant 
sources. In addition, the presence of Fv domain is not accounted as a species barrier 
when Fv-PrP aggregates are used to propagate wild type PrPc. Because Fv-PrP seeds 
can induce the aggregation of PrPc and the resulted do novo aggregates can be 
propagated through PMCA using soluble PrPc sources. Contrary to the previous PMCA 
methods, our dimerization-based PMCA assay does not contain detergents such as 
Triton X-100 or SDS (Atarashi et al., 2007), RNA (Deleault  et al., 2003) or 
polysynthetic anions (D eleault  et al., 2005). Our PMCA results are consistent with the 
'protein only hypothesis' proposing that infectious agent of prion disease is solely 
composed of protein. We show that in vitro dimerization of Fv-PrP is a minimal and 
sufficient event to induce aggregation and subsequent propagation of Fv-PrP8*8 
aggregates without the need of other factors. Several publications have characterized a 
pronounced relationship between the level of aggregate amplification and number of 
cycles used in PMCA . Successive rounds of PMCA can exponentially increase the 
amplification of PrP80 as reported in manual (Sabo rio  et al., 2001) and automated 
PMCA cycles (Saborio  et a l, 2001). In agreement with these results, in our PMCA 
assays there is an increase in the production of both Fv-PrP8*8 and Fv-MoPrP8*8 with 
increasing of the PMCA cycles.
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3. In vitro and in vivo toxicity of Fv-PrP aggregates
We have tested the toxicity of dimerization-induced Fv-PrP aggregates on the 
murine neuroblastoma cells as well as on the mouse brain. For this experiment we used 
two different methods to prepare Fv-MoPrP aggregates. In the first method, 
dimerization was induced with higher concentrations of AP20187 which produced 
instant aggregation with a high rate of amyloidogenesis. In the second method, lower 
concentration of AP20187 was used to decrease the kinetics of protein aggregation and 
to allow the characterization of the oligomeric species formed during amyloid formation 
process. The aggregates have high P-Sheet content and may adopt different structures 
ranging from small globular aggregates to higher ordered amorphous assemblies. These 
oligomeric structures are less PK-resistant and eventually transform into highly PK- 
resistant amyloid fibrils. Therefore, dimerization-induced pathway of amyloid formation 
can mimic the mechanism of PrPc —*■ PrP80 conversion which includes formation of 
intermediary structures (Baskakov  et al., 2002, R eza ei et al., 2005).
The intermediate protofibrillar aggregates as well as the amyloid fibrils were 
examined for their toxicity in vitro and in vivo. Aggregates of the recombinant Fv- 
MoPrP were highly toxic to the cell lines as characterized by DNA fragmentation assay 
on the cells. However, mature amyloid fibrils had no toxic effect when added to the 
cells. In order to confirm the in vitro results, we performed stereotaxic injection of the 
protein preparations including soluble proteins, small oligomeric aggregates and 
amyloid fibrils. In agreement with in vitro results, globular and pre-fibrillar aggregates 
of Fv-MoPrP were neurotoxic and caused apoptosis in the cells adjacent to the injection 
site, whereas amyloid fibrils did not induce cellular toxicity. Our results suggest that 
protofibrillar aggregates have two important biological characteristics including 
neurotoxicity and the capability to transform into amyloid fibrils. Baskakov et al., have 
shown that the oligomeric species cannot be served as substrate for the amyloid 
formation (Baskakov  et a l, 2002). Nevertheless, we have found that smaller 
aggregates and granular protofibrils are essentially produced as on-pathway products 
which naturally transform into amyloid fibrils by aging. It has been demonstrated that
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pre-fibrillar aggregates and smaller oligomeric species formed in the early stages of 
amyloidogenesis from different amyloidogenic proteins and even proteins not connected 
to any PMD are highly toxic, whereas amyloid fibrils are harmless to the cell lines 
(BUCCIANTINI et al., 2 0 0 2 ,  Hosffl et a l, 2 0 0 3 ,  LASHUEL et al., 2 0 0 3 ,  SlMONEAU et a l, 
2 0 0 7 ,  W a ls h  et al., 2 0 0 2 ) .  One study has shown slight toxicity caused by injection of 
the amyloid fibrils in the mice brain (S im o n eau  et a l,  2 0 0 7 ) .  This could be due to 
difference between amyloid preparations in the work of Simoneau et a l, and this study. 
For example, heterogeneous preparations which may contain oligomeric intermediates 
in their way of amyloid formation, can still induce some neurotoxicity. Our in vivo and 
in vitro results strongly indicate that homogenous preparations of mature amyloid fibrils 
are not neurotoxic.
The in vivo results presented herein are consistent with the theory that smaller 
oligomeric structures of prion and not higher structured amyloid deposits are involved 
in neurotoxicity and cell death. Supporting evidence for this hypothesis is the absence of 
any correlation between the deposition of amyloid plaques and neuronal toxicity ( B e l l  
& I ro n s id e , 1 9 9 3 ,  G a m b e tti  et al., 1 9 9 5 ,  G o n z a le z  et al, 2 0 0 3 ) .  In addition, 
anchorless PrPc-expressing mice display very little or no toxicity when infected with 
PrPSc. In the brain of these mice extracellular deposition of highly amyloid structures of 
prion is reported without inducing neurotoxicity (C h e s e b ro  et al., 2 0 0 5 ) .  The amyloid 
fibrils generated in our dimerizing system were successfully propagated in vitro through 
PMCA cycles. However, we failed to establish a PMCA assay in order to propagate 
oligomeric protofibrillar structures. To date, there is no in vivo or in vitro evidence on 
the amplification of neurotoxic oligomers of PrPc. This suggest that PrPSc and toxic 
oligomeric species may have biological and functional differences.
D e s p i t e  d i r e c t  i n v o l v e m e n t  o f  P r P 5 ® i n  t h e  d e v e l o p m e n t  o f  p r i o n  d i s e a s e  
n e u r o p a t h o l o g y ,  t h e r e  a r e  c a s e s  o f  n e u r o d e g e n e r a t i o n  i n  w h i c h  t h e  c o r r e l a t i o n  b e t w e e n  
P r P 5 ® f o r m a t i o n  a n d  n e u r o t o x i c i t y  i s  o b s c u r e .  F o r  e x a m p l e ,  n e u r o d e g e n e r a t i o n  c a n  o c c u r  
w h e n  l o w  o r  u n d e t e c t a b l e  P r P 5 ® l e v e l s  a r e  o b s e r v e d  i n  t h e  b r a i n  o f  m i c e  i n f e c t e d  w i t h  
p r i o n s  ( C O L L I N G E  et al., 1 9 9 5 ,  H s i A O  et a l,  1 9 9 0 ,  L a s m e z a s  et al., 1 9 9 7 ) .  A l s o ,  t h e r e
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are experimental reports where PrP80 displays high immunostaining in the brain tissue 
but the neuropathological signs are minimal or absent (Chesebro  et al., 2005). 
Experiments on transgenic mice lacking the expression of PrPc (Pmpm ) demonstrate 
that these mice are resistant to the prion pathology after inoculation of PrP80 into their 
brains and that PrPc —» PrP80 is essential for the propagation of infectivity and 
pathogenesis (Bueler  et al., 1993, M an so n  et al., 1994). Although in vitro 
neurotoxicity of a short PrP peptide (residues 106-126) and PrP80 has been demonstrated 
, opposing in vivo results show that neurotoxicity is not directly linked to PrP80. In the 
mice infected with PrP80 which show early symptoms of the prion disease, depletion of 
neuronal PrP expression can protect mice against development of clinical symptoms 
such as neuronal loss, hippocampus-related cognitive and behavioural abnormalities and 
reverses the early pathology (M a llu c c i et al., 2003, M allucci et al., 2007). These 
results propose that during pathway of prion conversion, PrPc may adopt some 
structures which are neurotoxic and these oligomeric structures are highly potential for 
conversion into PrP80.
The fact that PrP8° can be amplified without causing pathological signs and 
that neuropathology can occur in the absence of PrP80 proposes that other forms of PrP 
and not PrP80 are responsible for neurodegeneration in prion disease. Therefore, it is 
possible that in the pathway of PrP8° formation, intermediate assemblies are produced 
responsible for cellular toxicity and neurodegeneration. These intermediate structures 
are sometimes referred to as PrP* (A g u zzi & W eissm a n n , 1997). The question arising 
is what would be the mechanism of neurotoxicity induced by these intermediate 
oligomeric structures. We show that oligomeric pre-fibrilar structures of Fv-MoPrP 
have high hydrophobicity as characterized by the affinity of ANS to bind to these 
aggregates. These fi-sheet oligomers can readily internalize cells (S im o n ea u  et al., 
2007). One possibility would be that the increased hydrophobic surface of globular 
oligomers may facilitate their incorporation into lipid bilayers. This notion is supported 
by evidence on the neurotoxicity and membrane penetration of hydrophobic fragments 
of PrPc including PrP peptides 118-135 and 105-132. These fragments can destabilize 
cell membranes by insertion into lipid bilayer (Ha ik  et al., 2000). In agreement with
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these results, one study showed that a amyloid-forming PrP mutant fragment (PrP 82- 
146) that is involved in the pathogenesis of prion disease GSS can form ion channels 
and induce toxicity when introduced to the cell lines (Ba h a d i et al., 2003).
One intriguing finding of this study was that amyloid fibrils were propagative 
but had no neurotoxicity, whereas oligomeric intermediary structures were neurotoxic 
but could not be amplified in vitro using standard methods. This results are in 
agreement with the theories that try to distinguish between the mechanisms of prion 
toxicity and infectivity (C o ll in g e  & C la r k e ,  2007). Inoculation of PrPSc into mice 
brains with different levels of PrPc expression revealed that the infectivity reaches the 
same plateau in all brains and the plateau is defined as a stage beyond which there is no 
increase in concentration of infectious prions ( S a n d b e rg  et al., 2011). However, 
animals expressing lower levels of PrPc have longer life spans than those mice 
expressing higher amounts of PrP , suggesting that the same level of PrP can induce a 
faster neuropathology in the mice overexpressing PrPc. These results suggest that PrPSc 
by itself is not a neurotoxic entity but it can catalyze the formation of neurotoxic species 
via interaction with PrP0 (W ic k n e r, 2011). Our results are consistent with these finding 
and indicate that propagation of resistant forms of amyloid fibrils can be distinguished 
from toxicity of pre-fibrillar aggregates.
4. Dimerization involves in a-Syn aggregation
a-Syn aggregation is central to the pathogenesis of PD. Therefore, a detailed 
characterization of a-Syn aggregation is essential to comprehend the mechanism of PD 
pathology at the molecular level. Many studies have reported the existence of a-Syn 
dimeric forms in the aggregation experiments. In the in vitro aggregating experiments, 
dimers of a-Syn are detected after 8 h and inhibition of dimerization by Neurosin 
prevents a-Syn from polymerizing into aggregated structures (Iw a ta  et al., 2003). The 
dimerization of a-Syn induced by intramolecular oxidative cross-linking of tyrosine 
residues has been reported to induce the aggregation process and two disease causing
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mutants A30P and A53T show a higher propensity for dimer formation (K rish n a n  et 
al., 2003).
We show by CD that a-Syn dimerization is an important molecular event that 
accelerates structural transformation of a-Syn from a random coil structure into a P- 
Sheet conformation. Native a-Syn forms a helical structure during transition from 
random coil to p-Sheet conformation, consistent with recent finding that aggregation of 
a-Syn in the experimental conditions in the presence of trifluoroethanol (TFE) involves 
formation of a-helical intermediary structures (An d erso n  et al., 2010). The formation 
of this helical intermediate highly depends upon experimental conditions used to induce 
a-Syn aggregation. The TFE agent by itself can induce helical structures when it is 
introduced into the aggregation reactions of a-Syn. However, in our experimental 
conditions the helical conformation of a-Syn can be detected in the absence of helix- 
inducer agent and the observed a-helical transition is a result of protein aggregation in 
the physiological environment. The a-helical transition of a-Syn is not observed when 
higher protein concentrations (400 pM) is used in the aggregation reaction (Ser pell  et 
al., 2000), probably due to rapid aggregation of a-Syn. We report an accelerated 
transition of a-Syn from ransom coil to a p-Sheet structure when a-SynFv is incubated 
with AP20187. Indeed, in the dimerization assays, a-SynFv transformed into a P-Sheet 
conformation when 2Q0 pM protein was incubated in the physiological conditions. The 
difference between our results and the previously reports on the secondary structural 
changes of a-Syn (Serpell  et al., 2000) can be explained in terms of the available 
contact sites for aggregating a-Syn molecules. In our experiments dimerization of lower 
concentrations of a-Syn provides contact surfaces for proper interaction and aggreation 
of proteins which naturally undergo a random coil —► a-helix —> P-Sheet transition, 
whereas in those studies, high concentrations of a-Syn induces a massive and instant 
aggregation of the proteins. In this circumstances, either the helical transformation is so 
fast which would be hard to monitor or basically it does not occur.
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4.1. Acceleration of a-Syn oligomerization and amyloidogenesis induced by 
dimerization
In the current work, it is demonstrated that a-Syn dimerization accelerates both 
oligomerization and amyloid fibril formation from the recombinant a-SynFv constructs. 
In addition, different aggregated conformations of a-Syn were characterized in terms of 
morphology and binding affinities with fluorescence dyes such as ANS and ThT. The 
first products of dimerization-induced a-SynFv oligomerization or a-Syn agregation 
were globular oligomeric structures which had a high affinity for ANS binding. The 
kinetics of a-Syn aggregation was significantly higher in the reactions which initiated 
by dimerization. It is known that two diseases causing mutants of a-Syn A30P and 
A53T have a high capacity for dimer formation (Krish n a n  et al., 2003). Both mutants 
can form spherical oligomeric structures in vivo arid A53T can induce a faster rate of 
oligomerization and amyloidogenesis, comparing to the wild type protein (Co n w a y  et 
al., 1998). Both A30P and A53T accelerate the formation of oligomeric spherical 
aggregates which are assembled during amyloidogenesis of recombinant proteins 
(Conw ay  et a l, 2000). Therefore, it is possible that dimerization increases the rate of 
aggregation and amyloid formation in these mutants. Importantly, the morphology of 
oligomers obtained from a-Syn mutants (Con w a y  et al., 2000) is very similar to that of 
dimerized a-SynFv oligomers and wild-type a-Syn in our experiments. However, in that 
study an increase in the rate of oligomerization but not fibrillization was characterized 
as important biological property of a-Syn. It is possible that in the work of Conway et 
al., the experimental conditions favored oligomerization over fibrillization. Those 
experiments were performed in the stationary conditions in which aggregation might 
take up to one month. In this condition, the intrinsic property of recombinant a-Syn for 
missfolding in the experimental condition may provide substrates with less efficiency in 
making intermolecular interactions with polymerizing oligomers in the pathway of 
amyloidogenesis. In the pathology of PD, neurodegeneration is always associated with 
the detection of amyloid structures and LBs. Regardless of the pathogenic or protective 
role of LBs there is a tight correlation between a-Syn aggregation, pathology and the 
appearance of LBs. The dimerization model is therefore consistent with such a 
biological paradigm in which dimerization can accelerate the formation of pathogenic
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aggregates and the amyloid fibrils. The propagation of LBs across neuronal cells is 
known to occur via a seeding mechanism and in vitro experiments have shown that a- 
Syn amyloidogenesis is accelerated in the presence of protofibril seeds (K im  et al., 
2007). Our in vitro dimerization strategy can accelerate the formation of protofibrillar 
oligomers which can efficiently increase the rate of amyloid fibril formation, compatible 
to those reported in the previous studies.
4.2. Neurotoxicity of a-Syn aggregates
There is a lack of evidence on the exact identity and nature of neurotoxic 
species of a-Syn which are formed through amyloidogenesis and LB formation. During 
the pathology of PD, appearance of LB in different brain regions is always associated 
with neurodegeneration. Therefore, either LB or amyloid inclusions are directly toxic or 
there is assembly of oligomeric pre-fibrillar aggregates and intermediary structures 
which cause neurodegeneration. Indeed, finding the precise correlation between 
different oligomeric structures and neurotoxicity in PD pathogenesis is essential to 
comprehend the molecular mechanism of pathology. The important challenge is to 
establish a functional link between the in vitro produced oligomers/amyloid fibrils and 
the in vivo neurotoxicity. Main obstacles to address this issue are the dynamic nature of 
protein aggregation and the highly transient conformations of the pre-fibrillar 
oligomeric intermediates that makes them hard to be characterized. This is because 
these intermediary structures which are also designated as on-pathway products are 
highly potential to adopt a more stable conformation of amyloid fibrils, especially when 
oligomer concentration reaches certain threshold (Kim et al., 2009).
To overcome these challenges, an experimental approach is needed to precisely 
characterize different oligomeric structures of a-Syn and individually determine their 
neurotoxicities. The dimerizing strategy was used to produce and characterized 
metastable pre-fibrillar aggregates as well as the amyloid fibrils produced from 
dimerization of a-Syn. Neurotoxicity of oligomeric structures and amyloid fibrils was
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then examined by injection of protein samples into the mice brain. In order to scan the 
whole region of the brain which underwent apoptosis after injections, we scanned the 
whole upper brain area by confocal microscope. This allowed to characterize CA1, CA2 
and CA3 cells of hippocampus as well as neurons adjacent to the injection site and right 
ventricle as affected regions. We used TUNEL test to characterize apoptotic cells and an 
antibody which specifically recognizes neuronal cells. This way we could monitor the 
apoptotic neuronal regions.
As expected, neither of soluble a-Syn or a-SynFv proeins induced toxicity after 
injection into the mice brain. Globular aggregates and pre-fibrils were highly neurotoxic 
to the neuronal cells and induced severe apoptosis in CA1, CA2 and CA3 hippocampal 
neurons as well as in the region adjacent to the injection site. Immunofluorescence 
experiments show that these protofibrils can internalize neuronal cells and induce 
apoptosis. Although we did not characterize the molecular mechanism of neurotoxicity, 
the rapid internalization of aggregates into neurons associated with apoptosis may give 
clues to understand the mechanism of neuropathology. In vitro, p-Sheet-rich protofibrils 
of a-Syn display a pore-forming activity and bind with high affinity to acidic 
phospholipid vesicles and permeabilize them transiently (V olles et al., 2001). In 
addition, two pathogenic a-Syn mutants A30P and A53T which show an increased 
propensity for protofibril formation also induced leakage of vesicular contents as a 
result of membrane destabilization (V olles &  Lansbury , 2002). Membrane 
permeabilization induced by a-Syn protofibrils has been also shown in cell systems. 
Indeed, introduction of a-Syn oligomers to cell cultures can increase the level of 
calcium influx into the cells (Danzer  et al., 2007). This results in membrane potential 
change as well as the alteration of cellular ion homeostasis in living cells which may 
induce caspase activation and cell death. Other amyloidogenic oligomers of disease- 
related proteins such as Ap, polyglutamine, prion and islet amyloid polypeptide have 
been also shown to alter the levels of calcium in cells (De m u r o  et al., 2005). Moreover, 
the pre-fibrillar oligomers formed by amyloid forming proteins like Ap, Superoxide 
dismutase, Prion protein and Huntingtin are shown to form pore-like structures 
(Lashuel  & La n sb u r y , 2006). Other evidences also suggest a pore-forming
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mechanism for a-Syn spherical protofibrils. Synthetic annular protofibrils of a-Syn bind 
tightly to brain-derived membrane vesicles and make pores, a mechanism which has 
been also attributed to some bacterial toxins (Din g  et a l, 2002). These toxins which 
include a-hemolysin (Song  et al., 1996), perfringolysin (H otze et al., 2002), and 
anthrax protective antigen (Benso n  et a l, 1998) can also form membrane spanning 
pores which morphologically resemble a-Syn annular aggregates in their membrane 
bound state.
We show that mature amyloid fibrils are deprived of any neurotoxic activity 
when injected into mouse brain. This result is consistent with recent in vivo findings that 
expression of amyloid-forming mutants of a-Syn by lentivirus in the rat brains did not 
cause neurotoxicity but oligomeric structures produced under the same expression 
system caused pathology ( W i n n e r  et a l, 2 0 1 1 ) .  A  recent study have shown that 
synthetic a-Syn amyloids fragmented by sonication are neurotoxic in the mice brain 
( L u k  et a l, 2 0 1 2 ) .  However, the biophysical properties and the exact morphology of the 
neurotoxic species formed in vitro have not been characterized.
Studies on P D  and other neurodegenerative disorders have shown that amyloid 
inclusions may not play a major role in cellular toxicity and neurodegeneration. 
Analysis of post-mortem samples of Alzheimer's disease does not show a direct 
correlation between the severity of clinical signs and the density of AP amyloid plaques 
( T e r r y  et al., 1 9 9 1 ) .  Also, in P D  there is no direct link between appearance of L B  in 
pathology and cell death in the substantia nigra ( T o m p k i n s  & H ill ,  1 9 9 7 ) .  Similarly, in 
Huntington's disease amyloid inclusions are intensely present in the cerebral cortex and 
cause only a moderate neurodegeneration ( G u t e k u n s t  et a l, 1 9 9 9 ) .  In cell cultures 
GFP-fused N-terminal fragment of huntingtin, a protein responsible for amyloid 
formation in Huntington's disease, causes a moderate neurotoxicity in its amyloid form 
but proteins that do not form amyloids substantially reduce cell viability ( A r r a s a t e  et 
al., 2 0 0 4 ) .  There is evidence that in yeast, formation of amyloid fibrils induced by 
chaperones can protect cells from the prion toxicity ( D o u g l a s  et al., 2 0 0 8 ) .  These
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results may propose a protective role for the amyloid inclusions. However, in vivo 
studies on animal models are still lacking to support this hypothesis.
4.3. Prion-like mechanism of a-Syn propagation
There is emerging evidence of a prion-like mechanism of aggregation and 
propagation of a-Syn aggregates. We show that a-Syn aggregates can be amplified and 
propagated in vitro with the same mechanism as the prion protein. Indeed, using the 
PMCA method, de novo a-Syn aggregates are generated in vitro. This provides a direct 
evaluation of the in vivo theories on the propagation of a-Syn aggregates and amyloid 
fibrils. The neuropathology caused by a-Syn aggregates is not limited to the substantia 
nigra and progresses to the other brain regions such as dorsal JX/X motor nucleus, 
subnuclei of the ralph system and even the cortex (Br a a k  et al., 1998, B r a a k  et al., 
2003). The a-Syn aggregates can be also propagated from PD brains into transplanted 
mesencephalic dopaminergic cells (Li et al., 2008). Co-culturing of human 
dopaminergic neuronal cells demonstrate that a-Syn aggregates can transfer between 
neurons (Desplats et al., 2009). The neuron-to-neuron transmission of a-Syn 
aggregates is assocciated with a nucleation-polymerization reaction through which the 
transmitted aggregates can seed the unfolding of soluble a-Syn host proteins (Ha n sen  
et al., 2011). Seeding activity of a-Syn aggregates has been also shown in vitro where 
introduction of the recombinant a-Syn oligomers induces the unfolding of endogenously 
expressed a-Syn in neuroblastoma cells(DANZER et al., 2007) as well as in primary 
cortical neurons (Danzer  et al., 2007, D a n zer  et al., 2009).
Our PMCA provides direct in vitro evidence for a nucleation-polymerization 
mechanism of a-Syn aggregation and propagation. In addition, this important finding 
excludes the role of probable cellular factors that may influence a-Syn aggregation and 
proposes that only the interaction between aggregates and soluble a-Syn is sufficient to 
start the pathway of protein aggregation/amplification. Together, our results in 
association with current literature suggest that the mechanisms of initiation and
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propagation of aggregates for a-Syn and prion are similar during the pathology of PD 
and prion disease, respectively.
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Prion diseases are caused by the conversion of a cellular pro­
tein (PrPc) into a misfolded, aggregated isoform (PrP***). Mis­
folding of recombinant PrPc in the absence of PrP*** template, 
cellular factors, denaturing agents, or at neutral pH has not been 
achieved. A number of studies indicate that dimerization of 
PrP0 may be a key step in the aggregation process. In an effort to 
understand the molecular event that may activate misfolding of 
PrPc in more relevant physiological conditions, we tested if 
enforced dimerization of PrP° may induce a conformational 
change reminiscent of the conversion of PrPc to PrP***. We 
used a well described inducible dimerization strategy whereby a 
chimeric PrPc composed of a modified FK506-binding protein 
(Fv) fused with PrPc and termed Fv-PrP is incubated in the pres­
ence of a monomeric FK506 or dimerizing AP20187 ligand. 
Addition of AP20187 but not FK506 to recombinant Fv-PrP 
(rFv-PrP) in physiological-like conditions resulted in a rapid 
conformational change characterized by an increase in 0-sheet 
structure and simultaneous aggregation of the protein. Aggre­
gates were partially resistant to proteinase K and induced the 
conversion of soluble rFv-PrP in serial seeding experiments. As 
judged from thioflavin T binding and electron microscopy, 
aggregates converted to amyloid fibers. Aggregates were toxic to 
cultured cells, whereas soluble rFv-PrP and amyloid fibers were 
harmless. This study strongly supports the proposition that 
dimerization of PrPc is a key pathological primary event in the 
conversion of PrPc and may initiate the pathogenesis of prion 
diseases.
Prion diseases or transmissible spongiform encephalopa­
thies (TSEs)2 are fatal neurodegenerative disorders that affect 
both animals and humans. These diseases include scrapie in 
sheep, bovine spongiform encephalopathy (BSE) in cattle and 
Creutzfeldt-Jakob disease in humans. In humans, these disor­
ders can appear in three forms, sporadic, genetic, and iatro­
genic. All forms involve modification of the normal prion pro­
*This work was supported by a  grant from Canadian Institutes for Health 
Research (to X. RJ.
1 To whom correspondence should be addressed: D ept o f Biochemistry, Fac­
ulty of Medicine, University o f Sherbrooke, 3001 12th Ave. Nord, Sher­
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564-5340; E-mail: xavier.roucou0usherbrooke.ca.
2 The abbreviations used are: TSE, transmissible spongiform encephalopathy;
BSE, bovine spongiform encephalopathy; Fv, FK506 binding domain; 
GdnHCI, guanidinium hydrochloride; PK, proteinase K; PrP0, cellular prion 
protein; PrP"**, protease-resistant prion protein; StAR, steroidogenic acute 
regulatory protein; PBS, phosphate-buffered saline; ThT, thioflavin.
tein (PrPc), a secreted glycosylphosphatidylinositol-anchored 
sialoglycoprotein, into a disease-causing prion protein (PrP***) 
(1). Although the primary structures of PrPc and PrP*** have 
been found to be identical (2) the two isoforms have consider­
ably different physiochemical properties. PrPc is monomeric 
and degradable by proteinase K (PK), whereas PrP*“  exists as 
insoluble aggregates that show dramatically increased resist­
ance to digestion by PK (1). Furthermore, spectroscopic data 
indicate that the two prion protein isoforms are characterized 
by different secondary structures; PrPc is largely a-helical, 
whereas PrP*** is rich in 0-sheet structure (3,4). In designing 
strategies to prevent the propagation and the progression of 
TSEs, it is important to determine the molecular pathway lead­
ing to the aggregation of PrPc.
Substantial efforts have been devoted to reconstitute de novo 
misfolding of PrPc and prion infectivity and/or toxicity. In the 
first approach, PrP*** was amplified in PrP***-dependent con­
version reaction experimental conditions (see Refs. 5 and 6 for 
reviews). Experiments included the use of ionic or non-ionic 
detergents, or repeated sonication steps, or shaking for a long 
period of time. In the second approach, recombinant PrP (rPrP) 
was mixed in a combination of low concentrations of guani­
dinium chloride (GdnHCI) (7, 8) or urea and NaCl (9-11) in 
acidic or neutral conditions. Recent investigations showed that 
acidic conditions alone can induce the conversion of rPrP (12). 
Addition of lipids to rPrP also induces a conformational change 
into a form reminiscent of PrP*** (13). Furthermore, low con­
centrations of SDS induce a structural transition of PrP into a 
pathogenic conformation (14, 15). These approaches allowed 
purified PrP0 or rPrP to undergo a transition to an oligomeric 
0-sheet-rich structure with essential physiochemical proper­
ties similar to those of PrP*** and, in some instances, to recon­
stitute infectivity (16, 17). Recently, thermal refolding and 
expression of PrP in form of a tandem repeat resulted in the 
formation of soluble oligomers with high 0-sheet content (15, 
18). In vitro PrP conversion techniques have already contrib­
uted significant insights into the molecular mechanisms of 
prion diseases. However, an important issue remains unre­
solved: physiological circumstances mimicking in vitro condi­
tions used to induce misfolding of PrP° are unlikely to occur in 
vivo. Thus, elucidating what molecular event may induce the 
aggregation of PrP° in physiologically relevant conditions 
remains an important challenge.
In acquired TSEs, PrP*** physically interacts with PrP° and 
may force PrP° molecules to dimerize/oligomerize and aggre­
gate (19 -22). Thus, we reasoned that dimerization may be a key
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step toward aggregation of PrPc in vivo. In favor of this hypoth­
esis, several observations indicate that PrP can form dimers that 
could be intermediate states in PrPR** formation (23). Recently, 
we used a well described chemical dimerization strategy to test 
this proposition. In this technology, a synthetic homodimeriz- 
ing ligand termed AP20187 binds to and cross-links two FK506 
binding domains (Fv). A fusion protein between PrPc and Fv 
was engineered, and addition of AP20187to cultured cells 
expressing Fv-PrP resulted in the formation of extracellular 
deposits that are insoluble in non-ionic detergents and partially 
resistant to PK (24). These findings demonstrated that homol­
ogous interactions between PrP molecules constitute a minimal 
and sufficient molecular event leading to PrP aggregation and 
extracellular deposition of aggregates, at least in cultured cells. 
Dimerization-induced aggregation of PrP may either be an 
intrinsic property of the protein, or require other cellular fac­
tors. In the present study, we addressed this issue by inducing 
the dimerization of purified recombinant Fv-PrP (rFv-PrP) in 
physiological-like conditions. We show that addition of 
AP20187 but not control monomeric FK506 to rFv-PrP results 
in spontaneous misfolding and aggregation as judged by an 
increase in turbidity, by differential centrifugation, and by elec­
tron microscopy. CD experiments confirmed that AP20187 
induces a structural conversion characterized by a decrease in 
a-helices and a concomitant increase in j3-sheets. Furthermore, 
rFv-PrP aggregates induced the conversion of soluble rFv-PrP 
in serial seeding experiments. These results demonstrate that 
dimerization is a sufficient molecular event responsible for ini­
tiating misfolding and aggregation of PrP in vitro and support 
the hypothesis that dimerization of PrPc is a possible initial step 
in the pathogenesis of prion diseases.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification o f Recombinant 
Proteins—Recombinant human Fv-PrP (rFv-PrP) was ampli­
fied from pCEP4/3-FvPrP (24). PCR primers were forward 5'- 
ggaattccatatgaagaagcgcccgaagcctggag-3' and reverse 5'-cggaa- 
ttctcacgatcctctctggtaataggcctg-3'. Recombinant Fv-PrP23-124 
and rFv-PrP124-231 were generated by overlap extension PCR. 
For rFv-PrP23-124, Fv was amplified from pC4-FvlE (vector 
kindly provided by ARIAD Pharmaceuticals) using PCR prim­
ers forward 5' -actatacatacacatatggcttctagaggagtgcaggtggagact- 
atc-3' and reverse 5' -ggcttcgggcgcttcttgcatgcgtagtctggtacgtcg- 
3'. P r P 2 3 -1 2 4  was amplified from pCEP4/3-PrP (24), using PCR 
primers forward 5'-ccagactacgcatgcaagaagcgcccgaagcctgg- 
agg-3' and reverse 5'-cagtactaggaattcttacactgccccagctgctgcag- 
cacc-3'. Fv-PrP23-124 was generated by using the products of 
these two PCR as primers for the overlap extension. For rFv- 
prpi24-23i, pv was amplified from pC4-FvlE using PCR prim­
ers forward 5' -actatacatacacatatggcttctagaggagtgcaggtggagact- 
atc-3' and reverse 5'-gccgccaaggccccccactgcgtagtctggtacg-3'. 
prpi24-23i was amplified from pCEP40-PrP, using PCR prim­
ers forward 5 '-cgtaccagactacgcagtggggggccttggcggctac-3' and 
reverse 5' -taggaattctcacgatcctctctggtaataggcctgagattccctctcg- 
3'. rFv-PrP124-231 was generated by using the products of these 
two PCR as primers for the overlap extension. To generate 
recombinant mouse Fv-PrP, Fv was amplified from pC4-FvlE 
using PCR primers forward 5' -phospho-gggtctagaggagtgcagg-
tggagactatc-3' and reverse 5' -phospho-gggtgcgtagtctggtacgtc- 
gtacgg-3'. The PCR product was inserted in the natural Smal 
site of mouse Pmp at bp 116. Mouse Fv-PrP was amplified using 
PCR primers forward 5'-ggaattccatatgaaaaagcggccaaagcctg- 
gag-3' and reverse 5 '-cggaattctcaggatcttctcccgtcgtaataggc-3'. 
Recombinant human PrP was amplified from pCEP4/3-PrP 
using PCR primers forward 5' -attctagctagccaccaccaccaccacca- 
ctgcaagaagcgcc-3' and reverse 5'-gcggatcctcacgatcctctctggtaa- 
taggcctg-3'. The PCR products were inserted between the Ndel 
and EcoRI sites in pET28a(+), creating NH2-His6 tag con­
structs. PCR amplification fidelity was confirmed by sequenc­
ing. Constructs were overexpressed in BL-21 (DE3)pLys S cells, 
and inclusion bodies were purified (25). Purification of recom­
binant proteins from the inclusion bodies was performed using 
the artificial chaperone-assisted method (26). Inclusion bodies 
were resuspended in buffer D1 containing 6 m  GdnHCI, 100 i d m  
Na2HP04 , 10 m M  Tris-HCl, 10 m M  reduced glutathione, 1 m M  
Tris(2-carboxyethyl)phosphine, pH 8.0. Soluble protein frac­
tion obtained after harvesting (15,600 X g, 45 min) was added to 
20 ml of nickel-nitrilotriacetic acid resin followed by incubation 
for 3 h at 4 °C. Buffer D1 was gradually substituted by buffer D2 
(4 m M  GdnHCI, 100 mM NajHPO*, 10 m M  Tris-HCl, 5 m M  
reduced glutathione, 0.5 mM Tris(2-carboxyethyl)phosphine, 
pH 8.0). GdnHCI was then replaced by 14 m M  cetrimonium 
bromide in buffer D2, and samples were incubated at 4 ”C for 
2 h. Buffer D2 was exchanged by buffer R (100 m M  NaHjPO^ 10 
m M  Tris-HCl, 0.5 m M  Tris(2-carboxyethyl)phosphine, 5 m M  
/3-cyclodextrin, pH 8.0) followed by overnight incubation at 
4 *C. After a washing step with buffer R devoid of /3-cyclodex­
trin (Buffer W), the protein was eluted with the same buffer 
containing 500 mM imidazole and 100 mM GdnHCI (Buffer E). 
The eluted fractions were concentrated (27) in buffer W. All 
buffers contained 30 mM imidazole, unless indicated otherwise.
Assessment o f in Vitro Aggregation—Recombinant proteins 
(0.2 mg/ml) were incubated in the presence or absence of 
increasing concentrations of AP20187 or FK506 at 37 °C in 0.5 
ml of 25 mM sodium phosphate buffer, pH 7.4. After 30 min, the 
apparent optical density, which is proportional to turbidity, was 
measured at 340 nm using a Beckman model DU 70, multi­
sample UV-visible spectrometer. After recordings, samples 
including AP20187 were transferred to fresh tubes and spun at 
15,600 X g  for 15 min, and the absorbance of supernatant was 
recorded at 340 nm.
Aggregation was also assessed by differential centrifugation. 
Recombinant proteins (0.2 mg/ml) were incubated in the 
absence or in the presence of increasing concentrations of 
AP20187 in a 0.5 ml of a buffer containing 10 m M  Tris-HCl and 
100 mM  Na2HP04> pH 7.4. After 30 min at 37 *C, samples were 
centrifuged at 15,600 X g for 15 min. Supernatants containing 
soluble proteins were collected in fresh tubes, and proteins 
were precipitated with trichloroacetic acid, and pellets were 
solubilized in 30 pi of SDS loading buffer (0.5% SDS (w/v), 
1.25% /3-mercaptoethanol (v/v), 4% glycerol (v/v), 0.01% brom- 
phenol blue (w/v), 15 mM Tris-HCl, pH 6.8). Pellets containing 
aggregated proteins were directly solubilized in 30 pi of SDS 
loading buffer. A 10-p.l aliquot of each sample was analyzed in 
12% SDS-PAGE and proteins were stained with Coomassie 
Blue.
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CD Spectroscopy—CD measurements were carried out as 
previously described (28) using a protein concentration of 6  /am 
in a 25 mM sodium phosphate buffer at pH 7.4 (PBS) and at 
37 *C. The secondary structure changes of rFv-PrP were evalu­
ated by monitoring the ellipticity in the far-UV region (190- 
250 nm). In some experiments, CD data were collected at vari­
ous incubation time intervals after addition of AP20187. Three 
consecutive scans were accumulated, and the average spectra 
were stored. Protein thermal denaturation curves were deter­
mined by monitoring the CD values at 222 nm, with increasing 
temperature from 10 ”C to 90 *C. The temperature dependence 
of the mean residue ellipticity (0) at 222 nm was fitted using an 
in-house non-linear least-squares fitting program (29). To 
obtain the thermodynamic parameters (T°, AHU° (T°), ASU° 
(T‘), and AGU° (T°)) describing the stability of rFv-PrP struc­
tural species, thermal denaturation curves of rFv-PrP were sim­
ulated assuming a two-state unfolding mechanism (27-29). 
These experiments were performed in triplicates.
Data Analysis—The temperature dependence of mean resi­
due ellipticity (6) at 222 nm obtained from thermal denatur­
ation profiles were fitted using an in-house non-linear least- 
squares fitting program assuming a two-state unfolding 
reaction as in Equation 1,
©(7) =  (1 "  Pu(T))'&u(T) +  Pu(T)-©u(7) (Eq. 1)
where ©N(7) and S V(T) are the temperature dependence of the 
mean residue ellipticity of the macroscopic folded and unfolded 
states, respectively. They were both assumed to be linear, i.e. 
© n ( D  = ©N(0) -  d©N(7)/dr- T  and 0^,(7) = 0 ^ 0 )  -  
d€>v(T)/dT-T, where 0 N(O) and 0 ^ 0 )  are the mean residue 
ellipticities at 0 °C for the folded and unfolded states, respec­
tively; correspondingly d©N(T)/dT and d©u(7)/dT are the 
constant slopes of 0 N(T) and ©U(T). PU{T), the population of 
the unfolded state, is given by Equation 2,
_  exp(-AGu(7)/RT) 
u( ) 1 + exp(-AG(7)/RT) (Eq 2)
where the temperature dependence of the free energy of 
unfolding (AGU(7)) is described by Equation 3,
AGU(7) = AHu°(l -  £ )  + ACP,U(7 -  7") -  7 l n ^ )
(Eq. 3)
where T '  is the melting temperature, AHa° is the apparent 
enthalpy of unfolding at T° and ACp u is the temperature-inde­
pendent (30) heat capacity of unfolding. In the present study, 
ACp u was considered constant and equal to 1 kcal-mol-K-1 (1 
kcal *» 4.184 kj).
Thioflavin Assay—The kinetics of amyloid fibril formation 
was monitored by a benzothiazole dye thioflavin (ThT) binding 
assay (31). Briefly, 5 /am AP20187 was added to 50 /am rFv-PrP in 
a physiological buffer (PB buffer) (32), containing 10 mM 
K^PO ,^ 1 mM KC1, 50 mM CH3COOH, 5 mM KHaPO^ 5 mM 
NajHPO,*, pH 7.4, followed by incubation at 37 °C. Aliquots of 
30 /a1 were withdrawn and diluted to a final concentration of 5 
/am rFv-PrP in PBS buffer (pH 8) containing 10 /am ThT. ThT
fluorescence emission at 482 nm (450 nm excitation) was meas­
ured on an Hitachi F-2500 spectrofluorometer. For seeding 
experiments, freshly prepared seeded amyloid fibrils obtained 
after 48 h of incubation in the presence of AP20187 were soni­
cated on ice to disrupt large aggregates (33), and 2% (w/w) 
fibrillar material was added to 50 /am rFv-PrP.
PK Sensitivity—Analysis of PK resistance was performed by 
incubating 10 /Ag/ml of each protein for 15 min in the presence 
of various concentrations of PK at 37 °C in PB buffer. The sam­
ples were then precipitated with four volumes of methanol, 
resuspended in the loading buffer, and analyzed by Western 
blotting with 3F4 (Chemicon) or EP1802Y (Abeam) antibodies.
Electron Microscopy of rFv-PrP Samples—50 /am rFv-PrP was 
incubated with 5 /am AP20187 for 2 or 48 h at 37 *C. A 10-/d 
aliquot of protein preparation was applied to Formvar- and car­
bon-coated grids. The excess fluid was drained with filter paper, 
and the sample was stained for 1 min with 2% uranyl acetate. 
The grid was air-dried and examined in a Hitachi H-2500 elec­
tron microscope at 80 kV at a magnification of 15-75000.
Dimerization-induced Seeding Reactions—In a total reaction 
volume of 100 /d, 50 /am rFv-PrP was aggregated by addition of 
5 /am AP20187 in a buffer, including 130 m M  NaCl, 50 m M  
Na2HP04, pH 7.4, at 37 ‘C. From the reactions aliquots were 
withdrawn after 1 h of incubation and used in seeding experi­
ments after dilution 20 times in the same buffer containing 10 
/am rFv-PrP in the absence of AP20187. After dilution, samples 
were subjected to protein misfolding amplification cycles with 
shaking/incubation periods (34). Each cycle included 2-min 
shaking and 30-min incubation at 37 ”C. PK digestion of the 
samples was performed using 2 /Ag/ml PK. Proteins were pre­
cipitated with four volumes of cold methanol and analyzed by 
Western blotting.
The following modifications were introduced for rFv- 
MoPrP. Aliquots were withdrawn after 5 h of incubation with 
AP20187, and shaking and incubation times were 5 and 60 min, 
respectively. For the experiment in Fig. 10 (see below), rPrP was 
aggregated with 0.1% SDS and periodic sonication as previously 
described (35).
In Vitro Toxicity Experiments—For toxicity monitoring, N2a 
cells were seeded at a density of 0.5 X 106 cells per wells in a 
6-well plate. After 1 day in culture, cells were incubated in dif­
ferent conditions for 72 h. To keep steady culture medium con­
centrations, the proteins were diluted in 2X culture medium, 
and the proper volumes of water and vehicle solution were 
added to get a final 1X concentration. rFv-PrP aggregates were 
obtained by incubating freshly prepared 1 mM rFv-PrP with 100 
/ am AP20187 for 30 min. AP20187-treated rFv-PrP was directly 
added to cells at a final concentration of 10 /am. Staurosporine 
was used at a concentration of 100 h m  to induce apoptosis in 
control experiments (36). Control aggregates of steroidogenic 
acute regulatory protein (StAR) protein (27) were obtained 
with 2 m  urea at pH 5.0 and added to cells in the same concen­
tration as rFv-PrP.
RESULTS
Dimerization-induced Aggregation o f rFv-PrP—To test whether 
dimerization of PrP0 induces a conformational change, rFv-PrP 
was expressed and purified as described under “Experimental
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FIGURE 1. Expression and purification of rFv-PrP and detection o f rFv-PrP 
aggregates by light scattering and Coomassie Blue staining. A, rFv-PrP 
was produced in Escherichia coli cells, BL21(DEj)pLys S as described under 
'Experimental Procedures.* A  2/xgof rFv-PrP was subjected to  th e  SDS-PAGE 
analysis (/eft panel). Immunoblotting assay was performed using 3F4 anti­
body (right panel). B, light scattering: rFv-PrP (0.2 mg/ml, final volume 0.5 ml) 
was incubated in th e  presence of increasing concentrations of AP20187 ( • )  or 
FK506 (O) ligands a t 37 °C. Optical density resulting from light scattering of 
rFv-PrP aggregates or soluble proteins were measured a t 340 nm by UV- 
visible spectroscopy. Samples, including AP20187, were centrifuged, and the  
absorbance of supernatant is represented (Y). Values are expressed as the  
mean ±  S.E. of optical density a t 340 nm from three independent experi­
ments (p <  03). C, Coomassie Blue staining: 50 put rFv-PrP was incubated in 
the  presence of th e  indicated concentrations of AP20187 or FK506 at 37 “C for 
30 min. After centrifugation a t 15,600 X g  for 15 min supernatants were sep­
arated and precipitated by trichloroacetic acid. Aggregated rFv-PrP pellets 
and precipitated supernatant were solubilized in SDS loading buffer, and a 
10-pi aliquot from each sample was subjected to  a 12% SDS-PAGE analysis.
Procedures.” SDS-PAGE analysis showed that the 38-kDa rFv- 
PrP protein was the predominant polypeptide in the purified 
fraction (Fig. 1A, left panel). The identity of the protein was also 
confirmed by immunoblotting analysis, using a monospecific 
antibody (Fig. 1A, right panel).
Recombinant Fv-PrP was incubated in the presence of 
increasing concentration of the dimerizing ligand AP20187, 
and the turbidity associated with the formation of aggregated 
proteins was measured at 340 nm. A large increase in absorb­
ance was observed upon addition of AP20187, and maximal 
aggregation was achieved at 1.4 /xm AP20187 (Fig. IB, filled 
circles). Furthermore, all absorbance was lost after centrifuga­
tion of the samples in a table top centrifuge set at 15,600 X g 
(Fig. IB, empty circles). Addition of FK506, a monovalent ligand
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FIGURE 2. Titration o f rFv-PrP with AP20187  m onitored by CD. Titration of 
rFv-PrP with dimerizing ligand AP20187 (□ , 0 pM; 0 , 1.5 pM; ■ , 2 /am; • ,  3 pM) 
was carried ou t at a protein concentration of 6  pM in 25 mM PBS, pH 7.4, a t 
37 °C. The secondary structure changes were m onitored by CD in a  0.1 -cm 
path length quartz cell. Three consecutive scans in the  far-UV (190-250 nm) 
were accumulated, and th e  average spectra were stored. The arrow  repre­
sents the  isodichroic point.
unable to induce the dimerization of Fv domains did not induce 
any change in absorbance, indicating that dimerization is essential 
for tiie aggregation of rFv-PrP (Fig LB, filled triangles). Aggrega­
tion of rFv-PrP was confirmed by SDS-PAGE and Coomassie Blue 
staining (Fig 1C). In the absence of AP20187, rFv-PrP was 
detected in the supernatant after centrifugation at 15,600 X g. 
Addition of increasing concentrations of AP20187 induced the 
transfer of the protein from supernatant to pellet, while FK506 did 
not modify the distribution of rFv-PrP (Fig 1C).
Changes in the Secondary Structure o f rFv-PrP—The dra­
matic propensity of rFv-PrP to undergo dimerization-induced 
aggregation prompted us to examine whether AP20187 induces 
a structural change characterized by modifications in the con­
tent of a-helices and 0-sheets. Fig. 3A shows the for UV CD 
spectra for rFv-PrP in PBS, pH 7.4, at a protein concentration of 
6 /xm . In the absence of AP20187, the spectrum of rFv-PrP dis­
played a double minimum at 222 and 208 nm, characteristic of 
a-helical structure. Remarkably, upon the addition of AP20187, 
we observed a concentration-dependent decrease in negative 
ellipticity, concomitant with a change in the shape of the spec­
trum to one characteristic of 0-sheet structure. The continuous 
helical destabilization can be monitored by an isodichroic point 
near 203 nm (37), which was recorded after an increasing con­
centration of dimerizing ligand (Fig. 2A, arrow). The percent­
ages of protein secondary structure from CD spectra using the 
K2d program confirmed the structural changes and indicated 
similar proportions of a-helix, 0-sheet, and disordered struc­
tures after treatment with 3 pM AP20187 (Fig 2B). Importantly, 
the values obtained were consistent with values obtained for 
brain-derived PrP*** and after in vitro conversion of PrP° by 
protein misfolding cyclic amplification (Table 1 and Ref. 17). 
The spectra and values (Fig 2 and Table 1) show a still relatively 
high content of a-helical structure after AP20187 treatment, as 
expected for disease-associated misfolded prion protein (38). A 
low content or lack of a-helical structure is considered a draw­
back for many in vitro PrP refolding/misfolding assays in which 
the misfolded PrPRe* form is almost entirely organized in an
30910 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284- NUMBER 45 • NOVEMBER 6,2009
Downloaded 
from 
www.jbc.org 
at UNIV 
DE 
SHERBROOKE, on 
February 
16,2012
Dimerization-induced Prion Protein Aggregation
TABLE 1
P ercen tag e  o f  seco n d ary  s tru c tu re  c o n te n t
Secondary
structure
rFv-PrP*
Brain PrP**- PMCA PrP**-
-AP20187 +AP20187
a-Helix 56 34
*
36 36
8-Sheet 18 30 31 32
Random 26 36 33 32
* This study; values are derived from Fig. 3 (3 jim AP20187).
* From Ref. 17; PMCA, protein misfolding cydic amplification.
aggregated sheet structure (38). The addition of FK506 did 
not change the secondary structure of rFv-PrP (not shown).
Dimerization Increases the Conformational Stability of rFv- 
PrP—To gain more insights into the mechanism of PrP dimer­
ization and its aggregation, the stability of rFv-PrP in the 
monomeric and aggregated states was studied by temperature- 
induced denaturation monitored by CD spectroscopy. In this 
context, changes in heat-induced conformational stability of 
rFv-PrP were determined at 222 nm ([0}222) over a range of 
10-90 °C different times after addition of AP20187. The 
unfolding profiles of rFv-PrP were associated with a single and 
cooperative transition (Fig. 3A). Using an in-house non­
linear least-squares fitting program, temperature-denaturation 
curves ([B]222 (T)) were fitted to Equation 1, to obtain T°, AHu° 
(T°), ASu° (Tm), and AGu° (T°). All of the thermodynamic 
parameters were measured from the equations described under 
“Experimental Procedures.” Thermal denaturation of rFv-PrP 
initially revealed a midpoint of thermal transition (Tm) of 70 'C  
(Fig. 3A, filled circles), in accordance with values published in 
the literature for rPrP (39, 40). The addition of AP20187 
resulted in a slight decrease of the Tm value to 68.6 *C (Fig. 3A, 
empty circles). This can be assumed as the initial step of the 
binding where AP20187 docks into the Fv domain, which in 
turn increases the dynamics of binding site and a global desta­
bility in rFv-PrP structure. However, the stability of rFv-PrP 
was restored in a time-dependent manner with an increase in 
Tm after 1 h (Fig. 3A, filled triangles). Maximum stability was 
observed 24 h following chemical dimerization of rFv-PrP with 
a Tm value of 79.8 °C (Fig. 3A, empty triangles', Table 2). A com­
parison of stability curves revealed that dimerization of rFv-PrP 
favored spontaneous transformation of the protein into more 
stable conformations (Fig. 3B). As depicted in Table 2, at 37 °C 
the free energy of unfolding of the aggregated states reached a 
maximum value [AGU° (37 “C) = 7.1 ± 0.2 kcal.mol_1] when 
compared with that of the native soluble rFv-PrP [AGU° 
(37 "C) = 4.9 ± 0.1 kcal.mol-1], with a AAGU° (37 *Q = 2.2 ± 
0.1 kcalmol-1. To analyze the nature of this favorable struc­
tural transformation, variation in enthalpy and entropy of 
unfolding were determined as a function of temperature (Fig. 
3B). A comparison of AHa° (37 ’C) of rFv-PrP unfolding during 
the aggregation indicated that less favorable (enthalpic) inter­
actions are broken during the structural transformation (Table 
2). However, the variation in entropy TAA5U° (37 *C) of unfold­
ing of rFv-PrP caused by the dimerization-induced aggregation 
was calculated to be 12.2 ± 0.3 kcaLmol-1 after 24 h. That is, 
the unfolding of the aggregated rFv-PrP is accompanied with a 
reduction of favorable (less positive) entropy. This behavior 
could be the result of the exposure of more buried hydrophobic
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FIGURE 3. Therm al unfolding of rFv-PrP. A, thermal denaturations of 6  /xm 
soluble rFv-PrP in PBS, pH 7.4, were monitored by CD. Curves represent simu­
lation of molar ellipticity points (6 2 2 x)> obtained from therm al denaturation  
experiments. Temperature dependence of th e  unfolding of rFv-PrP was 
determined a t different tim e intervals after AP20187-mediated dimerization: 
0 h (•); 0.1 h (O); 1 h (▼); 24 h (V). B, stability curves of rFv-PrP at physiological 
pH.The stability curves were calculated from th e  simulated unfolding profiles 
shown in A. Solid line, 0 h; dotted line, 0.1 h; dash dotted line, 1 h; dashed line, 
24 h. The thermodynamic parameters calculated from stability curves are 
listed in Table 2.
TABLE 2
T herm odynam ic p a ram e te rs  of te m p e ra tu re - in d u c e d  d e n a tu ra t io n  
ofrFv-PrP
Time after addition 
of AP20187 Tm
AH.° 
(3 7 * 0
TAS.® 
(37-C)
AG„°- 
(37 *C)
h •c kcalmol 1
0 70.1 ±  0.3 37.4 ±  0.6 32.5 ±  0.5 4.9 ±  0.1
0.1 68.6 ± 0.7 36.8 ±  0.3 32.6 ±  0.9 4.2 ±  0.6
1 71.2 + 0.9 35.2 ±  0.8 29.1 ±  1.1 6.1 *  0.3
24 79.8 ± 0.2 27.4 ±  0.4 20.3 ±  0.2 7.1 ±  0.2
Parameters were determined from data shown in Fig. 48 as described under "Exper­
imental Procedures.’ Data represent the mean ± S.D. of three independent 
experiments.
surfaces upon chemical dimerization and structural transfor­
mation of the protein.
Dimerization-induced Amyloid Formation of rFv-PrP and  
Self-seeded Conversion—To further characterize the nature of 
dimerization-induced rFv-PrP aggregates, we used the ThT 
assay. ThT specifically binds to amyloid fibrils (31). The struc­
ture of rFv-PrP was very stable and no ThT binding occurred 
for over 60 h of incubation at 37 *C (Fig. 4A, empty squares). 
The addition of AP20187, but not monomeric FK506 to rFv- 
PrP resulted in a tune-dependent increase in ThT binding (Fig.
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FIGURE 4. rfv-PrP fibrilizatlon monitored by ThT-binding fluorescence 
assay. A, 50 /xm rFv-PrP was incubated in the  absence O . or in th e  presence 
of 5 nm  AP20187 ( T )  or 5 /am FK506 (■) in the standard physiological buffer. In 
the  seeded reactions, 2% w/w of preformed seeds were incubated with rFv- 
PrP (O) or rFv-PrP/AP20187 (•). The formation of amyloid fibrils was also 
induceid in physiological buffer containing 100 mM GdnHCI and 1 m urea (A). 
All reactions were performed at pH 7.4 a t a tem perature of 37 *C B and C, ThT 
fluorescence of rFv-PrP observed in a fluorescence microscope after excita­
tion with UV light. rFv-PrP was incubated for 48 h in the  presence of 3 /am 
AP20187 (B) or 3 /am FK506 (Q.
AA, filled triangles and filled squares, respectively). The kinetic 
curves for the assembly of amyloid structures were character­
ized by a lag phase of 4 h that was completely eliminated after 
addition of a small amount (2% wt/wt) of the preformed rFv- 
PrP amyloid to monomeric rFv-PrP (Fig. 4A, compare filled 
triangles with empty and filled circles). These results indicate 
that the conformational conversion of rFv-PrP is a self-seeded 
reaction that requires dimerization-induced oligomeric nuclei. 
In a positive control experiment, 0.1 mM GdnHCI and 1 m  Urea 
were added to rFv-PrP to induce the formation of amyloids (Fig. 
4A, empty triangles).
Recombinant Fv-PrP fibers showed a bright fluorescence 
characteristic of amyloids after excitation by UV light (Fig. 4B). 
In contrast, FK506-treated rFv-PrP did not show any specific 
staining (Fig. 4C). The morphology of rFv-PrP fibers was 
further studied by electron microscopy. The micrographs of 
the protein incubated for 2 h in the presence of AP20187 
showed amorphous aggregates of irregular shape (Fig. 5A). 
After 48 h of incubation, numerous fibrils of about 15-20 nm 
in diameter and of variable length were observed (Fig. 52J). 
The diameter of these fibers is consistent with values previ­
ously obtained after conversion of rPrP in denaturing condi­
tions (7,41). Aggregates or fibers were never observed in the 
presence of FK506 (Fig. SC).
Dimerization-induced Aggregates and Amyloids Are Slightly 
Resistant to PK Digestion—Next we sought to investigate the 
extent to which AP20187-treated rFv-PrP is resistant to PK
FIGURE 5. Morphology o f  rFv-PrP am yloid fibrils. A-D, electron micro­
graphs of negatively stained rFv-PrP taken after 2 h (A) or 48 h (S and Q  of 
incubation in physiological buffer a t 37 "C in th e  presence of AP20187, o r 48 h 
in the  presence ofFK5O6(0). Note th e  presence of amyloid fibers after 48  h (8 
and Q. C, higher magnification of section indicated by a black box in B. The bar 
represents 100 nm.
digestion. In these experiments, aggregates and amyloids were 
produced after incubation of rFv-PrP with 3 /xm  AP20187 for
1 h and 48 h, respectively. Untreated (not shown) or FK506- 
treated rFv-PrP was fully degraded in a 15-min incubation at 
37 'C in the presence of as little as 0.5 /xg/ml PK (Fig. 6A, left 
panel). In contrast, rFv-PrP incubated with AP20187 was 
slightly resistant to PK, and a number of fragments persisted at
2 /xg/ml of PK (Fig. 6A, middle panel). A concentration of 8 
/xg/ml was required to completely proteolyze amyloid fibers 
(Fig. 6A, right panel). These results were not specific to the 
human protein, because the mouse protein (rFv-MoPrP) also 
acquired some resistance to PK treatment after incubation with 
AP20187 (Fig. SB).
The C- terminal Structured Domain Is Responsible for Dimer­
ization-induced Aggregation o f PrP—To test which domain of 
PrP is involved in the aggregation of the protein after dimeriza- 
tion, we engineered two recombinant proteins, rFv-PrP23-124, 
representing the N-terminal unstructured domain between 
residues 23 and 124, and rFv-PrP124-231, representing the 
folded C-terminal domain between residues 124 and 231. Sim­
ilar to rFv-PrP, these two truncated molecules were also fused 
to Fv. rFv-PrP23-124 was slightly insoluble, because some pro­
tein was recovered in the pellet in the absence of any ligand after 
centrifugation at 15,600 X g (Fig. 7A). Addition of AP20187 or 
FK506 did not result in a significant increase of the protein 
in the pellet fraction, indicating that dimerization of rFv- 
PrP23-124 does not induce its aggregation. In contrast, addition 
of AP20187 but not FK506 to rFv-PrP124"231 triggered the 
transfer of the protein from the soluble to the insoluble fraction 
(Fig. 7A). In accordance to these results, aggregates formed
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FIGURE 6. Differential resistance o f th e  rFv-PrP species to  PK d igestion .
A, rFv-PrP (2 pg) was incubated in PB buffer a t 37 *C in th e  presence of 
FK506 for 48 h, or in th e  presence of AP20187 for 1 h or 48 h. Proteins w ere 
then  subjected to  PK digestion a t various concentrations of PK ranging 
from 50 ng to  3.2 p g  in a total volum e o f200 pi. W estern blo t analysis was 
perform ed using 3F4 antibody. The positions of rFv-PrP and PK-resistant 
(PK-res.) fragm ents are indicated. B, rFv-MoPrP (2 pg ) was incubated in PB 
at 37 *C in th e  presence o f FK506 or AP20187 for 48  h. Proteins w ere then  
subjected to  PK digestion a t various concentrations of PK ranging from 50 
ng to  3.2 p g  in a total volume of 200 pi. W estern blot analysis was per­
formed using EP1802Y antibody.
after dimerization of rFv-PrP124-231 were slightly resistant to 
PK treatment (Fig. 75). Incubation of rFv-PrP23-124 with 
AP20187 did not modify the resistance of the protein to PK 
treatment Interestingly, rFv-PrP124 -231 was more sensitive to 
PK than rFv-PrP (compare Figs. 6A and 75), suggesting that the 
N-terminal domain of PrP is important to acquire full resist­
ance to PK. All together, these results show that the C-terminal 
domain of PrP is essential for dimerization-mediated aggrega­
tion of PrP.
Recombinant Fv-PrP Conversion by Shaking— PrPR“ -seeded 
conversion of rPrP is an efficient method to demonstrate the 
presence and propagation of PrP*“  (34,35). Because dimeriza­
tion-induced rFv-PrP aggregates have seeding activity in amy­
loid formation assays (Fig. 4A), we tested if they also display 
seeding activity in misfolding cyclic amplification assays 
using the quaking-induced conversion method recently 
described (34). rFv-PrP aggregates were diluted 20 times into 
a buffer containing soluble rFv-PrP, and the reaction mix­
ture submitted to quaking-induced conversion. The genera­
tion of aggregates was determined by Western blotting after 
PK digestion (Fig. 8A). The conversion of rFv-PrP was 
observed through at least five serial reactions. The concen­
tration of AP20187 present in the initial innoculum after the 
dilutions was not sufficient to account for the conversion of 
rFv-PrP during the 30 min long quaking reactions (see Fig. 
15). Recombinant Fv-PrP incubated in the presence of 
monovalent FK506 did not sustain amplification of PK-re- 
sistant aggregates (Fig. 8A, right panel). The low levels of 
PK-resistant rFv-PrP resulted from shaking of the samples, 
because no PK-resistant rFv-PrP was observed in the 
absence of shaking (Fig. 8A, right panel, shaking cycle 0; see
kDa FK506 
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2 6 -  mm-
17 -  
11 -
AP20187 FK506
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FIGURE 7. Aggregation o f  truncated mutants o f rFv-PrP. A, Coomassie Blue 
staining: dimerization of 50 vm rFv-PrP2 3 - 1 2 4  or rFv-PrP1 2 4 - 2 3 1  was induced 
using the  indicated concentrations of AP20187 a t 37 °C for 30 min. After cen­
trifugation a t 15,600 X g for 15min supernatants were separated and precip­
itated by trichloroacetic acid. Pellets and precipitated supernatant w ere sol­
ubilized in SDS loading buffer, and a 10-/tl aliquot from each sam ple was 
subjected to  a  12% SDS-PAGE analysis. B, differential resistance of rFv-PrP23- 
1 2 4  and rFv-PrP1 2 4 - 2 3 1  to  PK digestion. Recombinant proteins (2 p.g) were 
incubated in PB buffer at 37 *C in the  presence of FK506 or AP20187 for 48 h. 
Proteins were then subjected to PK digestion a t various concentrations o f PK 
ranging from 50 to  250 ng  in a total volume of 200 p.1. Western blot anal­
ysis was performed using 3F4 (rFv-PrP23-124) or EP1802Y (rFv-PrP124-231) 
antibodies.
also Fig. 6A, left panel). Similarly, dimerization-induced rFv- 
MoPrP aggregates had also seeding activity as demonstrated 
in shaking-induced conversion experiments (Fig. 85).
Conversion of PrP with rFv-PrP Aggregates—One strategy to 
test if AP20187-mediated aggregation of rFv-PrP is relevant to 
the conformational conversion of PrP was to investigate if 
rFv-PrP aggregates are able to induce the conversion of rPrP. 
rFv-PrP aggregates were diluted 20 times into a buffer con­
taining soluble rPrP, and the reaction mixture submitted to 
quaking-induced conversion. The generation of aggregates 
was determined by Western blotting after PK digestion at a 
concentration of 2 jtg/ml (Fig. 9A). This concentration of PK 
allowed the detection of aggregated rFv-PrP in the first shak­
ing cycle (Fig. 9A). A concentration of 10 jig/ml of PK was 
otherwise required to completely digest rPrP aggregates 
seeded by rFv-PrP aggregates (Fig. 95), and soluble rPrP was 
completely degraded with 2 jxg/ml PK (Fig. 9C). The conver­
sion of rPrP with aggregated Fv-PrP was observed through at 
least six serial reactions (Fig. 9A). In a reverse experiment, 
aggregated rPrP was also able to convert soluble rFv-PrP in 
shaking reactions (Fig. 95).
Aggregates but Not fibrils Are Toxic to Cultured Cells—The 
toxicity of dimerization-induced aggregates was tested in N2a 
cells by the internucleosomal DNA fragmentation assay. 
Aggregates and amyloid fibers were produced as described
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1/20 1/20
above. Exposure of cells to 10 /am rFv-PrP aggregates for 72 h 
resulted in clear DNA fragmentation, similar to cells exposed to 
the apoptosis inducer staurosporine (Fig. 10). In contrast, amy­
loid fibers were completely innocuous, demonstrating that only 
non-amyloid PrP aggregates are toxic species. FK506-treated 
rFv-PrP was also not toxic to N2a cells. Aggregates from the 
steroidogenic acute regulatory protein (StAR) were innocuous, 
indicating that toxicity is specifically associated with PrP 
aggregates.
DISCUSSION
Misfolding of PrPc is the central pathogenic event in TSEs, 
yet what triggers de novo conformational change and aggrega­
tion of the protein in physiological conditions (e.g. no soni- 
cation, no chaotropic or denaturing agent, neutral pH) and 
in the absence of PrPR“  remains unknown. The most impor­
tant finding of this study is the recognition of dimerization as 
a minimal and sufficient mechanism leading to spontaneous 
aggregation of PrP in physiological conditions. Furthermore, 
dimerization-induced aggregation is an intrinsic property of 
PrP, because it occurs in vitro using the purified recombi­
nant protein.
Several lines of evidence indicate that dimerization-induced 
misfolding of PrPc may be relevant to the aggregation of the 
protein in prion diseases. First, our findings are consistent with 
previous reports based on theoretical and experimental data 
suggesting that dimerization has an important role in confor­
mational change of PrP0 (reviewed 
in Ref. 23). We have directly tested 
and confirmed this hypothesis by 
using a conditional dimerization 
strategy. Most importantly, aggre­
gates obtained after dimerization of 
rFv-PrP display seeded activity in 
amyloid fibrils formation and quak­
ing conversion assays. Second, the 
proposition that dimerization may 
be a key event in PrP aggregation 
implies that PrP dimers should exist 
in both physiological and patholog­
ical conditions. Indeed, the pres­
ence of PrP dimers has been 
detected in non-infected hamster 
and mouse brains (42) and in 
murine neuroblastoma cell line 
expressing hamster PrP (43). 
Dimers were also detected in 
Creutzfeldt-Jakob infectious mate­
rial disaggregated in gentle condi­
tions (44) and in infected hamster 
brains (43). Third, monomeric rPrP 
is able to spontaneously dimerize 
during its crystallization process 
(45). The structure of the dimer sug­
gested that dimerization may con­
stitute an important step in the con­
version PrPc  —» PrPRe‘. Finally, an in 
vitro study on the mechanism of PrP 
assembly into amyloid demonstrated that the precursor exists 
in a monomer-dimer equilibrium (46). The contact sites in the 
dimer were identified to residues 90-106 and 152-156.
What may trigger the dimerization of PrPc in prion diseases? 
In TSEs acquired by infection, PrPRe* interacts with and could 
force the dimerization/oligomerization of PrPc  molecules (22, 
47, 48). In TSEs non-acquired by infection, dimerization of 
PrPc may be triggered either by an unknown ligand (49), or by 
the concentration of the protein in a restricted environment 
Our thermodynamic data indicate that the population of 
rFv-PrP dimers are more stable than that of the soluble 
monomers. A progressive increase in the entropy of reaction 
(Table 2) is a consequence of the disruption of a hierarchy of 
different kinds of intermolecular interactions (hydrogen 
bonds, electrostatic, dispersion forces, and disulfide bridges) 
at the monomer-monomer interface. This evolution of inter­
nal dynamics in association with strong hydrophobic forces 
helps the system to cross the energy barriers according to the 
energy landscape model (50). This can result in the forma­
tion of a stable “seed,” which serves as a template for other 
soluble monomers. A global structural transformation in 
population of soluble rFv-PrP monomers shifts the equilib­
rium toward the massive rFv-PrP aggregation and subse­
quent amyloid fibril formation.
It is noteworthy that dimerization-induced aggregates 
form ThT-positive structures with typical amyloid morphol­
ogy after 48 h of incubation. Previous reports describing the
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ature (11, 51,52). Our observation 
indicates that dimerization-in­
duced aggregates are competent to 
form amyloids and demonstrate 
that it is possible to achieve the 
generation of PrP amyloid fi­
bers in  vitro  in physiological-like 
conditions.
Another interesting finding in 
this study is that rFv-PrP aggregates 
but not amyloids are cytotoxic. This 
result confirms previous evidence 
that small aggregates rather than 
amyloids are the toxic species in 
prion diseases and in other neuro- 
degenerative diseases (3,15,53) and 
underscores the relevance of dimer­
ization in prion diseases.
From our results, it is tempting to 
speculate that dimerization of PrPc 
in  vivo  would be a noxious event. 
This hypothesis is comforted by 
the observation that enforced 
dimerization of PrPc using cross- 
linking antibodies results in neuro­
nal toxicity in mice (54). In that study, 
the presence of PrP aggregates was 
not investigated. However, in con­
trast to chemical dimerization, it is 
likely that cross-linking antibody-me­
diated dimerization may interfere 
with further conformational changes 
and aggregation.
The present study establishes 
dimerization of PrPc as a potential 
toxic mechanism in TSEs. Future 
therapeutic strategies may be aimed 
between PrPc  monomers.
FIGURE 10. In vitro  toxicity of rFv-PrP aggregates. DNA fragm entation 
assay was performed on N2a cells incubated for 72 h with staurosporine (7), 
10 ptM rFv-PrP aggregates (2), 10 fit* rFv-PrP amyloids (3), or 10 j im  FK506- 
treated rFv-PrP (4). As an external control, N2a cells were incubated with 10 
fUA steroidogenic acute regulatory protein (StAR) aggregates (5).
production of amyloid fibers from rPrP are all associated 
with the use of denaturants, elevated temperatures, or a 
combination of phospholipids bicelles and elevated temper-
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